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Numerous natural products are widely used as first-line/alternative therapeutics and dietary 
supplements in both western and eastern society. However, the safety and efficacy profiles for 
herbal products are still limited. Organic anion transporters (OATs; SLC22 family) are expressed 
in many barrier organs and mediate in vivo body disposition of a broad array of endogenous 
substances and clinically important drugs. As some dietary flavonoids and phenolic acids were 
previously demonstrated to interact with OATs, it is necessary to explore the potential interaction 
 
 
 
 
of such components found in natural products in order to avoid potential OAT-mediated drug-
drug interactions (DDIs). 
The inhibitory effects of 23 natural products were assessed on the function of human (h) 
OATs, hOAT1 (SLC22A6), hOAT3 (SLC22A7), and hOAT4 (SLC22A11) and/or the murine (m) 
orthologs mOat1 and mOat3. For compounds exhibiting marked inhibition at initial screening, 
dose-response curves (IC50 values) and DDI indices were determined. At the initial screening 
concentrations, 14, 19, and 2 test compounds exhibited significant inhibition on hOAT1, hOAT3, 
and hOAT4, respectively. Additionally, all test Danshen (a Chinese herbal medicine) hydrophilic 
components significantly reduced mOat1- and mOat3-mediated substrate uptake at 1 mM. For 
selected compounds, the IC50 and Ki values were estimated to be in the micromolar or even 
nanomolar range. Considering the clinical plasma concentration and unbound fraction in plasma, 
DDI indices for gallic acid, gentisic acid, lithospermic acid, protocatechuic acid, rosmarinic acid, 
salvianolic acid B, and tanshinol indicated DDIs may occur in vivo in situations of co-
administration of these compounds and clinical therapeutics known to be OAT substrates. 
Finally, a new, rapid, and sensitive liquid chromatography-tandem mass spectrometry (LC-
MS/MS) method was developed and validated to quantify gallic acid and gentisic acid in cell 
lysates in order to measure cellular uptake of these compounds in mOat1- or mOat3-expressing 
cells. Significant cellular uptake of gallic acid was observed in mOat1-expressing cells, 
compared with background control cells. The absorptive uptake was completely blocked by 
probenecid (known OAT inhibitor) at 1 mM. These results indicate that gallic acid is a substrate 
for mOat1 and suggest that human OAT1 might be involved in the active renal secretion of gallic 
acid. 
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CHAPTER 1 
 
 
 
RENAL ORGANIC ANION TRANSPORTERS (SLC22 FAMILY): EXPRESSION, 
REGULATION, ROLES IN TOXICITY, AND IMPACT ON INJURY AND DISEASE 
 
Drawn from manuscript published in AAPS J. Jan 2013; 15(1): 53-69 
 
 
 
 
 
 
1.A INTRODUCTION 
Two vital functions performed by the kidney are the removal of substances from the blood 
followed by their elimination via urine and the reabsorption of specific compounds from the 
glomerular filtrate back into the systemic circulation. Much of the secretion and reabsorption of 
charged organic solutes occurs in the proximal tubule. However, the plasma membrane of the 
proximal tubule cells presents a barrier to the passive diffusion of such charged, hydrophilic 
molecules and renal transcellular solute flux is a complex process involving dozens of membrane 
bound transporter proteins. Two major superfamilies of transport proteins that have been 
identified are the ATP binding cassette (ABC) transporters, which can directly bind and 
hydrolyze ATP as a driving force for the unidirectional transport of substrates across cell 
membranes, and the solute carriers (SLC), transport proteins that are indirectly coupled to 
cellular energy and utilize the membrane potential difference and/or the stored energy of 
concentration gradients as driving forces (1-3). Currently, the human SLC superfamily has at 
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least 55 separate gene families encompassing a combination of 362 confirmed and putative 
transporter proteins (1). The SLC22 family is comprised of the organic cation/anion/zwitterion 
transporters with ~30 identified/putative members and includes the organic cation transporters 
(OCTs and OCTNs), which mainly interact with cationic and zwitterionic organic molecules, and 
the organic anion transporters (OATs), which predominantly interact with anionic and 
zwitterionic organic molecules (2-4). 
In vitro characterization of cloned transporters has demonstrated that OAT function is 
impacted by an enormous variety of structurally diverse organic anions. Many drugs, including 
diuretics, antihypertensives, antibiotics, antivirals, and anticancer agents, are organic anions at 
physiological pH and, thus, subject to active tubular secretion which, in turn, impacts their 
pharmacokinetic, pharmacodynamic, and toxic properties. In addition, endogenous substances 
(e.g., metabolic intermediates/byproducts and hormones) and environmental toxins and toxicants 
(e.g., mycotoxins and pesticides) also exist as anionic species. Indeed, the attributes of known 
OAT substrates indicate that renal OAT function is central to organism homeostasis and the 
progression of certain disease states. Further, interindividual variation in therapeutic response 
within human populations may be linked to altered renal OAT affinity, expression level, and/or 
spatial distribution as a result of dietary or genetic factors. Clearly, a more thorough 
understanding of OAT function is necessary if we wish to accurately assess their impact on drug 
efficacy and the extent of exposure to endogenous and xenobiotic toxins/toxicants. 
This review will focus on the OATs of the SLC22 transporter family and in particular on 
those OATs for which transport activity has been demonstrated and expression/function in 
kidney established (Table 1.1). Basic cloning, expression profile, and functional characterization 
information for each transporter has been summarized in great detail recently and will not be 
 
 
3 
 
repeated here (3, 4). Rather, evidence supporting the involvement of renally expressed OATs in 
drug clearance, food/drug-drug interactions, and renal pathology will be emphasized. Appendix I 
provides a listing of compounds demonstrated to interact with various OATs and reported kinetic 
parameters (Km, Ki, or IC50 values), when available, that serves as an update (2010-2012) to the 
comprehensive table from reference (3). An update of the current information regarding the 
regulation of OAT expression is also provided. Throughout this review the convention of 
referring to human transporters with all capital letters (i.e., OAT1) and non-human transporters 
with initial capital followed by lower case letters (i.e., Oat1), is used. 
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Table 1.1. Functional SLC22 family organic anion transporters 
Transporter 
(gene designation) 
Organic anion 
transport 
demonstrated 
mRNA expression 
detected in kidney 
Protein expression 
confirmed in kidney 
Human    
OAT1 (SLC22A6) ✓ ✓ ✓ 
OAT2 (SLC22A7) ✓ ✓ ✓ 
OAT3 (SLC22A8) ✓ ✓ ✓ 
OAT4 (SLC22A11) ✓ ✓ ✓ 
OAT5 (SLC22A10)a -- -- -- 
OAT7 (SLC22A9) ✓ -- -- 
OAT10 (SLC22A13) ✓ ✓ -- 
URAT1 (SLC22A12) ✓ ✓ ✓ 
Rodent    
Oat1 (Slc22a6) ✓ ✓ ✓ 
Oat2 (Slc22a7) ✓ ✓ ✓ 
Oat3 (Slc22a8) ✓ ✓ ✓ 
Oat5 (Slc22a19)a ✓ ✓ ✓ 
Oat6 (Slc22a20) ✓ -- -- 
Oat8 (Slc22a25) ✓ ✓ ✓ 
Oat9 (Slc22a27) ✓ ✓ ✓ 
Oat10 (Slc22a13) -- ✓ ✓ 
Urat1 (Slc22a12) ✓ ✓ ✓ 
 
aHuman OAT5 (SLC22A10) and rodent Oat5 (Slc22a19) are not orthologs, i.e., are not coded for 
by the same gene and therefore do not represent the same transporter; rat and mouse Oat5 are 
paralogs, i.e., represent the same gene across species and thus code for the same transporter 
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1.B ORGANIC ANION TRANSPORTERS IN RENAL PROXIMAL TUBULE 
As indicated in Table 1.1, species differences in known OAT family members do exist, with 
OAT4 (SLC22A11), OAT5 (SLC22A10), and OAT7 (SLC22A9) being unique to humans and 
Oat5 (Slc22a19), Oat6 (Slc22a20), Oat8 (Slc22a25), and Oat9 (Slc22a27) being restricted to 
non-human species (most thoroughly explored in mice and rats). It is important to clarify that 
OAT5 (SLC22A10) and Oat5 (Slc22a19) are not orthologs. Of the 11 OATs for which transport 
activity has been demonstrated, OAT1 (SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), 
OAT4, and URAT1 (SLC22A12) proteins have been detected and localized in human kidney and 
Oat1 (Slc22a6), Oat2 (Slc22a7), Oat3 (Slc22a8), Oat5, Oat8, Oat9, Oat10 (Slc22a13), and Urat1 
(Slc22a12) proteins have been detected and localized in rodent kidney (2-5). OAT1/Oat1, 
OAT2/Oat2, and OAT3/Oat3 are targeted to the basolateral membrane of renal proximal tubule 
cells (Figure 1.1) and mediate the movement of substrate molecules from the blood into the cells 
via dicarboxylate/organic anion exchange (2-4). In the apical membrane, OAT4 appears to 
mediate substrate reabsorption from urine through exchange with dicarboxylates or hydroxyl 
ions and URAT1/Urat1 mediates reabsorption of urate and other substrates by monocarboxylate 
exchange (Figure 1.1). In rodent proximal tubules, Oat5 may mediate substrate reabsorption via 
dicarboxylate exchange, however no information is available regarding the driving forces and 
directionality of Oat9 (2-5). While Oat8 was identified as a dicarboxylate/organic anion 
exchanger, immunohistochemistry localized this transporter to the apical membrane of 
intercalated cells in the collecting ducts, with no signal in proximal tubule. Finally, organic anion 
transport by OAT10 (SLC22A13) was reported to be driven by exchange with dicarboxylates or 
hydroxyl ions, similar to OAT4, however localization information is restricted to brush border 
membrane vesicles prepared from rat kidney (2-4). 
 
 
6 
 
 
Figure 1.1. Organic anion transporters of the SLC22 family in human and rodent renal 
proximal tubule cells 
 
As illustrated, human and rodent orthologs of OAT1/Oat1, OAT2/Oat2, OAT3/Oat3, 
OAT10/Oat10, and URAT1/Urat1 have been identified. Notable species differences are OAT4 
having no identified rodent ortholog and Oat5 and Oat9 having no known human orthologs. Oat8 
mRNA has been detected in rodent kidney, however it is expressed in cortical collecting ducts, 
not in the proximal tubule; its membrane targeting is not known. The driving forces governing 
Oat9 function have not been elucidated. 
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1.C REGULATION OF OAT EXPRESSION 
Mounting evidence suggests that OAT expression can be regulated at both the mRNA and 
protein level. Examination of the promoter regions of the hOAT1, hOAT2, hOAT3, hOAT4, and 
hURAT1 genes identified putative binding sequences for several transcription factors including 
activating transcription factor 1 (ATF1), cAMP responsive element binding protein 1 (CREB1), 
hepatocyte nuclear factors 1α, 1β, and 4α (HNF1α, HNF1β, HNF4α), paired box protein Pax-1, 
B-cell lymphoma 6 protein, and Wilm’s tumor protein 1  (6-9). The presence of DNA binding 
sequence motifs for known transcription factors suggest they might be involved in the regulation 
of OATs and a number of recent studies have investigated this possibility. 
Deletion analysis of the hOAT3 promoter indicated the sequence from -214 to -77 basepairs 
was required for basal level transcriptional activity and this region was found to contain a 
cAMP-response element (CRE) (8). Mutation of this sequence resulted in reduced hOAT3 
promoter activity. Both ATF1 and CREB1 are known to bind to CRE, and subsequent 
electrophoretic mobility shift assays (EMSA) confirmed binding of these transcription factors to 
the hOAT3 promoter (8). Further, phosphorylation of CREB1 and ATF1 in response to activation 
of protein kinase A (PKA) appeared to induce increased hOAT3 expression, suggesting 
stimulatory effects of PKA on hOAT3 activity might be explained through increased 
transcriptional activity (8). 
The transcription factors HNF1α and HNF1β are expressed in the epithelia of many organs 
including liver, kidney, and intestine (10-12). When explored in Hnf1α knockout mice, it was 
observed that renal mRNA expression of mOat1, mOat2, mOat3, and mUrat1 was reduced (13, 
14). Examination of the mOat1 and hOAT1 promoter regions revealed a HNF1 binding motif at -
56 to -44 basepairs (15). Forced expression of HNF1α and HNF1β increased activity of both 
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promoters, with HNF1α producing the greatest increase, followed by co-expression of HNF1α 
and HNF1β, and expression of HNF1β alone producing little to no effect. EMSA analysis 
detected binding of HNF1α homodimers and HNF1α/HNF1β heterodimers to the hOAT1 
promoter (15). The promoter sequence of hOAT3 (-308 to +6 basepairs) also contains a HNF1α 
motif, as do the rat and mouse orthologs (16). Mutation of the HNF1α motif reduced basal 
hOAT3 promoter activity. Similar to hOAT1, expression of HNF1α increased hOAT3 and mOat3 
promoter activity more than co-expression of HNF1α and HNF1β, however, in contrast, 
expression of HNF1β alone also increased activity, although to a lesser extent (16). EMSA 
analysis confirmed binding of HNF1α homodimers and HNF1α/HNF1β heterodimers to the 
hOAT3 promoter (16). Repression of endogenous HNF1α expression in a human-derived liver 
cell line (Huh7) with a small interfering RNA (siRNA) construct significantly decreased 
expression of hOAT5 and hOAT7 message, but was without effect on hOAT2 mRNA expression 
level (17). Binding and upregulation of hOAT5 and hOAT7 promoter activity by HNF1α was also 
demonstrated, but as mentioned previously, these OATs are not expressed in kidney (17). The 
hURAT1 (-253 to +83 basepairs) and mUrat1 (-261 to +80 basepairs) minimal promoter regions 
were found to contain a HNF1 motif and mutation of the sequence in hURAT1 abolished 
promoter activity (14). Both hURAT1 and mUrat1 responded to forced HNF1α and HNF1β 
expression like hOAT3 and mOat3, suggesting HNF1α homodimers, HNF1α/HNF1β 
heterodimers, and HNF1β homodimers all stimulate promoter activity with the same respective 
order of potency as on hOAT3/mOat3 (14). In contrast to the other OATs, EMSA analysis 
confirmed that HNF1β homodimers, in addition to HNF1α homodimers and HNF1α/HNF1β 
heterodimers, could bind to the promoter region of hURAT1 (14). Lastly, two HNF1 motifs (at -
97 to -85 and -41 to -29) were located in the hOAT4 promoter (18). Overexpression of either 
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HNF1α or HNF1β alone, or in combination, enhanced hOAT4 promoter activity, and this 
enhanced activity was blunted by mutation of either motif and abolished when both motifs were 
mutated (18). When examined under conditions of endogenous HNF1α expression level (HepG2 
cells), or endogenous HNF1α and HNF1β levels in combination (Caco-2 cells), promoter activity 
was only responsive to the HNF1 motif at the -97 to -85 positions (18). Like hURAT1, EMSA 
analysis demonstrated that HNF1β and HNF1α homodimers, as well as HNF1α/HNF1β 
heterodimers, could bind this HNF1 motif; binding to the -41 to -29 motif was reported as barely 
detectable (18). Since it has been determined that, in renal proximal tubules, HNF1α/HNF1β 
heterodimers and HNF1β/HNF1β homodimers predominate, one or both of these complexes 
likely influences OAT expression in vivo (12). 
Another HNF family member, HNF4α, was observed to enhance the activity of both hOAT1 
(-2747 to +88 basepairs) and hOAT2 (-679 to +54 basepairs) promoter constructs (19, 20). 
HNF4α is known to have several potential sequence motifs; a direct repeat of hexamers 
separated by one (DR-1) or two (DR-2) nucleotides, or an inverted repeat of hexamers separated 
by 8 nucleotides (IR-8). For hOAT1, promoter scanning revealed the presence of a DR-2 motif 
(at -875 to -862 basepairs) and an IR-8 motif (at -123 to -104 basepairs) (19). Co-expression of 
HNF4α with constructs containing either one or both of these motifs resulted in increased hOAT1 
promoter activity, which was diminished by mutation (19). Subsequent EMSA experiments 
confirmed binding of HNF4α homodimers to each of these motifs in the hOAT1 promoter (19). 
The promoter region of hOAT2 was found to contain a DR-1 type HNF4α consensus motif at 
position -329 to -317 that is conserved in the rat ortholog (20). Presence of the wildtype 
sequence correlated with HNF4α activated hOAT2 promoter activity and sequence mutation 
resulted in loss of HNF4α activation (20). EMSA analysis demonstrated HNF4α binding to 
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hOAT2 promoter fragments containing the motif and introduction of HNF4α siRNA constructs 
markedly reduced endogenous hOAT2 mRNA expression in Huh7 cells (20). 
Recently, microarray analysis identified B-cell lymphoma 6 protein (BCL6) as a transcription 
factor exhibiting male dominant expression in rats (9). Since rOat1 and rOat3 had previously 
been reported to exhibit male dominant expression that is modulated by steroid hormones (21), 
the investigators examined the promoter regions for BCL6 consensus binding motifs. Five 
putative BCL6 sequence motifs were identified in the promoter region of rOat1 and six in the 
promoter of rOat3, no mention of whether these sites are found in the promoters of hOAT1 
and/or hOAT3 was made (9). Expression activity of a construct corresponding to -2,252 to +113 
basepairs of the rOat1 promoter, which contained 4 of the identified BCL6 sites, was increased 
when BCL6 was co-expressed. Activity of a truncated construct (-1,266 to +113 basepairs) 
containing only 2 of the sites showed a similar level of activity, suggesting that either not all of 
the potential binding sites are functional or that response to binding of BCL6 is “all or none”, 
and interaction with multiple sites does not further modulate expression level (9). A similar 
effect was observed for rOat3, with a clear increase in promoter activity upon co-expression of 
BCL6, but with no difference in the magnitude of effect between constructs containing six (-
2,567 to +12 basepairs), three (-752 to +12 basepairs), or two (-444 to +12 basepairs) BCL6 
binding motifs (9). 
In addition to transcriptional regulation, there is evidence supporting post-translational 
regulation of OATs by protein kinases. As recently reviewed (3), there appeared to be a general 
trend for decreased OAT1/Oat1 and OAT3/Oat3 activity via non-specific protein kinase C (PKC) 
activation. However, a reported exception to this was stimulation of rat and mouse Oat1- and rat 
and mouse Oat3-mediated transport upon activation of the atypical isoform PKCζ (22). Increased 
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transport of para-aminohippurate (PAH), estrone sulfate, and adefovir was observed in renal 
cortical slices in response to PKCζ activation (22). The effect on estrone sulfate transport was 
not observed in slices prepared from Oat3 knockout mice. Direct binding of PKCζ to hOAT3 
was demonstrated in a yeast two-hybrid system and binding to rOat3 was demonstrated by 
immunoprecipitation and immunoblotting (22). Recently, another study confirmed the binding 
and stimulatory effects of PKCζ on hOAT3 (23). In addition, the isoforms PKCδ and PKCε, 
were observed to bind to hOAT3 (23). This was associated with increased hOAT3 at the cell 
surface, with no effect on total cellular hOAT3, suggesting redistribution of hOAT3 from 
intracellular compartments as the mechanism behind upregulation of transport activity (23). In 
contrast, activation of the PKCα isoform by angiotensin II has been demonstrated to decrease 
transport activity of hOAT1 and hOAT3 in concert with decreased cell surface expression (24). 
Therefore, it appears as though the effects of PKC activation on OAT activity are PKC isoform 
dependent, and can lead to either upregulation or downregulation of OAT activity depending 
upon the specificity of PKC isoform activation. Thus, rapid short-term modulation of OAT 
activity appears possible through changes in transporter cell surface expression via cycling in 
and out of the membrane from a cytoplasmic pool of transporters under the control of kinases, 
whereas long-term changes might involve alteration of gene transcriptional activity and, 
presumably, protein synthesis. 
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1.D OATs IN RENAL INJURY AND PROTECTION 
Many clinical therapeutics, endogenous metabolic toxins, and xenobiotic toxins/toxicants 
accumulate in renal proximal tubules cells and induce renal injury. Cellular damage can take a 
variety of forms including oxidative stress, protein acylation, DNA-adduct formation, 
mitochondrial dysfunction (impaired ATP synthesis), lipid peroxidation, and necrosis. In 
opposition, a number of molecules purported to exert protective effects, such as antioxidant, anti-
inflammatory and anti-proliferative activities, also enter renal proximal tubule cells. There is 
growing evidence from both in vitro and in vivo systems implicating OATs in the renal targeting 
of these substances. 
Inorganic mercury (Hg2+) accumulates preferentially in the kidneys and can result in acute 
renal failure. Typical manifestations of mercury intoxication include renal vasoconstriction, 
reduced glomerular filtration rate (GFR), enzymuria, tubular dilatation, and formation of 
epithelial cell casts. Early in vitro and in vivo studies indicated that entry of mercury from the 
systemic circulation into proximal tubule cells occurred via the same transport pathway as PAH 
(recently reviewed in (2, 4). Subsequent studies using Madin Darby canine kidney (MDCK) cells 
stably expressing hOAT1 indicated a direct correlation between hOAT1 expression and uptake 
and toxicity of mercury-thiol conjugates (25, 26). Recently, direct in vivo evidence supporting 
the role of OAT1/Oat1 in mediating mercury nephrotoxicity was obtained in studies utilizing 
Oat1 knockout mice (27). Renal function and histopathology were examined in wildtype and 
Oat1 knockout mice 18 hours post-intraperitoneal injection with HgCl2 (4 mg/kg). Wildtype 
mice treated with HgCl2 exhibited significantly increased kidney:body weight ratio (indicative of 
edema) and blood urea nitrogen (BUN) levels, as compared to saline injected wildtype animals 
(27). These indicators of renal injury and renal insufficiency were significantly blunted in Oat1 
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knockout mice treated with HgCl2 (27). Furthermore, histopathological markers of 
nephrotoxicity observed in mercury treated wildtype mice, including tubular dilatation and 
necrosis, and sloughing of the brush border membrane, were virtually undetectable in kidneys 
from Oat1 knockout mice (27). These findings strongly support a major role for OAT1/Oat1 in 
the pathology of renal mercury toxicity. 
Renewed interest in complementary and alternative therapies, particularly in Western 
cultures, has led to the increased use of herbal therapies. Often these are complex mixtures of 
dried plants or plant extracts with poorly defined active components and unregulated 
manufacturing processes. As they are marketed for their beneficial health effects, such therapies 
are frequently viewed as being safe, however, a number of herbal medicines have produced 
unwanted toxicities and drug interactions (28, 29). For example, Aristolochia plants, used in 
herbal remedies for thousands of years in both Eastern and Western countries, contain the 
nephrotoxic agent aristolochic acid (AA), identified as the causative agent in what is now 
referred to as aristolochic acid nephropathy (AAN) (30-33). The proximal tubule has been 
identified as the main target site for AAN in both humans and rodent models (34, 35). AA 
collectively refers to a complex mixture of carboxylic acids, the major components of which are 
AA-I and AA-II. The only structural difference between the two compounds is the presence of an 
O-methoxy group at the 8-position of AA-I (36). Both AA-I and AA-II have metabolic 
intermediates capable of forming DNA adducts that produce carcinogenic effects, however this 
property is not linked to their toxicity, as only AA-I is nephrotoxic (37, 38). When examined 
directly in overexpressing HEK-293 cell lines, AA-I was demonstrated to be a competitive 
inhibitor of hOAT1, hOAT3, and hOAT4 with Ki values of 0.63 ± 0.15, 0.50 ± 0.10 and 20.63 ± 
1.7 µM, respectively (39). Significantly increased AA-I DNA adducts were observed in all three 
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transporter expressing cell lines as compared to non-transporter expressing cells, and this 
increase was reversed in the presence of probenecid, supporting hOAT-mediated accumulation 
of AA-I (39). In another in vitro study, both AA-I and AA-II were shown to inhibit hOAT1, 
hOAT3, and hOAT4, but produced no effect on hOAT2 activity (40). Reported IC50 values 
indicated that AA-I was a slightly better inhibitor than AA-II on all three transporters, although 
the differences were not great; (in µM) 0.44 ± 0.08 and 1.06 ± 0.09 (hOAT1), 0.65 ± 0.08 and 
1.28 ± 0.18 (hOAT3), and 61.3 ± 8.35 and 72.0 ± 9.32 (hOAT4), for AA-I and AA-II, 
respectively (40). Recently, direct uptake of AA-I and AA-II was demonstrated for mOat1, 
mOat2, and mOat3 indicating both compounds are high affinity substrates for these transporters 
(36). Michaelis constants (Km values) correlated well with inhibitory values reported for the 
human orthologs; (in µM) 0.791 ± 0.007 and 1.498 ± 0.371 (mOat1), 0.356 ± 0.050 and 0.673 ± 
0.1192 (mOat2), and 0.514 ± 0.057 and 1.047 ± 0.360 (mOat3), for AA-I and AA-II, 
respectively (36). Discrepancy of the results for mOat2 and hOAT2 in cellular uptake of AA-I 
and AA-II may represent species differences. 
Analysis of structural determinant effects on uptake indicated that the carboxyl group of AA-
I is key to high-affinity interaction with mOat1, mOat2, and mOat3, whereas the nitro group only 
impacted interactions with mOat1 (36). Accumulation of AA-I in mouse renal cortical slices was 
found to be probenecid-, PAH-, and estrone sulfate-sensitive, correlating with an OAT-mediated 
transport process (36). Furthermore, this accumulation in slices resulted in AA-I DNA adduct 
formation that was reversed by probenecid (36). In agreement with these findings, a recent in 
vivo study in mice demonstrated that probenecid reduced the urinary excretion of AA-I and 
protected the kidney from AA-I induced nephrotoxicity (41). Results in mOat1 and mOat3 
knockout mice indicated that loss of function of either transporter was associated with decreased 
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renal accumulation of AA-I and lessened the severity of renal injury as compared to wildtype 
animals (41). Significant downregulation of rOat3, but not rOat1, protein also was observed after 
long-term (7 days) administration of an AA mixture (42). Taken together, these findings strongly 
suggest an OAT-mediated mechanism in the pathology of AAN and suggest inhibition of renal 
OAT activity might serve as a potential therapeutic strategy following AA exposure. 
Phenolic acids represent a growing class of OAT substrates/inhibitors. They are common 
dietary constituents as they are produced from the amino acids phenylalanine and tyrosine in 
plants (43). Many phenolic acids are also metabolically derived from anthocyanidins and 
anthocyanins after consumption (44). They are purported to have beneficial health effects in 
chronic diseases, e.g., diabetes, cardiovascular disorders, and cancer, through free radical 
scavenging, anti-proliferative, and anti-inflammatory activities (43, 45-47), hence their growing 
popularity as alternative medicines/dietary supplements. Interaction of the related dietary 
polyphenols and human OATs was being investigated as many as seven years ago, when ellagic 
acid was identified as a substrate for hOAT1 (IC50 = 207 nM), rOat1, and hOAT4, but not mOat2, 
hOAT3, or mOat5 (48). More recently, the phenolic acids, lithospermic acid, protocatechuic acid, 
rosmarinic acid, salvianolic acid A, salvianolic acid B, and tanshinol, identified as active 
components of the traditional Chinese medicine Danshen (Salvia miltiorrhiza) which is utilized 
in cardiovascular disease, were shown to inhibit mOat1- and mOat3-mediated transport (49). 
Lithospermic acid, rosmarinic acid, and salvianolic acid A were found to be potent competitive 
inhibitors; Ki constants were 14.9 ± 4.9 vs. 31.1 ± 7.0 for lithospermic acid, 5.5 ± 2.2 vs. 4.3 ± 
0.2 µM for rosmarinic acid, and 4.9 ± 2.2 µM vs. 21.3 ± 7.7 µM for salvianolic acid A, on 
mOat1 and mOat3, respectively (49). An extensive study showed the phenolic acids caffeic acid, 
dihydrocaffeic acid, dihydroferulic acid, and ferulic acid were substrates of hOAT1 and/or 
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hOAT3, while a number of their glucuronide- and sulfate-conjugated metabolites were effective 
inhibitors (50). An independent study identified caffeic acid as a competitive inhibitor of both 
hOAT1 and hOAT3 (IC50 = 16.6 and 5.4 µM, respectively) and demonstrated the potential for 
food-drug interactions via inhibition of hOAT1 and hOAT3-mediated transport of antifolates and 
antivirals (51). Inhibition of hOAT1 by gallic acid, protocatechuic acid, sinapinic acid, and 
vanillic acid, and of hOAT3, by ferulic acid, gallic acid, gentisic acid, protocatechuic acid, and 
sinapinic acid has been observed (52). IC50 values ranged from 1.24-18.08 µM on hOAT1 and 
from 7.53-87.36 µM on hOAT3 (Appendix I) (52). Inhibition of hOAT1 by gallic acid, and of 
hOAT3 by gallic or gentisic acid, was identified as having potential for clinically significant 
food/drug-drug interactions. Human OAT4 activity was not affected by any of these compounds 
(52). Whether or not any dietary polyphenols/phenolic acids actually promote human health or 
improve disease outcomes remains unresolved. However, these studies provide clear evidence 
for the potential of phenolic acids to interact with OATs and to produce food-drug interactions, 
emphasizing the need to better understand the impact of transport processes on the distribution 
and elimination of these compounds. Regardless of any health benefits through anti-oxidant or 
anti-inflammatory-type activities, these compounds might provide an alternative treatment in the 
management of OAT-mediated nephrotoxicity, without producing significant side effects. 
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1.E OAT FUNCTION AND EXPRESSION IN MODELS OF RENAL INJURY AND 
DISEASE 
Renal function plays a vital role in the clearance of drugs and endogenous/exogenous toxins 
and toxicants. The overall renal clearance of substances is determined by the net effect of 
glomerular filtration, tubular secretion, and reabsorption processes. Renal disease states that 
result in dysfunction or loss of function can greatly influence the rate of elimination and tissue 
level of transporter substrates (53, 54). OATs, which are known to mediate the accumulation of 
organic anions from the blood and urine into proximal tubule cells, can be affected by renal 
failure and disease in terms of mRNA and protein expression level, transport activity, and 
membrane cycling, showing altered renal clearance of their substrates (53-55). 
Progression of chronic renal failure (CRF) leads to impaired activity and function of the 
proximal tubule. In the laboratory, this pathological condition is mimicked with the 5/6 
nephrectomy model, which replicates the onset of uremia and chronic kidney disease-related 
complications observed in humans (56). More recently this model has been used to examine 
changes in OAT protein levels in response to CRF (57-59). When examined 14 days post-
surgery, Ji et al. found a 50% decrease in the renal clearance of unbound PAH, but no significant 
changes in rOat1 or rOat3 protein levels by Western blot (57). In agreement, Torres and co-
workers reported significant decreases in filtered, secreted, and excreted PAH at 168 days post-
surgery in 5/6 nephrectomized animals vs. sham-operated controls (59). However, in this study 
changes in renal PAH handling correlated with an ~40% decrease in rOat1 protein expression in 
kidney homogenates and basolateral membrane preparations from CRF rats. Rat Oat3 protein 
levels were also significantly reduced in kidney homogenates, but not in the basolateral 
membranes (59). Finally, Naud, et al. detected reduced rOat1 (~40%), rOat2 (~40%), rOat3 
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(~87%), and rUrat1 (~38%) proteins in CRF vs. control animals 42 days after surgery, but renal 
clearance was not examined in these animals (58). 
While this model has the potential to yield much information on the effects of CRF on renal 
OAT expression and function, several important differences between these studies need to be 
noted (57-59). First, while described generically as 5/6 nephrectomized animals, the 
methodologies used to establish the model varied considerably, with one study removing the 
right kidney and ligating the posterior and anterior segmental branches of the left renal artery in a 
single operation (57), and the others utilizing a “two-stage 5/6 nephrectomy” procedure wherein 
the two poles of the left kidney were removed in one operation, followed by removal of the right 
kidney during a second operation one week later (58, 59). Second, as indicated, the interval post-
surgery when the observations were made varied widely between the studies. Third, the origins 
of the antibodies used to visualize the OATs via immunoblotting, and the predicted weights of 
the protein bands detected, differed. Ji et al., developed custom antibodies that detected ~77 kD 
and ~72 kD bands for rOat1 and rOat3, respectively. These bands are bigger than the predicted 
molecular weights of ~61 kD for rOat1 and ~59 kD for rOat3, however there is evidence 
supporting post-translational glycosylation of OATs in vivo. Their findings are in good 
agreement with published results with a polyclonal antibody directed against hOAT1 which 
recognized an ~80 kD band in crude renal cortex homogenate that was reduced to ~60 kD upon 
treatment with glycosidase, and matched an ~60 kD band corresponding to an unglycosylated 
hOAT1 in vitro transcription/translation reaction product (60). The study by Torres, et al. used a 
commercial rOat1 antibody (Alpha Diagnostics, Inc.) and reported an ~57 kD rOat1 band, and a 
custom rOat3 antibody and reported an ~130 kD band for rOat3 (59). As indicated above, the 
result for rOat1 would correspond nicely with its unglycosylated form, however, these were 
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native kidney homogenates and no glycosidase treatment was performed. Since the protein 
samples were reduced (boiled in the presence of mercaptoethanol and sodium dodecyl sulfate) 
the reported rOat3 signal seems unexpectedly large. Naud, et al. used all commercial antibodies, 
with anti-rOat1 and anti-rUrat1 from Abbiotec and anti-rOat2 and anti-rOat3 from Alpha 
Diagnostics, Inc., and did not report the predicted molecular weight for any of the detected bands 
(58). To aid interpretation of future studies it may be useful to standardize the 5/6 nephrectomy 
surgical techniques used, optimize/standardize the time post-surgery experiments are conducted, 
and perform more rigorous antibody characterizations prior to use, e.g., comparison of signal 
across preparations from transporter expressing cell lines and/or transporter knockout mouse 
tissues to confirm specificity/lack of cross-reactivity and predicted molecular weight of detected 
protein(s). 
In contrast to CRF, even a small reduction in renal blood flow can lead to hypoxic injury 
and/or acute renal failure (ARF). ARF is commonly seen in critically ill patients and exhibits a 
mortality rate exceeding 50% (61). Ischemia/reperfusion injury associated with disease or 
physical injury is a common trigger for ARF, and once induced, ARF can lead to a systemic 
build up of uremic toxins via a combination of reduced GFR and impaired tubular transport. 
Ischemia/reperfusion injury is also observed in kidneys utilized for transplant and can result in 
marked impairment of PAH extraction (62). This observation led to immunohistochemical 
studies examining the cellular distribution of hOAT1 in biopsies obtained from cadaveric renal 
allografts 1 hour post-reperfusion (63). While most allografts were seen to maintain some degree 
of basolaterally targeted hOAT1, it appeared to be greatly reduced as compared to control tissues 
and was accompanied by the appearance of fine and coarse ‘cytoplasmic aggregates’ positive for 
hOAT1 (63). This correlated with depressed net tubular secretion of PAH in 15 out of 18 patients 
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examined 3-7 days post-transplant (63). No clear association between total ischemic time, which 
varied from 13-32 hours, could be made and it should be noted that patients were taking a 
number of drugs known to interact with hOAT1 and hOAT3 when PAH secretion was measured. 
None-the-less, these data support the contention that renal organic anion transport impairment 
observed in some instances of disease, injury, or transplant induced ARF might be due to loss of 
OATs in the proximal tubule cell membranes. 
Experimentally induced ARF, achieved via clamping of the renal arteries, is a common 
approach used to model this type of renal injury in the laboratory. When this same group 
examined localization of rOat1 in the induced ARF model, redistribution of rOat1 was 
observable with as little as 5 minutes of ischemia, but the amount of rOat1 protein did not 
diminish until 1 hour post-reperfusion, and was still not fully recovered after 10 days (64). A 
similar study examined rOat1 and rOat3 expression for 14 days following ischemia induced ARF 
(65). Both transporter proteins showed a similar response to ARF, exhibiting a significant 
reduction (~50%) from 6 hours to 3 days post-ischemia, returning to control levels by 7 days 
post-injury (65). This loss and recovery of transporter protein levels correlated with effects on 
the net renal secretion of PAH (a measure insulated from changes in GFR), which was 
significantly reduced from 6 hours to 3 days post-reperfusion as compared to sham-operated 
animals, returning to control levels by 7 days (65). Matsuzaki et al. also reported down-
regulation of rOat1 and rOat3 protein expression level in rat kidney 48 hours after ischemia (66). 
Significant decline in accumulation of PAH and estrone sulfate in renal slices from ARF animals 
suggested reduced transport capacity mediated by rOat1 and rOat3 (66). Interestingly, 
administration of cobalt, a treatment proposed to stabilize hypoxia inducible factor 1, an oxygen-
sensitive transcription factor which serves to upregulate certain genes under low oxygen 
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conditions, significantly blunted the downregulation of rOat3 protein, partially restoring estrone 
sulfate accumulation in renal slices (66). The treatment was without effect on rOat1 or PAH 
accumulation (66). 
The apical transporter rOat5 also has been demonstrated to be downregulated in response to 
ischemia induced ARF (67). When examined 1 hour post-reperfusion after 5 minutes of ischemia, 
no change in rOat5 protein level was detected in renal homogenates or apical membrane 
preparations. However, if ischemia was maintained for 1 hour, a significant reduction (~40%) in 
rOat5 was observed (67). Regardless, rOat5 protein levels detected in urine (relative to urinary 
creatinine) were significantly elevated 1 hour after either 5 or 60 minutes of ischemia, leading 
the authors to suggest that urinary excretion of rOat5 protein may serve as a sensitive, non-
invasive measure of renal functional and structural integrity following renal injury or during 
renal dysfunction (67). Since there is no identified human ortholog of rodent Oat5, the clinical 
utility of this finding is unclear. However, urinary hOAT1, hOAT3, and hOAT4 protein levels 
were recently examined in patients diagnosed with acute kidney injury (AKI) (68). Two AKI 
patient groups were identified, those who recovered without intervention (“early reversible 
proximal tubular damage”) and those who required intervention in the form of dialysis (“severe 
AKI”). Patients who suffered “early reversible proximal tubular damage” exhibited increased 
urinary levels of hOAT1 and hOAT3, but decreased levels of hOAT4, as compared to controls, 
and patients experiencing “severe AKI” exhibited increased urinary levels of all three 
transporters (68). The authors speculated that in patients with “early reversible proximal tubular 
damage” the transporters became mistargeted, with basolateral hOAT1 and hOAT3 translocating 
to the apical membrane and sloughing into the urine with apical hOAT4 moving ‘inward’, 
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whereas “severe AKI” resulted in proximal tubule cell apoptosis. Whether such a profound 
mechanism is the underlying cause of the observed patterns is unclear at this time. 
There is clear evidence that prostaglandin E2 (PGE2) plays a role in the downregulation of 
OAT1/Oat1 and OAT3/Oat3 in response to ARF and CRF. Dose-dependent downregulation of 
both rOat1 and rOat3 protein expression by PGE2 (IC50 ~25 nM) was demonstrated in NRK-52E 
cells, which are a rat renal proximal tubular cell model (69). Cortical PGE2 levels are elevated in 
response to ARF and CRF and inhibition of the cyclooxygenase (COX) cascade was shown to 
exert protective effects (70-72). Since COX-1 and COX-2 mediate prostaglandin synthesis from 
arachidonic acid, it is thought that COX inhibitors work by preventing generation of cortical 
PEG2 in response to injury. Accordingly, in the ischemia/reperfusion rat model, administration of 
the nonselective COX inhibitor indomethacin (1 mg/kg) immediately post-ischemia completely 
reversed ARF-induced downregulation of rOat1 and rOat3 protein expression levels within 24 
hours (73). Moreover, renal PAH net secretion was also recovered (73). In a different study, the 
COX-2 specific inhibitor, parecoxib, was found to produce similar effects when administered 1 
hour (20 mg/kg intraperitoneally) prior to the start of ischemia (74). When examined 12 hours 
post-reperfusion both rOat1 and rOat3 protein levels were significantly higher than in ARF 
animals that did not receive parecoxib, however the levels were still significantly reduced as 
compared to sham control animals (74). Similarly, PAH secretion was markedly restored in 
parecoxib animals, but still blunted as compared to sham controls (74). Whether this difference is 
due to the shorter duration post-reperfusion that the animals were examined (12 vs. 24 hours) or 
to the more selective action of parecoxib vs. indomethacin is not known. Together, these data 
strongly implicate induced PGE2 as being responsible for the downreguation of OATs observed 
in CRF, ARF, and human renal allografts. 
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1.F OATs AND DRUG-DRUG INTERACTIONS 
Following the development of probenecid as an agent to block the renal elimination of 
penicillin almost 70 years ago, clinical reports of probenecid-mediated DDIs resulting in altered 
distribution and renal elimination of a variety of drugs, including other β-lactams, cephalosporin 
antibiotics, fluoroquinolone antimicrobials, diuretics, and chemotherapeutic agents, began to 
appear (75-78). Modern studies using cloned transporters and knockout mouse lines have 
demonstrated a clear role for OATs in mediating, at least in part, a number of these DDIs (3, 79-
85). Recently, a clinical study using healthy volunteers demonstrated that when probenecid was 
administered concomitantly with mesna, a cancer chemotherapy adjuvant used to decrease the 
renal toxicity of some chemotherapeutic agents, the fraction of mesna secreted was reduced by 
67% and total mesna renal clearance was decreased by 55% (86). Moreover, hOAT1, hOAT3, 
and hOAT4 were demonstrated to mediate the probenecid-sensitive transport of mesna and 
dimensa in vitro, with inhibitory constants (Ki) in the ~15-30 µM range, values below their 
clinical concentrations, strongly implicating OATs in this DDI as well as having a vital role in 
the effectiveness of this therapy (86). 
Patients taking paravastatin and gemfibrozil in combination to control their cholesterol and 
triglyceride levels have experienced alterations in pravastatin pharmacokinetics (increased 
plasma levels and decreased renal clearance) and been reported to suffer from increased 
pravastatin-associated adverse events (87). Subsequent work indicated this DDI might be the 
result of gemfibrozil inhibition of hOAT3-mediated paravastatin transport in these patients (88). 
Another lipid altering agent, gemcabene, has been implicated in exacerbating blood pressure 
reduction when co-administered with the angiotensin converting enzyme inhibitor, quinapril, in 
hypertensive patients (89). When examined in vitro, gemcabene was found to inhibit hOAT3 
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transport of quinaprilat, the pharmacologically active quinapril metabolite, in a dose-dependent 
manner, suggesting a DDI involving hOAT3 as the molecular basis for the observed increase in 
pharmacological activity (89). 
Clearly, renally expressed OATs are poised to make great contributions to the 
pharmacokinetic profiles of many clinical therapeutics, having significant impact on their dosing 
regimens, pharmacodynamics, efficacy, and toxicity. OATs have great potential to be the sites for 
many clinically relevant DDIs, and the conclusive identification of their contributions to such 
interactions is expanding. In recognition of these facts, a recent whitepaper by the “International 
Transporter Consortium” (90), in conjunction with guidance documents issued by the United 
States Food and Drug Administration (FDA) 
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM292362.pdf) and by the European Medicines Agency 
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?
webContentId=WC500090112&murl=menus/document_library/document_library.jsp&mid=WC
0b01ac058009a3dc&jsenabled=true), have provided recommendations concerning which 
transporters are thought to have sufficient evidence regarding their impact on drug disposition 
and pharmacokinetics (e.g., hOAT1, hOAT2, and hOAT3) to warrant investigation of new 
molecular entities for interactions, as a substrate or inhibitor, during the drug development 
process. In the whitepaper, it was recommended that in vitro studies with transporter expressing 
cell lines should be conducted to determine if the compound is a substrate, if the renal clearance 
is greater than or equal to 50% of the total clearance (considered to be substantial and clinically 
important) and greater than 1.5 times the unbound fraction times the GFR (90). The FDA 
guidance recommends that greater than 2 fold accumulation over background in transporter 
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expressing cells is necessary to regard the compound as a substrate. If these conditions are met, 
clinical DDI studies should be considered. For compounds found to be inhibitors of these 
transporters, if the ratio of the unbound maximum serum level (Cmax or Css) divided by the 
compound-specific inhibition potency (Ki or IC50) is greater than or equal to 0.1, clinical DDI 
studies are recommended. In 2010, VanWert et al. provided a comprehensive table on OATs 
summarizing the orthologs studied, compounds reported to interact with each of the OATs, 
whether they were confirmed substrates or only examined as inhibitors, and their affinities 
(reported Km, Ki, or IC50 values) that is a useful reference tool when exploring such assessments 
(3). In Appendix I of this work we provide an update to the 2010 table, focusing on recent 
publications (2010-2012) in this area. 
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1.G CONCLUSIONS 
Over the last fifteen years great progress has been made in identifying the biological 
properties, physiological roles, and biopharmaceutical significance of OATs. However, more 
effort is required to better define the role of OATs in ‘normal’ physiology, their changing 
function across an organism’s lifespan, and their response to toxic exposure, whether 
environmental or as part of disease progression. While single nucleotide polymorphisms (SNPs) 
have been identified in both coding and regulatory regions of hOAT1, hOAT3, hOAT4, and 
hURAT1, most identified SNPs have failed to significantly impact OAT expression and function 
(91-96). Thus, modulations in OAT expression and transport activity through transcriptional and 
post-translational mechanisms might exert greater influence on the individual variations in 
pharmacokinetics and drug efficacy observed in clinical investigations, at different 
developmental stages (e.g., pediatric vs. geriatric), and during progression of certain diseases 
(97-99). A more thorough understanding of these processes, in addition to OAT substrate 
specificity, might lead to new approaches for protecting renal function after injury or toxic insult, 
or for manipulating renal secretory or reabsorptive pathways to more effectively remove or 
reclaim endogenous metabolites and xenobiotics. Greater insight to the pathophysiogical changes 
to normal renal proximal tubule cell functions vital to OAT activity, e.g., production of the 
intracellular mono- and dicarboxylates utilized as counterions by exchangers, would also be 
invaluable. As we move forward in our study of renal OAT function and make determinations as 
to the likely significance of DDIs involving OATs we need to remember that, while we have 
come a long way, there is still much we do not know and this changing context (e.g., 
developmental stage, long-term polypharmacy, disease) might transcend a previously trivial 
interaction to one of great significance. 
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CHAPTER 2 
 
 
 
RESEARCH HYPOTHESES AND SPECIFIC AIMS 
 
 
 
 
 
 
2.A HYPOTHESES: 
2.A.1 Flavonoids, phenolic acids, and other organic acid components of natural products exhibit 
significant inhibitory effects on human OATs (e.g., hOAT1, hOAT3, and hOAT4) and their 
murine orthologs (e.g., mOat1 and mOat3).  
2.A.2 Compounds identified as strong OAT inhibitors have the potential to perpetrate 
transporter-mediated drug-drug interactions based on their affinity (Ki and IC50) and clinical 
unbound plasma concentration. 
2.A.3 Compounds identified as strong OAT inhibitors and undergone active tubular secretion 
have the potential to be substrates for OATs.  
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2.B SPECIFIC AIMS TO ADDRESS THE ABOVE HYPOTHESES: 
2.B.1 SPECIFIC AIM 1 
To characterize the inhibitory effects of components of natural products on transport activity 
mediated by human (h) OATs, hOAT1, hOAT3, and hOAT4 and the murine orthologs mOat1 
and mOat3 using stably-expressing cell lines and radiolabeled prototypical substrates and known 
OAT inhibitors. 
2.B.2 SPECIFIC AIM 2 
1. To determine initial rates of cellular transport of prototypical substrates in OAT expressing 
cells and estimate the Km values for individual transporters. 
2. To estimate IC50 and Ki values for the selected compounds for individual transporters. 
3. To collect clinical literature values for unbound plasma concentrations of the selected 
compounds and calculate the DDI index (ratio of unbound Cmax/ IC50 (or Ki) based on 
“Guidance for Industry: Drug Interaction Studies” recently issued by the FDA. 
2.B.3 SPECIFIC AIM 3 
1.  To develop a robust, specific, and sensitive liquid chromatography tandem mass spectrometry 
(LC-MS/MS)-based method for quantification of gallic acid and gentisic acid in cell lysate. A 
complete method validation, required by “Guidance for Industry: Bioanalytical Method 
Validation” issued by the FDA, will be conducted to evaluate sensitivity, selectivity, within-
run and between-run precision and accuracy, recovery, stability, and matrix effects. 
2. To apply the developed assay on the measurement of the cellular uptake of gallic acid and 
gentisic acid in stably transfected mOat1- and mOat3-expressing cells. 
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CHAPTER 3 
 
 
 
ACTIVE HYDROPHILIC COMPONENTS OF THE MEDICINAL HERB SALVIA 
MILTIORRHIZA (DANSHEN) POTENTLY INHIBIT ORGANIC ANION 
TRANSPORTERS 1 (SLC22A6) and 3 (SLC22A8) 
 
Drawn from manuscript published in Evid Based Complement Alternat Med. vol.2012, Article ID 
872458, 8 pages, 2012. 
 
 
 
 
 
 
3.A INTRODUCTION 
The Chinese herbal medicine, Danshen (Salvia miltiorrhiza), has been employed for 
thousands of years in the relief of symptoms of cardiovascular disease (100-102).  Despite this 
long history of medicinal use, the issue of which component(s) is(are) responsible for its 
therapeutic effects, and the precise biochemical mechanisms underlying their absorption, 
distribution and elimination, remain largely unknown. Increasingly, six hydrophilic compounds, 
lithospermic acid (LSA), protocatechuic acid (PCA), rosmarinic acid (RMA), salvianolic acid A 
(SAA), salvianolic acid B (SAB), and tanshinol (TSL), are gaining favor as the Danshen 
components responsible for the beneficial effects on heart disease (103-105). Since these 
compounds are organic, small in size (154-718 Da), and exist as anions at physiological pH, it is 
possible that they are substrates and/or inhibitors of the organic anion transport pathway that 
exists in organs such as the kidney, liver, intestine, and choroid plexus (3). 
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We now know that this organic anion transport pathway is actually a complex system of 
transport proteins that belong to a variety of gene families. Members of the solute carrier (SLC) 
superfamily, composed of ~55 gene families containing almost 400 identified transporters, are an 
important component of this pathway (2, 3, 106). Of particular interest for the Danshen 
components examined in this work is the SLC22 (organic cation/anion/zwitterion transporters) 
family, which includes both the organic cation transporters and the organic anion transporters 
(OATs). Members of the OAT family are found in virtually every barrier tissue in the body and 
mediate the transepithelial flux (absorption, distribution and elimination) of a multitude of 
endogenous and xenobiotic compounds (2, 3, 106). Typical endogenous OAT substrates include 
sulfated steroid conjugates, indoxyl sulfate, uric acid, and acidic metabolites of monoamine 
neurotransmitters. Xenobiotic substrates include clinically important therapeutics such as 
antibiotic (benzylpenicillin), antiviral (adefovir, cidofovir) and anticancer (methotrexate) agents, 
statins, and angiotensin-converting enzyme inhibitors, as well as environmental toxins such as 
ochratoxin A and aristolochic acid (2, 3, 36)  
Currently, there are 29 putative SLC22 family members, 18 of which are believed to be 
OATs. Of those, transport activity has been demonstrated for eleven, OAT1-10 and URAT1 (2, 
3). OATs expressed in the proximal tubule cells of the kidney mediate the blood to urine 
secretory flux and urine to blood reabsorptive flux of substrate compounds (2, 3, 106). Since 
these compounds are negatively charged, OATs provide a passageway through which they can 
readily cross the lipid bilayer of cells. Substrate entry into proximal tubule cells from the blood 
across the basolateral membrane is energized by exchange for intracellular α-ketoglutarate (i.e., 
organic anion/dicarboxylate exchange). In humans and rodents this process involves the 
basolateral exchangers, organic anion transporter 1 (Oat1; Slc22a6) and 3 (Oat3; Slc22a8) (107, 
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108). OAT-mediated exit of organic anions from the cell into the urine is accomplished via 
facilitated diffusion using the electrochemical gradient. There appears to be distinct species 
differences between rodents and humans in terms of OATs targeted to the apical membrane of 
proximal tubule cells. For example, while both species express Urat1 (Slc22a12), humans also 
have OAT4 (SLC22A9; no current rodent ortholog), whereas rodents have Oat5 (Slc22a19; no 
human ortholog identified) (2, 3). 
The basolateral uptake transporters Oat1 and Oat3 share a high degree of amino acid 
sequence identity (mOat1 vs. mOat3 = 48% and hOAT1 vs. hOAT3 = 50%). This protein 
homology likely contributes to the greatly overlapping substrate profiles exhibited by these two 
transporters. However, despite this general similarity, the individual affinities for the same 
substrate often differ greatly between Oat1 and Oat3 (3). Further, unique substrates that interact 
with Oat1, but not with Oat3 (and vice-versa) have been identified (3). Preclinical in vivo studies 
utilizing knockout mouse lines have also demonstrated that, in terms of renal transport function, 
expression of Oat1 does not fully compensate for loss of Oat3 (and vice-versa) (80-82, 85). For 
example, Oat1 knockout mice exhibited complete loss of active tubular para-aminohippuric acid 
(PAH) secretion and decreased renal clearance of the diuretic, furosemide, which was 
accompanied by significantly decreased efficacy (monitored as decreased natriuresis and 
increased ED50) (85). Pharmacokinetic studies performed in Oat3 knockout mice detected 
reduced clearance and increased plasma half-life of benzylpenicillin, ciprofloxacin, and 
methotrexate (80-82). However, PAH clearance was unaffected in these animals (81). 
To more fully understand the therapeutic efficacy (and/or adverse effects) of herbal products 
and optimize their clinical use, a more thorough identification of the active components they 
contain and greater knowledge of the mechanisms determining their pharmacokinetic and 
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pharmacodynamic properties, e.g., transporter interactions, need to be elucidated. The aim of the 
present study was to characterize the effects of six active hydrophilic Danshen components on 
the transport activity of mOat1 and mOat3. Danshen components producing the greatest 
inhibition were examined further in studies designed to elucidate the mechanism of inhibition 
(competitive vs. non-competitive vs. uncompetitive). Combining this information with dose 
response data we derived inhibitory constants (Ki values). Evidence was gathered showing that 
LSA, RMA, and SAA serve as potent competitive inhibitors of mOat1 and mOat3 and indicating 
the potential for marked herb-drug interactions, such as altered pharmacokinetics and 
pharmacodynamics of co-administered clinical therapeutics that are OAT substrates. 
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3.B MATERIALS AND METHODS 
3.B.1 Purified chemicals 
The Danshen components LSA, PCA, RMA, SAA, SAB, and TSL (≥ 96% purity) were 
obtained from Tauto Biotech (Shanghai, China). Their chemical structures are illustrated in 
Figure 3.1. Tritiated PAH ([3H]PAH) and estrone sulfate ([3H]ES) were purchased from 
PerkinElmer Life and Analytical Sciences (Waltham, MA) and unlabeled PAH, ES, and 
probenecid were purchased from Sigma-Aldrich (St. Louis, MO).   
3.B.2 Tissue culture 
Derivation of the stably transfected Chinese hamster ovary (CHO) cell lines expressing 
mOat1 (CHO-mOat1), mOat3 (CHO-mOat3), and the empty vector (FRT) transfected control 
cell line (CHO-FRT), was described previously (80, 82). Cell lines were maintained at 37°C with 
5% CO2 in DMEM F-12 media (Mediatech, Inc., Herndon, VA) containing 10% serum, 1% 
Pen/Strep and 125 µg/ml hygromycin B. 
3.B.3 Cell accumulation assays 
Cell transport assay procedures were adapted from those previously published (82, 109). In 
brief, 2 × 105 cells/well were seeded in 24-well tissue culture plates and grown in the absence of 
antibiotics for 48 hr. On the day of the experiment cells were equilibrated with transport buffer 
for 10 min [500 µL of Hanks’ balanced salt solution containing 10 mM HEPES, pH 7.4]. 
Equilibration buffer was replaced with 500 µL of fresh transport buffer containing 5 µM 
[3H]PAH or 1 µM [3H]ES (0.25 µCi/mL) with or without inhibitors. After incubation, cells were 
immediately rinsed three times with ice-cold transport buffer, lysed, and analyzed via liquid 
scintillation counting. Uptake values were normalized to corresponding total protein content in 
cell lysates as determined by the Bradford method. Substrate accumulation is reported as  
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Figure 3.1. Chemical structures of six active hydrophilic Danshen components.  
 
MW, molecular weight. 
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picomoles of substrate per milligram protein. Substrate concentration and accumulation time 
used for kinetic analysis of mOat3 (1 µM ES for 1 min, Km = 12.2 ± 4.8 µM) were determined 
previously (82). Substrate concentration (Figure 3.3) and accumulation time (data not shown) for 
mOat1 kinetic analysis (5 µM PAH for 2 min, Km = 13.0 ± 3.3 µM) were determined in this 
study. Kinetic calculations were performed using GraphPad Prism Software version 5.0 
(GraphPad Software Inc., San Diego, CA). Michaelis constant (Km) values were calculated by 
nonlinear regression using the Michaelis-Menten model. Mode of inhibition was identified by 
using mixed model inhibition analysis (110): 
 
where Vmax, Ki, and I represent the maximum transport velocity without inhibitor, the inhibition 
constant generated from the data set under analysis, and the concentration of inhibitor, 
respectively. In this study, three curves were constructed (no inhibitor, plus two selected 
inhibitor concentrations) with uptake of substrate plotted as a function of its concentration for 
each condition. These untransformed data were fit to the equations shown above using nonlinear 
regression to estimate the α values summarized in Table 3.1. The parameter, α, can then be used 
to determine the mode of inhibition. When α is very large (α > 1), it indicates competitive 
inhibition. Otherwise, it indicates noncompetitive inhibition (α = 1) or uncompetitive inhibition 
(0 < α < 1). To estimate Ki values, IC50 values were calculated using nonlinear regression and 
inserted into the Cheng-Prusoff equation: Ki = IC50/(1 + [Substrate]/Km) (111). Results were 
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confirmed by repeating all experiments at least three times with triplicate wells for each data 
point in every experiment. 
3.B.4 Statistics 
Data are reported as mean ± S.D. or mean ± S.E.M. as indicated. Statistical differences were 
assessed using one-way ANOVA followed by post-hoc analysis with Dunnett’s t-test or using 
Student’s unpaired t-test, as indicated (α = 0.05). 
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3.C RESULTS 
3.C.1 Inhibition of mOat1 and mOat3 by hydrophilic Danshen components 
Accumulation of PAH in the CHO-mOat1 cell line (98.5 ± 14.6 pmol/mg protein/10 min) 
was ~30 fold greater than that in the background control CHO-FRT cells (3.3 ± 0.7 pmol/mg 
protein/10 min; Figure 3.2A). Initially, an uptake assay with excess (1 mM) Danshen 
components was performed to identify which, if any, of the compounds might interact with 
mOat1 (Figure 3.2A). Each of the Danshen components, LSA, PCA, RMA, SAA, SAB, and TSL, 
significantly inhibited PAH uptake in CHO-mOat1 cells (P < 0.001) under these conditions. LSA, 
SAB, and TSL produced approximately 70-85% inhibition, whereas PCA, RMA, and SAA, each 
reduced PAH accumulation to the background level (> 95% inhibition), similar to the 
prototypical OAT inhibitor, probenecid. Further, addition of these compounds (1 mM) did not 
significantly influence the low, probenecid-insensitive (i.e., non-specific) PAH uptake in the 
CHO-FRT cells (data not shown), indicating that the reduction in uptake of PAH in the CHO-
mOat1 cells is attributable to inhibition of mOat1 activity and that CHO-FRT PAH level serves 
as an appropriate background correction factor. 
Stably transfected mOat3-expressing (CHO-mOat3) cells showed significantly greater 
accumulation of ES (~20 fold) relative to control CHO-FRT cells (5.02 ± 0.19 vs. 0.25 ± 0.04 
pmol/mg protein/10 min, respectively; Figure 3.2B). Similar to mOat1, all of the Danshen 
components (1 mM) significantly inhibited mOAT3-mediated ES uptake (P < 0.001). SAB and 
TSL produced approximately 53% and 55% inhibition, respectively. LSA, PCA, RMA, and SAA, 
like probenecid, blocked virtually all (> 91%) mOat3-mediated ES transport (Figure 3.2B). As 
with PAH, these compounds (1 mM) failed to consistently or significantly influence non-specific 
ES uptake in CHO-FRT cells (data not shown), indicating that the reduction in uptake of ES in  
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Figure 3.2. Inhibition profile of mOat1 and mOat3 
 
A: Inhibition of mOat1-mediated uptake of [3H]PAH (5 µM) by LSA, PCA, RMA, SAA, SAB, 
TSL, and probenecid (1000 µM) was measured in the CHO-mOat1 cells (10 min). Background 
PAH accumulation was measured in CHO-FRT cells in the absence of inhibitor and is shown to 
provide a clear gauge of the low background in the experimental system. B: Inhibition of mOat3-
mediated uptake of [3H]ES (1 µM) by LSA, PCA, RMA, SAA, SAB, TSL, and probenecid (1000 
µM) was measured in the CHO-mOat3 cells (10 min). Background ES accumulation was 
measured in CHO-FRT cells in the absence of inhibitor and is shown to provide a clear gauge of 
the low background in the experimental system. Values are mean ± S.D. of triplicate values. *** 
denotes p < 0.001 as determined by one-way ANOVA followed by Dunnett’s t-test. 
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the CHO-mOat3 cells is attributable to inhibition of mOat3 activity and that CHO-FRT ES level 
serves as an appropriate background correction factor. 
3.C.2 Determination of the type of inhibition induced by Danshen components on mOat1 and 
mOat3 
Although PCA exhibited as potent inhibition as LSA, RMA, and SAA, it is not a major 
component in Danshen preparations. Therefore, the mechanism of inhibition of mOat1/mOat3-
mediated transport of PAH/ES was investigated for LSA, RMA, and SAA (Table 3.1). Our 
previous work with CHO-mOat3 cells showed that ES accumulation was linear through the first 
5 min and that ES exhibited a Km of 12.2 ± 4.8 μM (82). In this study, time course evaluations in 
CHO-mOat1 cells indicated PAH accumulation was linear through at least the first 5 min and Km 
was estimated as 13.0 ± 3.3 μM (Figure 3.3). Using these parameter estimates as guidelines, 
kinetic experiment conditions were set to 1 µM ES for 1 min and 5 µM PAH for 2 min. The 
background corrected untransformed data for LSA, RMA, and SAA on mOat1 or mOat3 were fit 
to the mixed inhibition model, which incorporates competitive, non-competitive, and 
uncompetitive inhibition modes. The estimated α values were found to be much larger than 1, 
indicating that inhibition of mOat1- and mOat3-mediated transport by LSA, RMA, and SAA was 
competitive in nature (Table 3.1). 
3.C.3 Inhibition potencies of LSA, RMA, and SAA 
To allow direct comparison of inhibition potencies of LSA, RMA, and SAA for mOat1 and 
mOat3, experiments were conducted to determine the inhibition constant (Ki) values (Figures 3.4 
and 3.5 and Table 3.2). Since LSA, RMA, and SAA were found to be competitive inhibitors of 
mOat1- and mOat3-mediated transport, subsequent Ki analysis was performed using competitive 
inhibition. Applying increasing concentrations of unlabeled test compounds (10-7 to 5×10-4 M), 
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inhibition of mOat1- or mOat3-mediated transport was measured (Figures 3.4 and 3.5). 
Inhibition constants were estimated as 14.9 ± 4.9 µM for LSA, 5.5 ± 2.2 µM for RMA, and 4.9 ± 
2.2 µM for SAA on mOat1-mediated transport (Table 3.2). Values determined in the CHO-
mOat3 cell line were 31.1 ± 7.0 µM for LSA, 4.3 ± 0.2 µM for RMA, and 21.3 ± 7.7 µM for 
SAA (Table 3.2). For all of these analyses the coefficient of determination (r2) was > 0.9. No 
significant differences between Ki values for mOat1 and mOat3 were detected as determined by 
a Student’s unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Michaelis-Menten kinetics of PAH transport in CHO-mOat1 cells 
 
In order to calculate Ki values for mOat1, the Km value for PAH needed to be determined in the 
CHO-mOat1 cell system. Uptake of [3H]PAH was measured for 2 min at room temperature in 
CHO-mOat1 (closed triangles) and CHO-FRT (open squares) cells in order to construct a 
saturation curve. The corrected curve (closed circles) was obtained by subtracting the non-
specific background uptake as measured in the CHO-FRT cells from CHO-mOat1 accumulation 
to allow analysis of mOat1-mediated activity. Experiments were repeated three times in triplicate 
and Michaelis constant (Km) values were calculated by nonlinear regression using the Michaelis-
Menten model. The Km for PAH on mOat1 was estimated as 13.0 ± 3.3 μM (mean ± S.E.M.). 
Graph shown is from a representative experiment with values plotted as mean ± S.D. (n=3). 
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Figure 3.4. Ki determination for LSA, RMA, and SAA in the CHO-mOat1 cell line 
 
Two minute uptake of [3H]PAH (5 µM) in CHO-mOat1 cells was measured in the presence of 
increasing concentrations (10-7 to 5×10-4 M) of LSA, RMA, and SAA. Data were corrected for 
non-specific background measured in the CHO-FRT cells prior to kinetic analysis. Ki values 
were determined with non-linear regression and the “one-site competition” model using 
GraphPad Prism software. Experiments were repeated three times in triplicate with the mean Ki 
± S.E.M. reported in Table 3.2. Graphs shown are from representative experiments with values 
plotted as mean ± S.D. (n=3). 
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Figure 3.5. Ki determination for LSA, RMA, and SAA in the CHO-mOat3 cell line 
 
One minute uptake of [3H]ES (1 µM) in CHO-mOat3 cells was measured in the presence of 
increasing concentrations (10-7 to 4×10-4 M) of LSA, RMA, and SAA. Data were corrected for 
non-specific background measured in the CHO-FRT cells prior to kinetic analysis. Ki values 
were determined with non-linear regression and the “one-site competition” model using 
GraphPad Prism software. Experiments were repeated three times in triplicate with the mean Ki 
± S.E.M. reported in Table 3.2. Graphs shown are from representative experiments with values 
plotted as mean ± S.D. (n=3). 
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Table 3.1. Estimated α values from a mixed inhibition model analysis for LSA, RMA, and 
SAA 
 
Compound mOat1 mOat3 
LSA 6.7 × 1011 1.9 × 1015 
RMA 1.3 × 1012 2.5 × 1019 
SAA 2.6 × 1014 3.4 × 1014 
 
Values are reported as mean. The S.E.M. is not applicable in this analysis. 
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Table 3.2. Estimated Ki (µM) values for mOat1- and mOat3-mediated transport 
 
Compound mOat1 mOat3 Ki Ratio (mOat1/ mOat3) 
LSA 14.9 ± 4.9 31.1 ± 7.0 0.48 
RMA 5.5 ± 2.2 4.3 ± 0.2 1.29 
SAA 4.9 ± 2.2 21.3 ± 7.7 0.23 
 
Values are reported as mean ± S.E.M. (n=3). No significant differences between Ki values for 
mOat1 and mOat3 were detected (P < 0.05) as determined by Student’s unpaired t-test. 
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3.D DISCUSSION 
Many natural products, which are extracted from living organisms, have beneficial biological 
or pharmacological activities and have been used as medicines throughout the world for more 
than 1,000 years. Today, they are often used as first-line therapeutics, dietary supplements, or 
complementary/alternative medicines and it is reported that ~20% of adults in the United States 
are taking an herbal product (112). Over the last decade a number of studies have identified 
transporter proteins, including OATs, as sites of drug-drug and natural product-drug interactions. 
For example, the dietary polyphenol, ellagic acid, which exhibits beneficial antioxidant and 
anticancer properties, was demonstrated to be one of the most potent inhibitors of hOAT1 (IC50 = 
207 nM) identified to date (48). Recently, the nephrotoxin aristolochic acid, which is produced 
by Aristolochia sp. plants, was identified as the causative agent for “Chinese herbs nephropathy” 
(now referred to as aristolochic acid nephropathy). When investigated, aristolochic acid was 
found to be a high affinity substrate for both mOat1 (Km = 790 nM) and mOat3 (Km = 514 nM), 
suggesting these transporters may be key mediators in the renal proximal tubule cell 
accumulation of this toxicant (36, 113). Thus, this interaction likely explains the biochemical 
mechanism underlying the acutely targeted, proximal tubule specific nature of aristolochic acid 
toxicity. Clearly, OATs expressed in the renal proximal tubule represent highly probable sites of 
natural product-drug (or natural product-endogenous substrate) interactions. Further studies such 
as these are needed in order to establish informed safety and efficacy profiles for herbal products. 
Danshen, a traditional herbal medicine, continues to be used in the treatment of angina, 
myocardial ischemia, and other cardiovascular diseases throughout the world including Asia, 
Europe, and North America (100). In 2010, the Danshen pharmaceutical product, Fufang 
Danshen Dripping Pill, successfully completed Phase II clinical trials in the United States 
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(http://clinicaltrial.gov/ct2/show/NCT00797953?term=tasly&rank=1). To date, however, no 
formal studies examining the interaction between OATs and hydrophilic Danshen compounds, 
which are small organic acids and known to be major components in its pharmaceutical products, 
have been reported. Therefore, in the present study we investigated whether any of the six 
purported active Danshen components, LSA, PCA, RMA, SAA, SAB, and TSL, interacted with 
the transporters mOat1 and/or mOat3 (Figures 3.1 and 3.2). 
A major advantage of this study is that, while Danshen preparations (and indeed the majority 
of herbal medicines) include multiple active components, purified preparations of individual 
Danshen extract components were used. Thus, the strength of interaction of each compound 
could be quantified independently vs. the merged effects of a mixture containing all of the 
compounds. Similarly, since the transporters were expressed in isolation, the interaction of each 
individual compound with each individual transporter could be specifically assessed vs. the in 
vivo situation where multiple transporter proteins are expressed simultaneously in a tissue and 
the measured response is possibly an amalgamation of the activities of multiple transporter 
proteins. While under certain conditions all six compounds significantly inhibited mOat1- and 
mOat3-mediated transport, LSA, RMA, and SAA emerged as potent competitive inhibitors, 
(Figures 3.4 and 3.5 and Tables 3.1 and 3.2). The rank order of their potencies was different 
between the two transporters with RMA ≈ SAA > LSA for mOat1 and RMA > SAA ≈ LSA for 
mOat3. While statistically not different, the Ki ratio (Table 3.2) suggests that mOat1 may have a 
slightly higher affinity (lower Ki) for LSA and SAA than mOat3. However, in general all of the 
values are quite similar and exhibit well below an order of magnitude in difference. The 
estimates are comparable to those reported for the strong OAT inhibitor, probenecid, Ki = 6.4 
and 4.6 µM for mOat1 and mOat3, respectively (114, 115). Thus, LSA, RMA, and SAA may 
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affect the disposition and elimination of co-administered drugs that are also mOat1 and mOat3 
substrates. This may be particularly relevant in patients suffering from coronary disease where 
Danshen pharmaceutical products could be combined with drugs such as angiotensin converting 
enzyme inhibitors and studies with the human orthologs of these transporters need to be 
conducted. 
In vivo pharmacokinetic studies have indicated that elimination of hydrophilic Danshen 
components involves active renal secretory pathways. In rats, the unbound renal clearance of 
TSL was ~5X greater than the glomerular filtration rate (116). A separate study in rats found that 
spiking additional SAA into Danshen preparations increased the AUC of SAB (82.4%) and TSL 
(26.7%), and markedly reduced their clearances (46.8% and 32.9% for SAB and TSL, 
respectively) (117). As we determined SAA was a potent competitive mOat1/mOat3 inhibitor, 
and SAB and TSL can interact with mOat1 and mOat3, our data suggest that these in vivo results 
may be explained by competition for transport on Oat1/Oat3. An in vivo pilot study conducted in 
healthy humans reported Cmax values for LSA and RMA of 2.1 μM and 6.7 μM after i.v. dosing 
of a Danshen product (104). These Cmax values are ~0.07-1.56 fold higher than the Ki values for 
mOat1 and mOat3 determined in the present study (Table 3.2). As recommended by the FDA 
Guidance for Drug Interaction Studies, when unbound Cmax/IC50(or Ki) ≥ 0.1, it indicates that 
drug-drug interactions may occur in vivo (118). Unfortunately, the plasma protein binding for 
LSA and RMA have not been reported, while TSL showed 25% plasma protein binding in rat 
plasma (116). However, if we assume RMA to be highly protein bound (90%), the unbound 
Cmax/Ki ratio for RMA would be 0.12 and 0.16 on mOat1 and mOat3, respectively, indicating 
potential for herb-drug interactions. Naturally, if human OAT orthologs show similar (or higher) 
affinities, possible herb-drug interactions should be considered.  
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A recent investigation indicated that flavonoid and hydroxycinnamic acid aglycones and their 
phase II metabolites (e.g., sulfate and glucuronide conjugates) significantly inhibit hOAT1 and 
hOAT3 transport activity (50, 119). It is known that after oral administration in healthy 
volunteers, the majority of RMA exists as such conjugated forms, as well (120, 121). Currently, 
there are no reports on characterization of LSA and SAA metabolites in human plasma, while 
SAA might undergo methylation and glucuronidation in rats (122). Therefore, studies elucidating 
the metabolic pathways of these compounds are needed such that potential interactions of their 
metabolites with Oat1 and/or Oat3 can be examined. 
In addition, there are other transporter families known to interact with small organic anions, 
e.g., the multidrug resistance associated proteins (MRPs, ABCC family) and the organic anion 
transporting polypeptides (OATPs, SLCO family). For the most part these latter two transporter 
families and the OATs have fairly distinct substrate interactions, however, the possibility that 
they also may contribute to the overall clinical pharmacokinetic profile of Danshen components 
in vivo needs to be considered until investigated directly. For example, it was recently suggested 
that SAB might be an OATP substrate based upon inhibition of total and biliary clearance of 
SAB by rifampicin, an OATP inhibitor, in rats (123). 
Finally, the amount of each active component in Danshen preparations varies with different 
cultivation regions and manufacturing processes (103). The variation of RMA in raw plant 
material was observed to be ~16 fold between different growing regions and the dose of RMA 
ranged from 4.1-160 mg (~40 fold) in injectable dosage forms produced by different 
manufacturers (103, 104). In a clinical study, the Cmax of RMA after i.v. infusion of a 160 mg 
dose was 1.2-1.6 fold higher than the Ki values for mOat1 and mOat3 (104). These data suggest 
that, clinically, patients either would or would not have the potential for significant herb-drug 
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interactions solely depending upon which manufacturer’s product they were administered. Thus, 
although tanshinone II A, SAB, and protocatechuic aldehyde have been used as quality control 
markers in the manufacture of Danshen pharmaceutical dosage forms, the work presented here 
indicates that perhaps the content of LSA, RMA, and SAA, should be monitored and controlled 
as well. 
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CHAPTER 4 
 
 
 
COMPETITIVE INHIBITION OF HUMAN ORGANIC ANION TRANSPORTERS 1 
(SLC22A6) AND 3 (SLC22A8) BY MAJOR COMPONENTS OF THE MEDICINAL 
HERB SALVIA MILTIORRHIZA (DANSHEN)  
 
Drawn from manuscript published in Drug Metab Pharmacokinet 2012; 28(3):220-8 
 
 
 
 
 
 
4.A INTRODUCTION 
Danshen, the dried root of Salvia miltiorrhiza, has been used as a traditional Chinese 
medicine for thousands of years in the treatment of angina, myocardial ischemia, and other 
cardiovascular diseases (100-102). In vitro and in vivo studies demonstrated that Danshen could 
improve microcirculation, facilitate coronary vasodilatation, and increase blood flow (124-127). 
Danshen products are readily available throughout the world including Asia, Europe, and North 
America, and annual sales volume is in the hundreds of millions of dollars (100). According to 
the China State Food and Drug Administration database of drug manufacturing certificates, there 
are currently more than 980 commercial Danshen preparations, 289 of which are injectable 
dosage forms (http://www.sda.gov.cn/WS01/CL0001/). The oral dosage form, Fufang Danshen 
Dripping Pill, was approved for Phase II and Phase III clinical trials by the United States Food 
and Drug Administration in 1997 (IND No. 56956). In 2010, the Phase II clinical trials were 
successfully completed (http://clinicaltrial.gov/ct2/show/NCT00797953?term=tasly&rank=1), 
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but no formal clinical trials for any injectable Danshen formulations have been reported. Use of 
the injectable products is of particular concern, as the spectra and amounts of the compounds 
they contain are not well standardized. More than 70 lipophilic and hydrophilic compounds have 
been separated and identified from Danshen extract (128). However, which component(s) is/are 
responsible for the beneficial pharmacological effects of Danshen is virtually unknown. Among 
hundreds of Danshen pharmaceutical products, lithospermic acid (LSA), rosmarinic acid (RMA), 
salvianolic acid A (SAA), salvianolic acid B (SAB), and tanshinol (TSL) exhibited markedly 
high content and were considered as major components (103-105). 
Currently, the clinical pharmacokinetic literature on Danshen is extremely limited. One study 
assayed LSA, RMA, SAA, SAB, and TSL in human urine and plasma samples obtained after 
oral dosing and found TSL was the only compound detectable (116). However, this study 
examined just a single formulation and dose. In contrast, LSA, RMA, SAA, SAB, and TSL were 
all detected after administration of an injectable Danshen preparation (104). To improve the 
clinical safety of Danshen herbal therapies (especially injectables), better estimation of the 
composition and dose of active components, as well as a greater knowledge of the processes 
affecting their pharmacokinetic and pharmacodynamic properties, including potential 
transporter-mediated herb-drug interactions, is required. 
Since these Danshen components are relatively small (198-718 Da) and exist as anions at 
physiological pH, it is possible that they are organic anion transporter (OAT; SLC22) family 
substrates or inhibitors. OATs are key mediators in the distribution and elimination of a 
multitude of endogenous compounds and xenobiotics, which include clinically important 
therapeutics such as antibiotics, antiviral and anticancer agents, statins, and angiotensin-
converting enzyme inhibitors (2, 3, 106). A number of clinical and pre-clinical studies have 
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demonstrated that concomitant administration of drugs that are eliminated from the body by 
renally expressed OATs may result in longer plasma half-life and reduced renal clearance. 
For example, co-administration of probenecid, a known OAT inhibitor, has been 
demonstrated to diminish the renal clearance of benzylpenicillin and ciprofloxacin (77, 129). In 
accord with these clinical findings, in vivo pharmacokinetic studies using organic anion 
transporter 3 (Oat3) knockout mice demonstrated that loss of murine Oat3 (mOat3) activity 
increased the plasma half-life and reduced the clearance of benzylpenicillin, ciprofloxacin, and 
methotrexate (80-82). Further, cephalosporin antibiotics, including cephaloridine, cephalothin, 
cefadroxil, cefamandole, cefazolin, cefoperazone, cefotaxime, and ceftriaxone, exhibited low 
inhibition constant (Ki) values for hOAT1 (0.03-6.14 µM), indicating the potential for drug-drug 
interactions during combined therapy with other therapeutics that are hOAT1 substrates (84). 
Recent work with the cancer chemotherapy adjuvants, mesna and dimesna, demonstrated in vitro 
that hOAT1 and hOAT3 transport these compounds and in vivo that concomitant probenecid 
administration reduced their renal elimination in healthy human volunteers (86). In addition, 
concomitant gemfibrozil administration was found to influence the pharmacokinetic properties of 
pravastatin in patients, increasing pravastatin-related adverse effects, and it has been proposed 
that the mechanism may be due to competition for hOAT3-mediated tubular secretion (87, 88). 
Similarly, co-administration of the lipid altering compound, gemcabene, with the angiotensin 
converting enzyme inhibitor, quinapril, resulted in a reduction in blood pressure in hypertensive 
humans and rats (89). In rats, co-dosing of gemcabene and quinapril resulted in significantly 
elevated plasma levels of quinaprilat, the pharmacologically active metabolite of quinapril (89). 
Further, in vitro experiments demonstrated dose-dependent inhibition of hOAT3- and rat Oat3-
mediated quinaprilat transport by gemcabene, at clinically relevant levels, implicating drug-drug 
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interaction on hOAT3 as the mechanism for elevated circulating levels of quinaprilat and greater 
pharmacological activity (89). In response to the increase in known transporter-mediated drug-
drug interactions such as these the United States Food and Drug Administration and the 
European Medicines Agency have issued guidance documents regarding circumstances under 
which drug interactions with specified transporters (including hOAT1 and hOAT3) need to be 
investigated 
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM292362.pdf 
and http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.js
p?webContentId=WC500090112&murl=menus/document_library/document_library.jsp&mid=
WC0b01ac058009a3dc&jsenabled=true). 
Our recent study investigating the inhibition profiles of LSA, RMA, SAA, SAB, and TSL on 
murine Oat1 and Oat3 (mOat1 and mOat3)-mediated substrate uptake demonstrated that LSA, 
RMA, and SAA exerted markedly stronger inhibitory effects compared to SAB and TSL (49). 
Kinetic analysis revealed that LSA, RMA, SAA were potent competitive inhibitors of both 
transporters, exhibiting Ki values ranging from 4.9-14.9 µM for mOat1 and from 4.3-31.1 µM 
for mOat3. However, the affinities of Danshen compounds with human OATs remained 
unknown, and the potential for marked species differences between transporter orthologs has 
been well documented (3). Therefore, the aim of the present study was to characterize the 
inhibitory effects of LSA, RMA, and SAA on para-aminohippuric acid (PAH) transport 
mediated by hOAT1 or estrone sulfate (ES) transport mediated by hOAT3. Further, studies 
designed to elucidate the mechanism of inhibition (competitive vs. non-competitive vs. 
uncompetitive) were also conducted. Using this information we derived inhibitory constants (Ki 
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values) for each compound to allow direct comparison of their potencies between transporter 
paralogs and orthologs. Finally, using published human pharmacokinetic values, unbound 
Cmax/Ki (recommended by FDA Guidance for Drug Interaction Studies) were calculated as an 
indicator of the in vivo drug-drug interaction potential for these compounds (49). Together, these 
data demonstrated that LSA, RMA, and SAA serve as potent competitive inhibitors of hOAT1 
and hOAT3 and that there is strong potential for herb-drug interactions, such as altered 
pharmacokinetics and pharmacodynamics of co-administered clinical therapeutics that are OAT 
substrates. 
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Figure 4.1. Chemical structures for the Danshen components LSA, RMA, and SAA.  
MW, molecular mass. 
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4.B MATERIALS AND METHODS 
4.B.1 Chemicals 
Purified (≥ 96.0%) lithospermic acid (LSA), rosmarinic acid (RMA), salvianolic acid A 
(SAA), were purchased from Tauto Biotech (Shanghai, China). The chemical structures are 
shown in Figure 4.1. Tritiated para-aminohippuric acid ([3H]PAH) and estrone sulfate ([3H]ES) 
were purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA).  Unlabeled 
PAH, ES, and probenecid were obtained from Sigma-Aldrich (St. Louis, MO). 
4.B.2 Tissue culture 
The derivation of stably transfected Chinese hamster ovary (CHO) cells expressing hOAT1, 
human embryonic kidney 293 (HEK) cells expressing hOAT3, and their corresponding empty 
vector transfected control cell lines, has been described previously (20, 29). The CHO and HEK 
cell lines were maintained at 37°C with 5% CO2 in DMEM F-12 or DMEM high glucose media 
(Mediatech, Inc., Herndon, VA) containing 10% serum, 1% Pen/Strep and either 1 mg/mL G418 
(CHO cell lines) or 125 µg/ml hygromycin B (HEK cell lines), respectively. 
4.B.3 Cell accumulation assays 
Accumulation assay protocols were adapted from those previously published (82, 109). In 
brief, cells were seeded in 24-well tissue culture plates (2 × 105 cells/well) and grown in the 
absence of antibiotics for two days prior to uptake assays. Before initiation of transport 
experiments, the cells were equilibrated with 500 µL of transport buffer [Hanks’ balanced salt 
solution containing 10 mM HEPES (Sigma-Aldrich, St. Louis, MO), pH 7.4] for 10 min. The 
equilibration buffer was replaced with 500 µL of fresh transport buffer containing 1 µM 
[3H]PAH or 1 µM [3H]ES (0.25 µCi/mL) in the presence or absence of inhibitors as indicated in 
the figure legends. Substrate concentration and accumulation time used for kinetic analysis of 
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hOAT1 (1 µM PAH for 3 min, Km = 15.4 µM) were based upon previous determinations in this 
cell line (130) and those for hOAT3 were determined in this study. After incubation for the 
indicated time, cells were immediately rinsed three times with ice-cold transport buffer, lysed 
with 1 M NaOH, and neutralized with 1 M HCl and 0.1 M HEPEs. Aliquots were removed for 
liquid scintillation counting and total protein determination using a Bio-Rad Protein Assay Kit 
(Bio-Rad Laboratories, Hercules, CA). Substrate accumulation was calculated as picomoles of 
substrate per milligram of protein. Michaelis constant (Km) and inhibition constants (Ki) were 
determined using nonlinear regression with the appropriate models in GraphPad Prism Software 
version 5.0 (GraphPad Software Inc., San Diego, CA). Mode of inhibition was identified by 
using mixed-model inhibition analysis as described in our previous work (49). The mode of 
inhibition was determined by the parameter α. Large value of α (α > 1) indicates competitive 
inhibition. Results were confirmed by performing experiments at least three times with triplicate 
samples. 
4.B.4 Statistics 
Statistical analysis was done with one-way ANOVA followed by post-hoc analysis with 
Dunnett’s t-test or using Student’s two-tailed unpaired t-test (α for significance set at 0.05). Data 
are reported as mean ± S.D. or mean ± S.E.M., as indicated. 
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4.C RESULTS 
4.C.1 Inhibitory effects of hydrophilic Danshen components on hOAT1 and hOAT3 function 
The stably transfected hOAT1-expressing (CHO-hOAT1) cell line exhibited marked (~5x) 
accumulation of PAH relative to empty vector-transfected CHO-ev (background) cells (Figure 
4.2A). CHO (background) cells exhibited a probenecid-insensitive background for PAH that was 
equal to ~20% of the total accumulation obtained in transporter expressing cells (CHO-ev 
(background): 0.93 ± 0.19 pmol/mg protein/10 min vs. CHO-hOAT1 (control): 4.39 ± 0.20 
pmol/mg protein/10 min). This non-specific PAH signal was not significantly influenced by 
addition of the Danshen compounds (1 mM), indicating that the reduction in substrate 
accumulation in CHO-hOAT1 cells is attributable to inhibition of hOAT1 activity and this value 
represents an appropriate background correction factor (data not shown). Rudimentary 
assessment of the ability of the three Danshen components (1 mM), LSA, RMA, and SAA, to 
inhibit hOAT1 revealed that, similar to the OAT inhibitor probenecid, each of the compounds 
significantly inhibited (> 83%) PAH uptake in CHO-hOAT1 cells (p < 0.001) under these 
conditions (Figure 4.2A).  
ES accumulation in hOAT3-expressing (HEK-hOAT3) cells was significantly greater of (~4-
fold) than that observed in empty vector-transfected HEK-ev (background) cells (HEK-ev: 2.46 
± 0.80 pmol/mg protein/10 min vs. HEK-hOAT3: 9.55 ± 1.41 pmol/mg protein/10 min, Figure 
4.2B). As with hOAT1, hOAT3-mediated uptake was significantly (p < 0.001) inhibited by each 
Danshen component (> 98% inhibition at 1 mM; Figure 4.2B). LSA, RMA, and SAA (1 mM) 
failed to significantly influence non-specific uptake of ES in HEK-ev (background) cells (data 
not shown). Thus, illustrating that hOAT3 expression correlates with ES accumulation and that 
HEK-ev ES level can be used for background correction. 
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Figure 4.2. Inhibition of hOAT1- and hOAT3-mediated transport by Danshen components 
 
A: Inhibition of hOAT1-mediated uptake of [3H]PAH (1 µM) by LSA, RMA, SAA, and 
probenecid (1000 µM) was measured in the CHO-hOAT1 cell line (10 min). B: Inhibition of 
hOAT3-mediated uptake of [3H]ES (1 µM) by LSA, RMA, SAA, and probenecid (1000 µM) 
was measured in the HEK-hOAT3 cells (10 min). Background PAH and ES accumulation was 
measured in the respective empty vector transfected control cell lines and is included to provide 
a clear gauge of the background in the experimental system. Graphs shown are from 
representative experiments with values plotted as mean ± S.D. of triplicate values. Black bars: 
substrate accumulation in the absence of inhibitor in transporter expressing cells, open bars: 
substrate accumulation in mock transfected cells, grey bars: substrate accumulation in the 
presence of inhibitors in transporter expressing cells; *** denotes p < 0.001 as determined by 
one-way ANOVA followed by Dunnett’s t-test. 
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4.C.2 Mode of inhibition 
In order to calculate the more universal kinetic parameter, Ki, studies were conducted to 
determine the mechanism of inhibition of hOAT1 and hOAT3 by LSA, RMA, and SAA. 
Substrate concentration and accumulation time used for kinetic analysis of hOAT1 (1 µM PAH 
for 3 min, Km = 15.4 µM) were based upon previous determinations in this cell line (130). For 
HEK-hOAT3 cells, ES accumulation was linear through at least the first minute and Km was 
estimated as 14.5 ± 4.5 μM (data not shown and Figure 4.3). These parameters were then used to 
design saturation analysis experiments for hOAT1 and hOAT3 in the absence vs. presence of 
two different concentrations of LSA, RMA, or SAA. Substrate uptake under these conditions 
was determined, background corrected, and fit to the mixed-model inhibition, which incorporates 
competitive, non-competitive, and uncompetitive inhibition modes. Estimated α values were 
much greater than 1, indicating that LSA, RMA, and SAA inhibition of hOAT1- and hOAT3-
mediated transport was competitive in nature (Table 4.1). 
4.C.3 Determination of inhibition potencies of LSA, RMA, and SAA for hOAT1 and hOAT3 
Using increasing concentrations of unlabeled test compounds (10-9 to 2×10-4 M), inhibition 
of hOAT1- and hOAT3-mediated transport of ([3H]PAH) or ([3H]ES), respectively, was 
measured (Figures 4.4 and 4.5 and Table 4.2). As indicated above, LSA, RMA, and SAA were 
determined to be competitive inhibitors of hOAT1 and hOAT3, thus Ki, rather than IC50 values, 
could be calculated by selecting competitive inhibition during analysis. Ki values were estimated 
as 20.8 ± 2.1 µM for LSA, 0.35 ± 0.06 µM for RMA, and 5.58 ± 0.29 µM for SAA on hOAT1-
mediated transport and as 0.59 ± 0.26 µM for LSA, 0.55 ± 0.25 µM for RMA, and 0.16 ± 0.03 
µM for SAA on hOAT3-mediated transport. For all of these analyses the coefficient of 
determination (r2) was > 0.9. The Ki values for LSA and SAA on hOAT3 were ~1-2 orders of 
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magnitude lower than those for hOAT1 (p < 0.001, Ki ratio = 35 for each), whereas the Ki for 
RMA was similar between the two transporters (Table 4.2). 
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Figure 4.3. Michaelis-Menten kinetics of ES transport in HEK-hOAT3 cells 
 
Uptake of [3H]ES was measured for 1 min at room temperature in HEK-hOAT3 cells (closed 
triangles) and HEK-ev (background) cells (open squares) across increasing ES concentrations. 
The background corrected curve (closed circles) was obtained by subtracting the non-specific 
background uptake as measured in the HEK-ev cells from HEK-hOAT3 accumulation to allow 
analysis of hOAT3-mediated activity. Experiments were repeated three times in triplicate and 
Michaelis constant (Km) values were calculated by nonlinear regression using the Michaelis-
Menten model. The Km for ES on hOAT3 was estimated as 14.5 ± 4.5 μM (mean ± S.E.M.). 
Graph shown is from a representative experiment with values plotted as mean ± S.D. (n=3). 
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Figure 4.4. Ki determination for LSA, RMA, SAA, SAB, and TSL on hOAT1 
 
One minute uptake of [3H]PAH (1 µM) in CHO-hOAT1 cells was measured in the presence of 
increasing concentrations (10-7 to 2×10-3 M) of LSA, RMA, SAA, SAB, and TSL. Data were 
corrected for non-specific background measured in the CHO-ev1 (background) cells prior to 
kinetic analysis. Ki values were determined with non-linear regression and the “one-site 
competition” model using GraphPad Prism software. Experiments were repeated three times in 
triplicate with the mean Ki ± S.E.M. reported in Table 4.2. Graphs shown are from representative 
experiments with values plotted as mean ± S.D. (n=3). 
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Figure 4.5. Ki determination for LSA, RMA, and SAA, SAB, and TSL on hOAT3 
 
One minute uptake of [3H]ES (1 µM) in HEK-hOAT3 cells was measured in the presence of 
increasing concentrations (10-8 to 2×10-3 M) of LSA, RMA, SAA, SAB, and TSL. Data were 
corrected for non-specific background measured in the HEK-ev (background) cells prior to 
kinetic analysis. Ki values were determined with non-linear regression and the “one-site 
competition” model using GraphPad Prism software. Experiments were repeated three times in 
triplicate with the mean Ki ± S.E.M. reported in Table 4.2. Graphs shown are from representative 
experiments with values plotted as mean ± S.D. (n=3). 
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Figure 4.6. Dose-response curves for SAB and TSL with respect to mOat1 and mOat3 
 
One minute uptake of [3H]PAH or [3H]ES (1 µM) in CHO-mOat1 (upper panels) or CHO-mOat3 
(lower panels) cells was measured in the presence of increasing concentrations (10-7 to 5×10-3 M) 
of SAB and TSL. Data were corrected for non-specific background measured in the CHO-FRT 
(background) cells prior to kinetic analysis. IC50 values were determined with non-linear 
regression and the “log(inhibitor) vs. response” model using GraphPad Prism software. 
Experiments were repeated three times in triplicate with the mean IC50 ± S.E.M. reported in 
Table 4.3. Graphs shown are from representative experiments with values plotted as mean ± S.D. 
(n=3). 
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Table 4.1. Estimated α values from mixed-model inhibition analysis 
 
Compound hOAT1 hOAT3 
LSA 1.5 × 1015 9.6 × 1013 
RMA 2.1 × 1014 3.2 × 1017 
SAA 3.1 × 1015 4.2 × 1016 
SAB 6.8 × 1019 8.2 × 1017 
TSL 8.8 × 1016 3.5 × 1015 
 
Values are reported as mean. The S.E.M. is not applicable in this analysis. 
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Table 4.2. Estimated Ki values (µM) and DDI indices for hOAT1 and hOAT3 
 
Compound hOAT1 hOAT3 Ki Ratio (hOAT1/hOAT3) 
fua 
(%) 
DDI indexb 
hOAT1 hOAT3 
LSA 20.8 ± 2.1 0.59 ± 0.26*** 35 -c 0.01d 0.4d 
RMA 0.35 ± 0.06 0.55 ± 0.25 0.6 9.5e 1.6 1.0 
SAA 5.6 ± 0.3 0.16 ± 0.03*** 35 - - - 
SAB 22.2 ± 1.9 19.8 ± 8.4 1.1 6.8e  0.02 0.02 
TSL 40.4 ± 12.9 8.6 ± 3.3 4.7 100e  0.5 2.1 
 
Values are reported as mean ± S.E.M. (n=3). ***, significance of Ki values between hOAT1 and 
hOAT3 is p < 0.001 as determined by two-tailed Student’s unpaired t-test. afu: Fraction unbound 
in plasma; bClinical data taken from reference (104); c-: Unknown; dAssuming LSA is highly 
protein bound (fu = 10%); e Fraction unbound in plasma from reference (137). 
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Table 4.3. Comparison of Ki values (µM) between mOat1 and mOat3 and their human 
orthologs 
 
Compound mOat1a mOat3a Ki Ratio (mOat1/hOAT1) 
Ki Ratio 
(mOat3/hOAT3) 
LSA 14.9 ± 4.9 31.1 ± 7.0 0.7 53* 
RMA 5.5 ± 2.2 4.3 ± 0.2 16 7.8*** 
SAA 4.9 ± 2.2 21.3 ± 7.7 0.9 133 
SAB 236 ± 90b 845 ± 287b  11 43* 
TSL 136 ± 17b 1940 ± 486b 3.4* 226* 
 
Values are reported as mean ± S.E.M. (n=3). * denotes significant difference between murine 
and human Ki values p < 0.05 and *** denotes significant difference between murine and human 
Ki values p < 0.001 as determined by two-tailed Student’s unpaired t-test. aData for LSA, RMA 
and SAA were taken from reference (49). bCorresponding Ki values assuming competitive 
inhibition (see text for explanation). 
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4.D DISCUSSION 
The popularity of natural products as dietary supplements and/or alternative medicines has 
been increasing. Indeed, a recent survey found that ~20% of the adult population in the United 
States reported using one or more natural products (112). Because herbal medicines are produced 
from plants they are considered “natural” and, therefore, are often perceived as having no toxic 
effects by patients. However, many different side effects/adverse events are known to be 
associated with natural products, including herb-drug interactions (131, 132). A number of herb-
drug interactions involving metabolic enzymes (e.g., CYP450’s) are well established, however, 
herb-drug interactions at the level of transporter proteins are not as well characterized. 
Despite this, there is a growing literature base concerning the interaction of natural products 
with OATs. For example, the dietary polyphenol, ellagic acid, was found to potently inhibit 
hOAT1 (IC50 = 207 nM) and hOAT4 (48). The aglycone of the natural sweetener, stevioside, 
was identified as an inhibitor of both hOAT1 (Ki = 2.0 μM) and hOAT3 (Ki = 5.4 μM) (133). 
Similarly, dietary flavonoid and hydroxycinnamic acid aglycones, as well as their Phase II 
glucuronide and sulfate conjugates, produced pronounced inhibition of hOAT1- and hOAT3-
mediated transport (50, 119). Finally, the nephrotoxin, aristolochic acid, the causative agent for 
“Chinese herbs nephropathy” which is found in herbal products containing Aristolochia sp., 
exhibited significant interaction with hOAT1 (Ki = 600 nM), hOAT3 (Ki = 500 nM), and hOAT4 
(Ki = 20.6 μM) (39). Thus, herb-drug interactions involving OATs and components of natural 
products, that impact the pharmacokinetics and pharmacodynamics of administered drugs, may 
occur. 
In the present study, we sought to determine the inhibitory effects of three major Danshen 
components, LSA, RMA, and SAA on hOAT1- and hOAT3-mediated transport (Figures 4.2, 4.4, 
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and 4.5). In order to calculate Ki values on hOAT3, the Km value for ES (test substrate) needed to 
be determined in the HEK-hOAT3 cell system (Figure 4.3). Saturation analysis revealed an 
estimated Km of 14.5 ± 4.5 μM, which is similar to other reported values of 6.3-9.5 μM (98, 134, 
135). LSA, RMA, and SAA were found to be potent competitive inhibitors of hOAT1- and 
hOAT3-mediated transport (Figures 4.4 and 4.5 and Tables 4.1 and 4.2). Their calculated Ki 
values are similar to reported Km and Ki values for endogenous steroid and prostaglandin 
hormones on hOAT1 and hOAT3 (3). Therefore, LSA, RMA, and SAA may affect the 
disposition and elimination of not only co-administered drugs, but also of endogenous substances 
that are OAT substrates. The rank order of their potencies was different between the two 
transporters with RMA > SAA > LSA for hOAT1 and SAA > LSA ≈ RMA for hOAT3. 
Regardless, LSA and SAA exhibited significantly higher affinity (lower Ki values) for hOAT3 
than for hOAT1, with each compound showing a ~35-fold preference, whereas, RMA exhibited 
similar affinity for both transporters (Table 4.2). 
In the draft guidance for industry, “Drug Interaction Studies — Study Design, Data Analysis, 
Implications for Dosing, and Labeling Recommendations”, re-issued by the Food and Drug 
Administration in February 2012, it was proposed that a DDI index, indicative of a compound’s 
potential to cause marked in vivo drug-drug interactions when its value exceeds 0.1, can be 
calculated as the [unbound] Cmax/Ki (or IC50) ratio (136). In 2005, an in vivo pilot study 
conducted in healthy humans reported Cmax values for LSA and RMA of 2.23 μM and 5.55 μM 
after i.v. administration of a Danshen product, in which the dose of LSA and RMA were 3 and 
160 mg, respectively (104). Further, Yang et al. (2007) determined that, for RMA, the fraction 
unbound in plasma was 9.5% (137). Thus, using the published Cmax and plasma protein binding 
values for RMA, as well as the Ki values determined in this study (Table 4.2), DDI indices of 1.6 
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and 1.0 were calculated for hOAT1 and hOAT3, respectively, indicating a strong potential for 
clinical herb-drug interactions. In the absence of plasma protein binding data for LSA, DDI 
indices for hOAT1 (0.01) and hOAT3 (0.4) were calculated assuming LSA to be highly (90%) 
protein bound (Table 4.2). Under such circumstances, the DDI index for hOAT3 would be 
greater than 0.1. The pharmacokinetic profile of SAA is virtually unknown. Clearly, greater 
understanding of the pharmacokinetic properties of LSA, RMA, and SAA, and the transporters 
that help determine them, is necessary to avoid potential herb-drug interactions. For Danshen 
pharmaceutical products this would be particularly relevant in coronary patients, where they may 
be taken in combination with drugs, such as angiotensin converting enzyme inhibitors, which are 
known to be hOAT1/hOAT3 substrates.  
Additionally, there is marked variation in the amount of each active component in plant 
cultivated in different regions and in Danshen products prepared by different manufacturing 
processes (103, 104, 138). For example, the content of RMA in raw plant material varied as 
much as 16 fold between different cultivation regions and the dose of RMA ranged from 4.1-160 
mg (~40 fold) in Danshen injectables produced by different manufacturers (103, 104). Moreover, 
the dose of RMA ranged from 1.16-3.47 mg from different batches of a Danshen injectable from 
the same pharmaceutical manufacturer (138). These data illustrate that clinically significant herb-
drug interactions would or would not occur depending upon which manufacturer’s product was 
administered and/or the diligence of the quality control protocol utilized by a single 
manufacturer. Therefore, although tanshinone II A, SAB, and protocatechuic aldehyde have been 
chosen as quality control markers for Danshen pharmaceutical dosage forms in accordance with 
the Chinese Pharmacopeia, our data suggest that the content of other Danshen components, e.g., 
LSA and RMA, should be considered for monitoring and control as well. 
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Recently, we investigated the interaction between mOat1 and mOat3 and Danshen’s 
hydrophilic components (49). As for the human orthologs, the rank order of potencies was 
slightly different between the two transporters with RMA ≈ SAA > LSA for mOat1 and RMA > 
SAA ≈ LSA for mOat3.  On comparing the mouse and human data, notable species differences 
appear to exist in terms of inhibitory potency (Table 4.3). Human OAT1 exhibited ~16-fold 
higher affinity for RMA as compared to mOat1, while LSA and SAA showed similar inhibition 
potencies across species. In contrast, all three compounds exhibited much higher affinity for 
hOAT3 over mOat3, by 1 order of magnitude for RMA and by ~2 orders of magnitude for LSA 
and SAA. Interestingly, for LSA and SAA the two species are reversed, with hOAT3 having 
higher affinity for both over hOAT1 vs. mOat1 having higher affinity for both over mOat3 
(Tables 4.2 and 4.3). While the human orthologs had ~10 fold lower Ki values for RMA than the 
murine transporters, within species the values were similar for each transporter. These species 
differences indicate that any interactions observed in vivo in mice at clinically relevant doses of 
LSA, RMA, and SAA would potentially be of even greater magnitude in humans. This highlights 
the importance of delineating species differences in affinity in vitro prior to interpreting results 
from in vivo pharmacokinetic studies in pre-clinical models and attempting to extrapolate them 
to humans.  
As discussed earlier, additional Danshen components also might show significant inhibitory 
effects on OATs. For example, caffeic acid was demonstrated to be an OAT inhibitor, with 
reported IC50 values of 16.6 µM for hOAT1 and 5.4 µM for hOAT3 (51). However, because of 
low plasma concentration (0.56 µM) and modest plasma protein binding (66%), the calculated 
DDI index is less than 0.1, indicating caffeic acid was not likely to cause significant OAT 
inhibition at clinically relevant concentrations (104, 139). Protocatechuic acid and some 
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hydroxycinnamates (major metabolites of chlorogenic acids) were also identified as inhibitors of 
hOAT1 and hOAT3 (52). However, again, the extremely low content in Danshen products 
renders them unlikely to contribute to OAT-mediated Danshen-drug interactions in vivo. 
In summary, the active Danshen components, LSA, RMA, and SAA were demonstrated to 
elicit significant competitive inhibition on hOAT1- and hOAT3-mediated substrate uptake at 
clinically relevant concentrations. DDI indices for RMA on hOAT1 and hOAT3, and for LSA on 
hOAT3, suggest a strong potential for drug-drug interactions in patients when coadministered 
with drugs that are known hOAT1 and/or hOAT3 substrates. In addition, notable species 
differences were observed between human and murine OAT orthologs with human OATs 
showing higher affinity. All of these Danshen components preferentially interacted with hOAT3 
compared to mOat3, while only RMA showed higher affinity with hOAT1 (vs. mOat1). This 
information should improve interpretation and extrapolation of pharmacokinetic data generated 
in pre-clinical studies. Finally, these components might serve as effective quality control markers 
to be monitored during the manufacturing process to improve product consistency, efficacy, and 
safety.  
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CHAPTER 5 
 
 
 
POTENTIAL FOR FOOD/DRUG-DRUG INTERACTIONS BY PHENOLIC ACIDS ON 
HUMAN ORGANIC ANION TRANSPORTERS 1 (SLC22A6), 3 (SLC22A8), AND 4 
(SLC22A11) 
 
Drawn from manuscript published in Biochem Pharmacol. Oct 2012; 84(8): 1088-1095 
 
 
 
 
 
 
5.A INTRODUCTION 
The term, phenolic acid, describes a large group of compounds that contain an aromatic ring 
bearing hydroxyl and carboxyl substituents (140). In plants, phenolic acids are synthesized from 
phenylalanine or tyrosine via the shikimate pathway and they are widely distributed in fruits, 
vegetables, and beverages (43). As phenolic acids have been reported to possess anti-oxidant, 
anti-carcinogenic, and anti-inflammatory activities, they are believed to reduce the risk of 
developing chronic diseases, e.g., diabetes, cardiovascular disorders, and certain cancers (43, 140, 
141). A number of phenolic acids showed marked systemic exposure in vivo after daily 
consumption of phenolic acid-rich food (141, 142). 
Additionally, in vivo metabolism generates phenolic acids. For example, gentisic acid was 
identified as one of the major metabolites of salicylate, and urinary elimination of gentisic acid 
accounted for 0.4-1.7% of the total administered dose of salicylate drugs (143, 144). Another 
study indicated that ferulic and isoferulic acids may be metabolites of caffeic acid (145). Finally, 
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anthocyanins (ACNs) were recently identified as an important dietary source of phenolic acids. 
ACNs are flavonoids which are widely distributed in flowers, berries, grapes, red wine, and 
blood orange juice, producing blue and red color (146). Daily consumption of ACNs was 
estimated as 3-215 mg (146). Yet, it was reported in clinical studies that the bioavailability of 
ACNs was poor (146). However, in vitro studies demonstrated that phenolic acids represent 
major stable degradation products of ACNs, and this was confirmed in clinical studies (44, 147, 
148). Thus, phenolic acids are commonly found in the systemic circulation even in individuals 
not actively taking phenolic acid containing dietary supplements or alternative medicines. 
Several transporter families are responsible for the systemic disposition of organic acids. 
Among these, the Solute Carrier 22 (SLC22; organic cation/anion/zwitterion transporters) family 
is a key mediator in the distribution and renal tubular secretion of a multitude of endogenous and 
exogenous organic anions (2, 3). Many toxins, toxicants, and drugs (including antibiotics, 
antiviral and anticancer agents) are known organic anion transporter (OAT) substrates (2, 3). 
Further, some phenolic acids, e.g., tanshinol, rosmarinic acid, and salvianolic acid B, exhibit 
their highest tissue concentration in the kidney compared to other tissues, e.g., liver, intestine, 
and brain, after dosing (116, 149). In accordance, the kidney is known to express more OAT 
family members than any other tissue (3). In particular, human organic anion transporter 1 
(hOAT1; SLC22A6), hOAT2 (SLC22A7), and hOAT3 (SLC22A8), expressed in the basolateral 
membrane of renal proximal tubule cells, and hOAT4 (SLC22A11), hURAT1 (SLC22A12), and 
hOAT10 (SLC22A13) located in the apical membrane, are major constituents of the renal 
organic anion transport pathway. 
OAT-mediated drug-drug interactions (DDIs), manifesting as altered renal clearance and 
longer terminal plasma half-life, have been observed in a number of clinical and pre-clinical 
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studies. For example, renal clearance of benzylpenicillin and ciprofloxacin was reduced when 
co-administered with probenecid, a known OAT inhibitor, in clinical practice (77, 129). In accord 
with these clinical findings, pharmacokinetic studies using organic anion transporter 3 knockout 
mice demonstrated significantly reduced renal elimination of benzylpenicillin, ciprofloxacin, and 
methotrexate (80, 81). In response to our increased knowledge of such clinically relevant drug-
transporter interactions, and the impact they have on drug safety, the United States Food and 
Drug Administration (FDA) and the European Medicines Agency have issued guidance 
documents outlining conditions under which, prior to approval, any new drug entity should be 
investigated for potential DDIs on seven identified transporters; OAT1, OAT3, organic cation 
transporter 2 (OCT2), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, 
multidrug resistance transporter 1 (MDR1), and breast cancer resistance protein (BCRP) 
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM292362.pdf 
and http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.js
p?webContentId=WC500090112&murl=menus/document_library/document_library.jsp&mid=
WC0b01ac058009a3dc&jsenabled=true). Thus, the potential clinical significance of OAT1- and 
OAT3-mediated DDIs is already clearly recognized. 
As most phenolic acids are small and mainly exist as anions at physiological pH, it is 
possible that they are OAT substrates or inhibitors. For example, some hydroxycinnamic acids, 
including caffeic acid, dihydrocaffeic acid, dihydroferulic acid, and ferulic acid were identified 
as hOAT1 and/or hOAT3 substrates (50). This study further demonstrated that these compounds, 
as well as their glucuronide- and sulfate-conjugated metabolites, inhibited hOAT1 or hOAT3 
transport activity (50). Caffeic acid was identified as a competitive inhibitor for hOAT1 and 
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hOAT3, with IC50 estimates of 16.6 µM and 5.4 µM, respectively (51). As a consequence, 
hOAT1/hOAT3-mediated transport of antifolates and antivirals was inhibited by caffeic acid 
(51). Finally, ellagic acid, which is a dietary polyphenol found in many fruits and vegetables, 
was demonstrated to be a potent inhibitor for hOAT1 (IC50 = 207 nM) and hOAT4 (48). 
Therefore, it is necessary to explore the potential interaction of phenolic acids with OATs, in 
order to determine what transport processes influence the distribution and elimination (and hence 
efficacy and toxicity) of these compounds. This information is also vital to avoid potential 
drug/food-drug interactions. 
In the present study, the inhibitory effects of nine dietary phenolic acids, p-coumaric acid, 
ferulic acid, gallic acid, gentisic acid, 4-hydroxybenzoic acid, protocatechuic acid, sinapinic acid, 
syringic acid, and vanillic acid, on the transport of para-aminohippuric acid (PAH) mediated by 
hOAT1 and the transport of estrone sulfate (ES) mediated by hOAT3 and hOAT4 were 
characterized. For potent inhibitors, dose-response studies were conducted in order to derive 
inhibitory constants (IC50 and Ki values) to aid evaluation of potential for clinical DDIs. Among 
these phenolic acids, gallic acid exhibited highest affinity for hOAT1 and hOAT3, with 
corresponding maximum DDI indices (unbound maximum plasma concentration/IC50) of 5.52 
and 0.76, respectively. Gentisic acid exhibited a marked DDI index of 7.25 for hOAT3 
(assuming 90% binding to plasma protein). These findings suggested there is a strong potential 
for gallic acid- and gentisic acid-associated food/drug-drug interactions with co-administered 
clinical therapeutics that are OAT substrates, including altered drug pharmacokinetics, 
pharmacodynamics, and toxicity. 
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5.B MATERIALS AND METHODS 
5.B.1 Chemicals 
p-Coumaric acid, ferulic acid, gallic acid, gentisic acid, 4-hydroxybenzoic acid, sinapinic 
acid, and vanillic acid (≥ 97% purity) were purchased from Sigma -Aldrich (St. Louis, MO).  
Protocatechuic acid and syringic acid (≥ 95% purity) were obtained from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA). The chemical structures for these compounds are shown 
in Figure 5.1. Tritiated para-aminohippuric acid ([3H]PAH) and estrone sulfate ([3H]ES) were 
purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA) and unlabeled PAH, 
ES, and probenecid were purchased from Sigma-Aldrich.  
5.B.2 Tissue culture 
Derivation of stably transfected Chinese hamster ovary (CHO) cells expressing hOAT1 
(CHO-hOAT1) and hOAT4 (CHO-hOAT4), as well as stably transfected human embryonic 
kidney 293 (HEK) cells expressing hOAT3 (HEK-hOAT3), and their corresponding empty 
vector transfected background control cell lines, has been described previously (82, 130, 150). 
CHO-hOAT1 cells were maintained at 37°C with 5% CO2 in phenol red-free RPMI 1640 media 
(Gibco-Invitrogen, Grand Island, NY) containing 10% serum, 1% Pen/Strep and 1 mg/mL G418. 
CHO-hOAT4 cells were maintained at 37°C with 5% CO2 in EMEM Alpha Modification media 
(Sigma-Aldrich) containing 10% serum, 1% Pen/Strep and 0.5 mg/mL G418. HEK cell lines 
were maintained at 37°C with 5% CO2 in DMEM high glucose media (Mediatech, Inc., Herndon, 
VA) containing 10% serum, 1% Pen/Strep and 125 µg/ml hygromycin B. 
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Figure 5.1. Chemical structures of the nine dietary phenolic acids investigated in this study 
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5.B.3 Cell accumulation assay 
The procedure for the cell accumulation assay was described in previous publications (82). In 
brief, 2 × 105 cells/well were seeded in 24-well tissue culture plates and grown in the absence of 
antibiotics for 48 hr. Before initiating the cell transport experiment, cells were preincubated in 
transport buffer for 10 min [500 µL of Hanks’ balanced salt solution containing 10 mM HEPES, 
pH 7.4]. After equilibration, this solution was replaced with 500 µL of fresh transport buffer 
containing 1 µM non-radiolabeled substrates spiked with trace amounts of [3H]PAH (0.5 µCi/mL) 
or [3H]ES (0.25 µCi/mL) with or without test compounds. At the end of incubation, cells were 
quickly rinsed three times with ice-cold transport buffer and lysed. The intracellular 
accumulation of tritiated substrates was counted by liquid scintillation and reported as picomoles 
of substrate per milligram total protein. All uptake data were corrected for background 
accumulation in corresponding control cells. Exposure to as high as 1 mM of each phenolic acid 
did not significantly influence the non-specific substrate signal observed in CHO empty vector 
control cells or HEK empty vector control cells, as compared to unexposed cells (data not 
shown). Therefore, substrate accumulation in corresponding empty vector control cell lines 
under control conditions represents appropriate values for background correction. Substrate 
concentrations and accumulation times used for kinetic analysis of hOAT1 (1 µM PAH for 3 min, 
Km = 15.4 µM) were determined previously (130) and for kinetic analysis of hOAT3 (ES for 1 
min, Km = 14.5 ± 4.5 µM) were measured in our laboratory (data not shown). Kinetic 
calculations were performed using GraphPad Prism Software version 5.0 (GraphPad Software 
Inc., San Diego, CA). The half maximal inhibitory concentrations (IC50) were calculated using 
nonlinear regression with the appropriate model. Assuming competitive inhibition, Ki values 
were derived using the Cheng-Prusoff equation: Ki = IC50/(1 + [Substrate]/Km). Results were 
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confirmed by repeating all experiments at least three times with triplicate wells for each data 
point in every experiment. 
5.B.4 Statistics 
Data are reported as mean ± S.D. or mean ± S.E.M. as indicated. Statistical differences were 
assessed using one-way ANOVA followed by post-hoc analysis with Dunnett’s t-test (α = 0.05).
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5.C RESULTS 
5.C.1 Inhibitory effects of phenolic acids on hOAT1-mediated PAH uptake. 
CHO-hOAT1 cells showed significant accumulation of PAH (6.23 ± 0.89 pmol mg protein-1 
10 min-1) compared to that in the empty vector transfected background control cells (2.34 ± 0.50 
pmol mg protein-1 10 min-1), and this OAT1-mediated accumulation was inhibited by probenecid 
(Figure 5.2). The dietary phenolic acids, p-coumaric acid, ferulic acid, gallic acid, gentisic acid, 
4-hydroxybenzoic acid, protocatechuic acid, sinapinic acid, syringic acid, and vanillic acid, were 
assessed for inhibitory effects on PAH uptake in CHO-hOAT1 cells at 100 µM (Figure 5.2). 
Protocatechuic acid and vanillic acid produced approximately 53% and 80% inhibition, whereas 
ferulic acid, gallic acid, and sinapinic acid completely blocked PAH accumulation (> 99% 
inhibition). p-Coumaric acid produced no effect, while gentisic acid, 4-hydroxybenzoic acid, and 
syringic acid actually stimulated uptake. Exposure to 100 µM of each phenolic acid had no effect 
on CHO-hOAT1 cell viability or integrity (data not shown). 
Dose-response studies, applying increasing concentrations of test compounds (10-7 to 5×10-4 
M), were performed to determine the IC50 values for gallic acid, protocatechuic acid, sinapinic 
acid, and vanillic acid in order to allow direct comparison of inhibition potencies of these 
compounds (Figure 5.3 and Table 5.1). The IC50 value for ferulic acid on hOAT1 has been 
reported as 9.01 µM (50). Gallic acid showed stronger affinity with hOAT1 (IC50=1.24 ± 0.36 
µM), compared to protocatechuic acid (IC50=18.08 ± 2.59 µM), sinapinic acid (IC50=11.02 ± 
1.55 µM), and vanillic acid (7.65 ± 2.92 µM). Previous studies investigating the type of 
inhibition (competitive vs. uncompetitive vs. noncompetitive) produced on hOAT1 and hOAT3 
for a variety of compounds have all determined the interaction to be competitive (51, 151). 
Therefore, assuming competitive inhibition, inhibition constants (Ki) were estimated as 1.08 ±  
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Figure 5.2. Inhibition of hOAT1-mediated uptake by dietary phenolic acids 
 
Ten minute cellular uptake of [3H]PAH (1 µM) was measured in CHO-hOAT1 cells in the 
absence (6.23 ± 0.89 pmol mg protein-1 10 min-1) and presence of dietary phenolic acids (100 µM) 
or probenecid (1,000 µM). All data were corrected by background PAH accumulation measured 
in corresponding empty vector transfected background control cell (2.34 ± 0.50 pmol mg protein-
1 10 min-1). Values are mean ± S.D. of triplicate values. Significant inhibition denoted by ** p < 
0.01 and *** p < 0.001 as determined by one-way ANOVA followed by Dunnett’s t-test. 
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Figure 5.3. Dose-response curves for gallic acid, protocatechuic acid, sinapinic acid, and 
vanillic acid with respect to hOAT1 
 
One minute uptake of [3H]PAH (1 µM) in CHO-hOAT1 cells was measured in the presence of 
increasing concentrations (10-7 to 5×10-4 M) of test compounds. Data were corrected for non-
specific background measured in the corresponding empty vector transfected background control 
cell. IC50 values were determined with nonlinear regression and the “log(inhibitor) vs. response” 
model using GraphPad Prism software. Experiments were repeated three times in triplicate with 
the mean IC50 ± S.E.M. reported in Table 5.1. Graphs shown are from representative experiments 
with values plotted as mean ± S.D. (n=3). 
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0.26 µM for gallic acid, 13.36 ± 1.60 µM for protocatechuic acid, 10.05 ± 1.74 µM for sinapinic 
acid, and 7.19 ± 2.74 µM for vanillic acid on hOAT1-mediated transport (Table 5.1). 
5.C.2 Inhibitory effects of phenolic acids on hOAT3-mediated ES uptake. 
We next examined the effects of these compounds on hOAT3-mediated transport. ES, a 
model substrate for hOAT3, was used to evaluate the transport activity of hOAT3 expressing 
cells. Significantly greater accumulation of ES (~5 fold) was observed in stably transfected 
hOAT3-expressing cells (HEK-hOAT3) relative to empty vector transfected background control 
cells (20.7 ± 3.5 vs. 4.10 ± 0.92 pmol mg protein-1 10 min-1, respectively). Similar to hOAT1, 
probenecid completely inhibited (> 99% inhibition) hOAT3-mediated ES uptake (Figure 5.4). 
However, unlike hOAT1, all of the tested compounds (100 µM) significantly inhibited hOAT3-
mediated ES uptake. Gallic acid and sinapinic acid showed the strongest inhibitory effects on 
hOAT3-mediated ES uptake (> 84% inhibition), followed by ferulic acid (79% inhibition), 
gentisic acid (75% inhibition), and protocatechuic acid (61% inhibition). The inhibitory effects 
for the remaining compounds on hOAT3 transport activity were less than 60% (p-coumaric acid: 
59% inhibition; 4-hydroxybenzoic acid: 38% inhibition; syringic acid: 46% inhibition; vanillic 
acid: 42% inhibition). Exposure to 100 µM of each phenolic acid had no effect on HEK-hOAT3 
cell viability or integrity (data not shown). 
Based on known plasma concentration levels, plasma protein binding, and the level of 
inhibition observed, kinetic studies were conducted to derive IC50 values for ferulic acid, gallic 
acid, gentisic acid, protocatechuic acid, and sinapinic acid on hOAT3 transport activity. Using 
increasing concentrations of unlabeled test compounds (10-6 to 10-3 M), IC50 values were 
measured as 7.35 ± 3.73 µM for ferulic acid, 9.02 ± 3.24 µM for gallic acid, 81.34 ± 20.50 µM 
for gentisic acid, 81.82 ± 26.82 µM for protocatechuic acid, and 24.08 ± 1.46 µM for sinapinic 
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acid (Figure 5.5 and Table 5.1). Estimated Ki values were calculated assuming that these 
compounds were competitive inhibitors (Table 5.1). 
5.C.3. Inhibitory effects of hydrophilic Danshen components on hOAT4-mediated ES uptake. 
As shown in Figure 5.6, stably transfected hOAT4-expressing (CHO-hOAT4) cells showed 
marked accumulation of ES (~13 fold) compared to empty vector transfected background control 
cells (64.1 ± 6.6 vs. 5.34 ± 0.36 pmol mg protein-1 10 min-1, respectively). ES (1 mM) exhibited 
self-inhibition on hOAT4-mediated ES uptake (> 99% inhibition). Among the test compounds, 
only sinapinic acid (100 µM) showed a significant inhibitory effect (33% inhibition). 
Accordingly, the IC50 value for sinapinic acid on hOAT4 transport activity is likely to be greater 
than 100 µM, therefore, no further kinetic studies were performed. As observed for hOAT1, but 
in contrast to hOAT3, syringic acid showed significant stimulation (35%) of hOAT4-mediated 
ES uptake. 
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Figure 5.4. Inhibition of hOAT3-mediated uptake by dietary phenolic acids 
 
Ten minute cellular uptake of [3H]ES (1 µM) was measured in HEK-hOAT3 cells in the absence 
(20.7 ± 3.5 pmol mg protein-1 10 min-1) and presence of dietary phenolic acids (100 µM) or 
probenecid (1,000 µM). All data were corrected by background ES accumulation measured in 
HEK-FRT cells (4.10 ± 0.92 pmol mg protein-1 10 min-1). Values are mean ± S.D. of triplicate 
values. Significant inhibition denoted by *** p < 0.001 as determined by one-way ANOVA 
followed by Dunnett’s t-test. 
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Figure 5.5. Dose-response curves for ferulic acid, gallic acid, gentisic acid, protocatechuic 
acid, and sinapinic acid, with respect to hOAT3 
 
One minute uptake of [3H]ES (1 µM) in HEK-hOAT3 cells was measured in the presence of 
increasing concentrations (10-6 to 10-3 M) of tested compounds. Data were corrected for non-
specific background measured in the HEK-FRT cells. IC50 values were determined with non-
linear regression and the “log(inhibitor) vs. response” model using GraphPad Prism software. 
Experiments were repeated three times in triplicate with the mean IC50 ± S.E.M. reported in 
Table 5.1. Graphs shown are from representative experiments with values plotted as mean ± S.D. 
(n=3). 
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Figure 5.6. Inhibition of hOAT4-mediated uptake by dietary phenolic acids 
 
Ten minute cellular uptake of [3H]ES (1 µM) was measured in CHO-hOAT4 cells in the absence 
(64.1 ± 6.6 pmol mg protein-1 10 min-1) and presence of dietary phenolic acids (100 µM) or 
unlabeled ES (1,000 µM). All data were corrected by background ES accumulation measured in 
corresponding empty vector transfected background control cell (5.34 ± 0.36 pmol mg protein-1 
10 min-1). Values are mean ± S.D. of triplicate values. Significant inhibition denoted by * p < 
0.05 as determined by one-way ANOVA followed by Dunnett’s t-test. 
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Table 5.1. Estimated IC50 (µM), Ki (µM) and DDI index values for hOAT1- and hOAT3-mediated transport of dietary phenolic acids 
 
Compounds 
hOAT1  hOAT3 fub 
(%) 
Reported 
Cmax 
(µM) 
DDI index References 
(for fu and Cmax) IC50 (µM) Ki (µM)a  IC50 (µM) Ki (µM) hOAT1 hOAT3 
Ferulic acid 9.01c NDd  7.35±3.73 6.87±3.49 26.5 0.012-1.04 0.0004-0.03 0.0004-0.04 (142, 152-154) 
Gallic acid 1.24±0.36 1.08±0.26  9.02±3.24 8.44±3.03 68.4 0.22-10 0.12-5.52 0.02-0.76 (142, 154, 155) 
Gentisic acid ND ND  86.81±21.78 81.34±20.50 ?e 0.7-6,290 ND 0.0008-7.25 (156-159) 
Protocatechuic acid 18.08±2.59 13.36±1.60  87.36±28.57 81.82±26.82 79.3 0.12-0.49 0.005-0.02 0.001-0.004 (148, 154, 156, 160, 161) 
Sinapinic acid 11.02±1.55 10.05±1.74  25.74±1.56 24.08±1.46 ? ? ? ?  
Vanillic acid 7.65±2.92 7.19±2.74  ND ND 43.7 0.03-0.10 0.002-0.006 ND (154, 156, 161) 
 
Values are reported as mean ± S.E.M. a Ki values were estimated assuming competitive inhibition; b fu: Fraction unbound in plasma; c Reported from  (50); d ND: Not 
determined; e ?: unknown; f Assuming gentisic acid is highly protein bound (fu = 10%)
 
 
 92 
5.D DISCUSSION 
Phenolic acids have consistently displayed beneficial therapeutic effects for cardiovascular 
diseases, cancers, and chronic inflammation both in vitro and in vivo (160). In addition to 
‘natural’ exposure to phenolic acids through dietary sources such as many fruits and vegetables, 
phenolic acids are increasingly used in clinical practice as complementary/alternative medicines 
(162). This has resulted in a greater understanding of the clinical pharmacokinetic properties of 
phenolic acids. However, to understand their pharmacological actions and pharmacokinetic 
behaviors at the biochemical level and, thus, better predict potential DDIs and/or toxicities, it is 
essential to identify and characterize the active transport mechanisms that impact these processes. 
Such information may explain how and why these compounds are targeted to specific organ(s) 
for therapeutic effects and elimination from the body.  
In the present study, we characterized the interactions of nine phenolic acids with three 
human OATs; hOAT1, hOAT3, and hOAT4. All of the phenolic acids examined are bioavailable 
as indicated by plasma or urinary data. As illustrated, each transporter exhibited a unique pattern 
of interaction with the examined phenolic acids (Figures 5.2, 5.4, and 5.6). In general, all of the 
compounds produced an effect on hOAT1 and hOAT3, whereas, only two compounds showed 
interaction with hOAT4. All of the tested compounds exhibited significant inhibition for hOAT3 
transport activity at 100 µM, while there were only five compounds (ferulic acid, gallic acid, 
protocatechuic acid, sinapinic acid, and vanillic acid) that significantly blocked hOAT1-mediated 
PAH uptake under the same condition. Sinapinic acid (100 µM) was the only phenolic acid 
showing significant inhibition of hOAT4-mediated ES uptake. However, given the modest nature 
of the interaction on hOAT4 at 100 µM, it was concluded that this was highly unlikely to be 
clinically relevant. Overall, these data implicated hOAT1 and hOAT3, but not hOAT4, as having 
 
 
 93 
an important role in potential food/drug-drug interactions involving these phenolic acids. 
Whether or not these transporters handle these compounds as actual substrates requires further 
investigation. 
Compounds reported to have relatively high Cmax values in humans (except for sinapinic acid) 
and producing inhibition > ~60% at 100 µM on hOAT1 and/or hOAT3 were selected for IC50 (Ki) 
determination (Figures 5.3 and 5.5 and Table 5.1). Subsequently, Cmax, % protein binding, and 
IC50 values were used to calculate the drug-drug interaction index [DDI = unbound Cmax / IC50] 
for each relevant transporter:compound combination (Table 5.1), where a value greater than 0.1 
indicates the potential for drug-drug interactions and the need for an in vivo DDI study for any 
investigational drug (recommended by FDA Guidance for Drug Interaction Studies). Clearly, 
gallic acid (maximum DDI index of 5.52 and 0.76 for hOAT1 and hOAT3, respectively) and 
gentisic acid (maximum DDI index of 7.25 for hOAT3) have a very strong potential for 
producing DDIs in vivo. 
Gallic acid has been demonstrated to have anti-oxidant, anti-inflammatory, anti-allergenic, 
and anti-cancer properties (162). Currently, gallic acid is consumed as a major component in 
fruits, vegetables, beverages, herbal supplements, homeopathic remedies, and pharmaceutical 
products (162, 163). Pharmacokinetic studies have reported maximum plasma concentrations for 
gallic acid ranging from 0.22-10 µM in humans after drinking red wine (300 mL) or after oral 
administration of acidum gallicum tablets (50 mg GA), Assam black tea brews (50 mg GA), or a 
dietary herbal supplement (800 mg GA) (142, 155). Since the renal clearance of gallic acid was 
~8.4 L/h, the unbound renal clearance of gallic acid was estimated as 206 mL/min, which is 1.7 
fold higher than the glomerular filtration rate (~120 mL/min) (163). Thus, gallic acid might 
undergo active tubular secretion in the kidney. In this study, gallic acid emerged as a potent 
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inhibitor for hOAT1 and hOAT3 (IC50: 1.24 and 9.02 µM, respectively), indicating that these 
transporters might be involved in its active secretion. Furthermore, the DDI index for hOAT1 at 
the lowest reported Cmax (0.22 µM) is 0.12 and, thus, still meets the criteria for warranting in vivo 
DDI studies. Human OAT3 requires a Cmax of only 1.5 µM (reported range 0.22-10 µM) to reach 
a DDI index > 0.1. Future studies also should focus on gallic acid’s major metabolites, 
particularly 4-O-methylgallic acid, which showed an even higher Cmax than unchanged gallic 
acid (142). Since these compounds possess a carboxyl group in the aromatic ring, they might be 
OAT substrates or inhibitors, and potentially exacerbate gallic acid-associated DDIs. 
For gentisic acid on hOAT3 (IC50 = 86.81 µM), the DDI index becomes 0.1 at a Cmax of just 
10 µM (reported range 0.7-6,290 µM), if we assume high protein binding of 90% (actual lower 
protein binding would serve to decrease the Cmax at which the 0.1 cut-off is reached). Clinically, 
gentisic acid becomes very important, as it is a major metabolite of salicylate, one of the most 
commonly used non-steroidal anti-inflammatory drugs (NSAIDs) (164). For example, in clinical 
practice methotrexate is often taken concomitantly with NSAIDs in the treatment of rheumatoid 
arthritis. However, it was reported that this combined therapy might increase methotrexate-
related adverse effects, and aspirin was found to reduce the renal clearance of methotrexate by 30% 
(164, 165). Although NSAIDs can reduce glomerular filtration of methotrexate and influence its 
fraction of plasma protein binding, inhibition of active renal tubular secretion via OATs might be 
an important elimination mechanism, as methotrexate is an organic acid mainly excreted 
unchanged in the urine (166, 167). Accordingly, transport of methotrexate by hOAT1 (Km = 554 
µM) and hOAT3 (Km = 21.1 µM) was investigated and results indicated a possible role for 
hOAT3 in its renal elimination, yet, salicylate showed extremely poor affinity for hOAT3 (Ki = 
2.2 mM) (168). However, as the results of the present study suggest, gentisic acid, formed as a 
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salicylate metabolite, could inhibit hOAT3 transport activity at clinical concentrations (2-6.29 
mM) and be responsible for the observed DDIs (157-159). This may prove to be particularly 
relevant for the pediatric population, as the highest reported Cmax value was observed in a clinical 
study with subjects aged 2 to 16 y (159). 
As indicated, gentisic acid and 4-hydroxybenzoic acid stimulated hOAT1-mediated uptake 
and syringic acid stimulated both hOAT1- and hOAT4-mediated uptake, yet all three compounds 
inhibited hOAT3 (Figures 5.2, 5.4 and 5.6). Thus, the stimulatory effects were varied and no 
consistent pattern or association with compound structural features was identified. Such sporadic 
in vitro stimulation/inhibition of transporter activity has been reported previously in the literature 
for several drug classes including steroids, anticancer chemotherapeutics, non-steroidal anti-
inflammatory drugs, and fluoroquinolone antimicrobials (82, 169, 170). For example, 
ciprofloxacin stimulated hOAT1 transport activity, but inhibited hOAT3 (82). Stimulation of 
MRP2 was observed for sparfloxacin (170). It has been theorized that these effects might be the 
result of allosteric interactions with the transporters, with binding promoting conformational 
changes that modulate the transport kinetics of substrates (169, 170). The interactions reported 
here are certainly consistent with this theory, however the nature and position of any potential 
allosteric binding sites within the hOATs remains unclear and requires further investigation, 
particularly given the close sequence homology of the OATs and varied effects of the studied 
phenolic acids. Regardless, such stimulatory interactions could have important in vivo 
consequences. For example, while a gentisic acid-drug interaction on hOAT3 might produce 
altered drug pharmacokinetics exhibiting decreased drug elimination and increased terminal half-
life, such an interaction on hOAT1 might produce the opposite effect, resulting in increased 
elimination and shortened terminal half-life causing a marked loss of drug efficacy. 
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Recent studies have identified that some ACNs are degraded to phenolic acids (44, 147, 148). 
It was identified in vitro that 4-hydroxybenzoic acid, protocatechuic acid, syringic acid, and 
vanillic acid, are the major degradation products of cyanidin, malvidin, peonidin, and 
pelargonidin (44). In addition, 4-hydroxybenzoic acid and protocatechuic acid were confirmed as 
the major human metabolites of cyanidin-glucosides and pelargonidin-3-glucoside, respectively, 
in vivo (148, 160). Thus, while the bioavailability of ACNs is poor, a large portion of ACNs are 
degraded to phenolic acids and the concentration of these phenolic acid metabolites might reach 
much higher levels than indicated by their bioavailability and actual quantity in dietary sources. 
Due to the large amount of ACNs in the human diet, it is vital to investigate the potential 
transporter-mediated DDIs induced by these ACN metabolites. 
Over 170 species of plants have been used as herbal medicines in the treatment of kidney 
injury and disease, and phenolic acids (e.g., p-coumaric acid, ferulic acid, gallic acid, sinapinic 
acid) were identified as major components in them (171). Oxidative damage induced by the 
formation of free radicals is one mechanism that results in nephropathy (171). Phenolic acids, 
bearing oxidizable functional groups, exhibit strong reactive oxygen species/free radical 
scavenging ability (140, 172, 173). A ranked order of antioxidant activity for some phenolic 
acids, according to their EC50 values, has been reported as gallic acid (0.0237 µM) > gentisic 
acid (0.0292 µM) > syringic acid (0.0427 µM) > caffeic acid (0.0478 µM) > protocatechuic acid 
(0.0574 µM) > sinapinic acid (0.0724 µM) > ferulic acid (0.0927 µM) > isoferulic acid (5.68 
µM) > vanillic acid (14.37 µM) > p-coumaric acid (66.29 µM) > o-coumaric acid (130.05 µM) > 
m-coumaric acid (>300 µM) > 4-hydroxybenzoic acid (>800 µM) ≈ salicylic acid (>800 µM) 
(172, 173). All of the compounds tested in the present study showed significant interactions with 
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hOAT3, while five of them showed significant inhibition on hOAT1, thus OAT-mediated 
accumulation in renal proximal tubule cells might explain their nephroprotective effects. 
In addition, these phenolic acids might have the potential to treat renal injury induced by 
nephrotoxic drugs including β-lactam antibiotics (cephalosporins and penems) and antivirals 
(adefovir and cidofovir). OATs have been demonstrated to be involved in the uptake of these 
nephrotoxic drugs in proximal tubule cells (174, 175). Some OAT inhibitors, including 
probenecid and NSAIDs, efficiently attenuated this drug-induced renal damage at clinically 
relevant concentrations (130, 176). Therefore, phenolic acids might prove useful as an alternative 
treatment in the management of OAT-mediated nephrotoxicity of drugs, without producing side 
effects. 
In summary, we have demonstrated the interaction of dietary phenolic acids with hOAT1, 
hOAT3, and hOAT4. These results indicated that OAT-mediated food/drug-drug interactions 
involving these phenolic acids might occur in vivo. Among the tested compounds, gallic acid and 
gentisic acid showed strong potential for food/drug-drug interactions. In the absence of protein 
binding and Cmax information, the DDI potential of sinapinic acid could not be fully addressed, 
however the IC50/Ki values are consistent with this possibility. Future in vivo interaction studies 
between gallic acid and gentisic acid and clinical therapeutics that are known hOAT1 and 
hOAT3 substrates appear necessary in order to establish safety guidelines for relevant 
pharmaceutical products. 
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CHAPTER 6 
 
 
 
INTERACTION OF NATURAL DIETARY AND HERBAL ANIONIC COMPOUNDS 
AND FLAVONOIDS WITH HUMAN ORGANIC ANION TRANSPORTERS 1 
(SLC22A6), 3 (SLC22A8), AND 4 (SLC22A11) 
 
Drawn from manuscript published in Evid Based Complement Alternat Med. Vol.2013, Article 
ID 612527, 7 pages, 2013. 
 
 
 
 
 
 
6.A INTRODUCTION 
In concert with our growing knowledge of drug transporter expression and function, 
transporter-mediated drug-drug interactions (DDIs) are being increasingly identified by 
numerous in vitro and in vivo studies (3, 177). Recently, government agencies in the United 
States (Food and Drug Administration) and Europe (European Medicines Agency), as well as the 
pharmaceutical industry, have acknowledged that transporters play a key role in the absorption, 
distribution, and excretion of many clinical therapeutics. Organic anion transporter 1 (OAT1; 
SLC22A6), OAT3 (SLC22A8), and OAT4 (SLC22A11) are among the transporters identified, 
thus far, to impact the pharmacokinetics, and hence dosing, efficacy and toxicity, of some drugs. 
OAT1 and OAT3, expressed in the basolateral membrane of renal proximal tubule cells in both 
humans and preclinical species, function as key mediators for organic solute flux from blood to 
the glomerular filtrate (3, 177). Additionally, OAT4, which is exclusively expressed in the apical 
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membrane of human proximal tubules, reabsorbs anionic compounds from the urine (177). 
Further, many endogenous substances, including hormones, neurotransmitters and toxins, have 
been identified as substrates and/or inhibitors of OATs (3, 177). Thus, the potential clinical 
significance of OAT-mediated DDIs is firmly recognized.  
Although many studies have exhibited OAT-mediated DDIs for synthesized drugs, relatively 
little is known about the potential interaction between OATs and natural products, including 
various organic anions, phenolic acids and flavonoids found in herbal supplements and food. 
Several dietary flavonoids and their metabolic conjugates (e.g., sulfates and glucuronides) were 
identified as potent inhibitors and/or substrates of human (h) OAT1, hOAT3 and hOAT4 (48, 
119). Phenolic acids, e.g., contained in the widely used Chinese herbal medicine Danshen (Salvia 
miltiorrhiza) or common berries such as strawberries or blueberries, were similarly demonstrated 
to interact with these three transporters (52). These studies highlight the strong potential for 
hOAT-mediated natural product-drug interaction and the need to investigate further anionic 
compounds and flavonoids that are found in popular complementary/alternative medicines and 
natural supplements. 
Catechin and epicatechin are major components of tea products, possessing anti-oxidative 
and purported anti-cancer properties (178, 179). 1,3- and 1,5-dicaffeoylquinic acids are two 
enantiomers of dicaffeoylquinic acid with various pharmacological effects, which are widely 
distributed in plants (e.g., coffee beans, sweet potato leaves, and fennels) (180). Indeed, 1,3- 
dicaffeoylquinic acid (also known as cynarin) is being actively investigated for its anti-HIV and 
immunosuppressive properties (181). Extracts of Ginkgo biloba have gained popularity as an 
herbal supplement because they are believed to improve mental sharpness and memory, while 
slowing brain aging, and were hoped to be effective in relieving symptoms associated with 
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Alzheimer’s disease. Regardless, it is well recognized that several ginkgolic acids, particularly 
(13:0), (15:1) and (17:1) (designating the number of carbon atoms in the alkyl side chain) can 
produce severe allergic, cytotoxic, mutagenic, carcinogenic, and genotoxic effects (182). 
Licorice root (Radix Glycyrrhizae) is employed to relieve a number of maladies including 
stomach ulcers, colic, chronic gastritis, sore throat, bronchitis, osteoarthritis, liver disorders, 
malaria and tuberculosis. One major component of Radix Glycyrrhizae preparations, glycyrrhizin, 
gives rise to two bioactive metabolites, 18α- and 18β-glycyrrhetinic acid, thought to play a role 
in these beneficial effects (183). Ursolic acid is a pentacylic triterpene acid occurring naturally in 
herbs and fruits. It exhibits anti-inflammatory and anti-carcinogenic activities (184) and is 
marketed as an herbal supplement to promote weight loss. Since these compounds have been 
identified as major components of first-line/complementary/alternative medicines, foods, and 
beverages, humans can be exposed to these compounds through clinical therapies and the daily 
diet. Many of these compounds have shown systemic exposure in humans (Table 6.1). Based on 
their chemical structures and previous studies, these compounds have the potential to interact 
with OATs. Thus, OAT-mediated DDIs may occur in vivo when combined with known OAT 
substrates and such information should prove helpful in guiding the safe use and development of 
products that contain these compounds. 
Therefore, the purpose of the present study was to investigate the inhibitory potential of these 
nine compounds, catechin, epicatechin, 1,3- and 1,5-dicaffeoylquinic acids, ginkgolic acids 
(13:0), (15:1) and (17:1), 18β-glycyrrhetinic acid, and ursolic acid, on hOAT1-, hOAT3- and 
hOAT4-mediated transport. In addition to generating transporter specific inhibition profiles, 
dose-response studies were conducted for potent inhibitors in order to derive inhibitory constants 
(IC50 and Ki values) to aid evaluation of their potential for clinical OAT-mediated DDIs. 
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Table 6.1. Maximum plasma concentration (Cmax) reported in human subjects 
 
Compound Cmax (µM) Route of administration Dose (mg) Reference 
Epicatechin 0.20 Oral 37 (178) 
1,5-Dicaffeoylquinic acid 0.14 Oral 600 (185) 
18β-Glycyrrhetinic acid 0.11-2.9a Oral 130-144 (Glycyrrhizin) (183, 186, 187) 
Ursolic acid 7.4 i.v. 186 (184) 
 
aAssuming plasma concentration of 18α- and 18β-glycyrrhetinic acid is about 1:3 as reported in (183). 
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6.B MATERIALS AND METHODS  
6.B.1 Purified chemicals 
Catechin, 1,3- and 1,5-dicaffeoylquinic acids, epicatechin, ginkgolic acids (13:0), (15:1), and 
(17:1), and ursolic acid (all ≥ 97% purity) were purchased from Tauto Biotech (Shanghai, China). 
18β-Glycyrrhetinic acid (≥ 97% purity) was obtained from Sigma -Aldrich (St. Louis, MO). The 
chemical structures of these compounds are shown in Figure 6.1. Tritiated p-aminohippuric acid 
([3H]PAH) and estrone sulfate ([3H]ES) were purchased from PerkinElmer Life and Analytical 
Sciences (Waltham, MA) and unlabeled PAH, ES, and probenecid were purchased from Sigma-
Aldrich (St. Louis, MO).  
6.B.2 Cell culture 
Derivation and culture of stably transfected Chinese hamster ovary (CHO) cells expressing 
hOAT1 (CHO-hOAT1) and hOAT4 (CHO-hOAT4), and stably transfected human embryonic 
kidney 293 (HEK) cells expressing hOAT3 (HEK-hOAT3), as well as their corresponding empty 
vector transfected background control cell lines, has been described previously (82, 130, 150). 
6.B.3 Cell accumulation assays 
The cell accumulation assay protocol was performed as described in our recent publications 
with minor modifications (82, 109). In brief, 2 × 105 cells/well were seeded in 24-well tissue 
culture plates and grown in the absence of antibiotics for two days. For transport experiments 
cells were pre-incubated in transport buffer without substrates or inhibitors for 10 min after 
which time the buffer was replaced with 400 µL of fresh transport buffer containing 1 µM 
[3H]PAH (0.5 µCi/mL) or [3H]ES (0.25 µCi/mL) with or without test compounds. After 
incubation for times specified in the figure legends, cellular uptake was quenched by quickly 
rinsing each well three times with fresh ice-cold transport buffer. Cells were lysed with 1 M 
 
 
 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Chemical structures of compounds investigated in this study.  
 
MW, molecular weight. 
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NaOH and radioactivity was measured with a liquid scintillation counter and reported as 
picomoles of substrate per milligram total protein. All intracellular uptake data were corrected 
for background accumulation in corresponding empty vector transfected control cells. Kinetic 
calculations were performed using GraphPad Prism Software version 5.0 (GraphPad Software 
Inc., San Diego, CA). The half maximal inhibitory concentrations (IC50) and inhibitory constants 
(Ki) were calculated using nonlinear regression with the appropriate models. Results were 
confirmed by repeating all experiments at least three times with triplicate wells for each data 
point. For kinetic analysis, hOAT1 expressing cells showed linear PAH uptake for the initial 3 
min with Km = 15.4 µM (130), while hOAT3 expressing cells exhibited linear ES uptake for the 
initial 1 min with Km = 14.5 µM (52). 
6.B.4 Statistics 
Values are expressed as mean ± S.D. or mean ± S.E.M. as indicated. Statistical differences 
were assessed using one-way analysis of variance (ANOVA) followed by post-hoc analysis with 
Dunnett’s t-test (α = 0.05). 
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6.C RESULTS 
6.C.1 Inhibition of hOAT1 by natural anionic compounds and flavonoids 
Approximately three fold greater accumulation of PAH was observed in CHO-hOAT1 cells 
(6.30 ± 0.97 pmol mg protein‒1 10 min‒1) than in empty vector transfected background control 
cells (2.12 ± 0.19 pmol mg protein‒1 10 min‒1). The hOAT1-mediated PAH accumulation was 
almost completely inhibited by probenecid (Figure 6.2). The nine test compounds, catechin, 1,3- 
and 1,5-dicaffeoylquinic acid, epicatechin, ginkgolic acids (13:0), (15:1) and (17:1), 18β-
glycyrrhetinic acid, and ursolic acid, were assessed for inhibitory effects on hOAT1-mediated 
uptake (Figure 6.2). 1,3- and 1,5-Dicaffeoylquinic acid (64% and 22% inhibition, respectively), 
ginkgolic acid (17:1) (42% inhibition) and 18β-glycyrrhetinic acid (56% inhibition) each 
significantly inhibited hOAT1-mediated PAH uptake at 50 fold excess. Ursolic acid produced a 
significant stimulation of uptake and the other compounds were without effect. Since 1,3-
dicaffeoylquinic acid and 18β-glycyrrhetinic acid produced inhibition greater than 50%, they 
were further characterized by dose-response studies (0.01–500 μM, shown in Figure 6.3). 
Estimated IC50 values were 1.2 ± 0.4 µM for 1,3-dicaffeoylquinic acid and 2.7 ± 0.2 µM for 18β-
glycyrrhetinic acid. Numerous studies investigating the mode of inhibition produced on hOAT1 
and hOAT3 for a broad array of compounds have demonstrated the interaction to be competitive 
(51, 151, 188-190). Therefore, assuming competitive inhibition of hOAT1, inhibition constants 
(Ki) were estimated as 1.1 ± 0.2 µM for 1,3-dicaffeoylquinic acid and 2.5 ± 0.2 µM for 18β-
glycyrrhetinic acid. 
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Figure 6.2. Inhibitory effects of the nine test compounds on hOAT1-mediated PAH uptake 
 
Ten minute uptake of [3H]PAH (1 µM) was measured in CHO-hOAT1 cells in the absence and 
presence of test compounds (50 µM) or probenecid (1000 µM). Data represent hOAT1-mediated 
transport specifically, i.e., data have been corrected for background PAH accumulation measured 
in empty vector transfected cells. Values are mean ± S.D. of triplicate values from a 
representative experiment. ** denotes p < 0.01, and *** denotes p < 0.001 as determined by one-
way ANOVA followed by Dunnett’s t-test. 
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Figure 6.3. Dose-response effects for 1,3-dicaffeoylquinic acid and 18β-glycyrrhetinic acid 
on hOAT1-mediated PAH transport 
 
One minute uptake of [3H]PAH (1 µM) in CHO-hOAT1 cells was measured in the presence of 
increasing concentrations (10-7 to 5×10-4 M) of test compounds. Data were corrected by 
subtracting background PAH accumulation measured in empty vector transfected cells. IC50 
values were determined with nonlinear regression and the “log(inhibitor) vs. response” model 
using GraphPad Prism software. Experiments were repeated three times with triplicate samples 
and graphs shown are from representative experiments with values plotted as mean ± S.D. (n=3). 
The data were used to generate mean IC50 ± S.E.M. estimates. 
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6.C.2 Inhibition of hOAT3 by natural anionic compounds and flavonoids 
Human OAT3 expressing cells showed about 4 fold greater accumulation of ES as compared 
to background control cells (10.6 ± 0.5 vs. 2.6 ± 0.3 pmol mg protein‒1 10 min‒1, respectively). 
Similar to hOAT1, hOAT3-mediated ES uptake was completely (> 96% inhibition) blocked by 
probenecid (Figure 6.4). Five of the compounds, 1,3- and 1,5-dicaffeoylquinic acid, epicatechin, 
and ginkgolic acids (15:1) and (17:1) significantly inhibited hOAT3-mediated transport at 50 
fold excess (Figure 6.4). 1,3-Dicaffeoylquinic acid and ginkgolic acid (17:1) exhibited 41% 
inhibition, while 30-35% reduction of hOAT3-mediated ES uptake was observed for 1,5-
dicaffeoylquinic acid, epicatechin, and ginkgolic acid (15:1). Catechin, 18β-glycyrrhetinic acid 
and ursolic acid failed to produce significant inhibition. Based on the level of inhibition observed, 
IC50 values for all of these compounds would be greater than 50 µM, much higher than clinically 
relevant concentrations (Table 6.1). Therefore, further dose-response studies were not performed.  
6.C.3 Inhibition of hOAT4 by natural anionic compounds and flavonoids 
Stably transfected hOAT4-expressing cells showed ~18 fold higher accumulation of ES than 
background control cells (42.5 ± 5.1 vs. 2.4 ± 0.2 pmol mg protein‒1 10 min‒1, respectively). 
Human OAT4-mediated ES uptake was virtually completely blocked (> 96% inhibition) by self-
inhibition (Figure 6.5). Catechin (50 µM) was the only compound that showed a significant 
inhibitory effect (32%) on hOAT4 (Figure 6.5). 1,5-Dicaffeoylquinic acid and 18β-glycyrrhetinic 
acid produced significant stimulation of ES uptake. Accordingly, the IC50 value for catechin on 
hOAT4 transport activity should be greater than 50 µM and no further kinetic studies were 
performed. 
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Figure 6.4. Inhibitory effects of the nine test compounds on hOAT3-mediated ES uptake 
 
Ten minute uptake of [3H]ES (1 µM) was measured in HEK-hOAT3 cells in the absence and 
presence of test compounds (50 µM) or probenecid (1000 µM). Data represent hOAT3-mediated 
transport specifically, i.e., data have been corrected for background ES accumulation measured 
in empty vector transfected cells. Values are mean ± S.D. of triplicate values from a 
representative experiment. * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 as 
determined by one-way ANOVA followed by Dunnett’s t-test. 
 
 
 
 
 
 
 
 
 
 110 
 
 
 
 
 
 
 
Figure 6.5. Inhibitory effects of the nine test compounds on hOAT4-mediated ES uptake 
 
Ten minute uptake of [3H]ES (1 µM) was measured in CHO-hOAT4 cells in the absence and 
presence of test compounds (50 µM) or ES (1000 µM for self-inhibition). Data represent 
hOAT4-mediated transport specifically, i.e., data have been corrected for background ES 
accumulation measured in empty vector transfected cells. Values are mean ± S.D. of triplicate 
values from a representative experiment. * denotes p < 0.05, and *** denotes p < 0.001 as 
determined by one-way ANOVA followed by Dunnett’s t-test. 
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6.D DISCUSSION 
Literally hundreds of therapeutic and endogenous compounds have been demonstrated to 
interact with OATs (3, 177). Precisely because of their broad, polyspecific nature, OATs are 
likely sites for DDIs in vivo. As a consequence, they have been identified worldwide as a family 
of “clinically relevant” transporters in recent government guidances to the pharmaceutical 
industry (3, 177). Unlike Western drugs, the pharmacokinetic and pharmacological properties of 
botanical drug products and natural supplements have not been well investigated. Being naturally 
derived, people often view these compounds as “safe” and without potential for causing adverse 
events. However, there is increasing evidence demonstrating potent interactions between 
components of natural products and OATs, resulting in possible toxicity and DDIs (3, 177). For 
example, aristolochic acid, a potent nephrotoxic contaminant sometimes found in certain Chinese 
herbal therapies, was identified as a high affinity substrate of murine Oat1, Oat2 and Oat3, as 
well as a potent inhibitor of hOAT1, hOAT3 and hOAT4 (36, 39). Additional studies have 
demonstrated the OAT-mediated DDI potential for common flavonoid and phenolic acid 
components of foods and herbal medicines (48, 119). These investigations showed that many 
dietary/phytomedicine-derived organic acids and flavonoids have a high inhibitory potency for 
hOAT1, hOAT3 and/or hOAT4 and, according to proposed guidelines established by the FDA 
and EMA, high likelihood to result in significant DDIs in vivo (3, 48, 119, 177). Therefore, 
further studies on OAT-mediated natural product/drug interactions are needed in order to 
establish informed safety and efficacy profiles for botanical products. 
In the present study, we characterized the interactions of nine chemically diverse compounds 
including flavonoids, chlorogenic acids, phenolic acids, and other organic acids, found as major 
dietary or phytomedicine components, with three human OATs: hOAT1, hOAT3, and hOAT4. 
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As illustrated, most of the compounds produced significant inhibition of hOAT1 and hOAT3 at a 
50 fold excess concentration (Figures 6.2 and 6.4). In marked contrast, only catechin 
significantly inhibited hOAT4 under this condition (Figure 6.5). Interestingly, ursolic acid 
caused a significant stimulation of hOAT1-mediated PAH uptake while it was without effect on 
either hOAT3 or hOAT4 transport activity. Similarly, 1,5-dicaffeoylquinic acid and 18β-
glycyrrhetinic acid appeared to significantly stimulate hOAT4 transport while decreasing 
hOAT1- and hOAT3-mediated uptake. Such sporadic transporter stimulation/inhibition has been 
previously reported in the literature for other compounds. For example, for fluoroquinolone 
antimicrobials, ciprofloxacin inhibited hOAT3, but stimulated hOAT1 (82) and sparfloxacin was 
reported to stimulate multidrug resistance-associated protein 2 activity (170). Such stimulation of 
transport activity in vitro also has been reported for steroids, chemotherapeutic agents, and non-
steroidal anti-inflammatory drugs (82, 169, 170, 191). One potential explanation is allosteric 
binding of the compounds to the transporters with subsequent alteration of substrate affinity (169, 
170). However, these transporters share a high degree of sequence identity and no readily 
discernible structural differences corresponding to such a binding site are apparent, and these 
effects do not exhibit a consistent pattern among the hOATs. Whether these effects will be 
observed in vivo is yet to be determined, however, in such an instance increased (vs. decreased) 
elimination and shortened (vs. lengthened) terminal half-life of victim drugs could occur causing 
loss of efficacy. 
The FDA guidance on drug interaction studies proposed using the DDI index, calculated as 
the ratio of unbound Cmax over IC50 or Ki, as an indicator for the assessment of a compound’s 
DDI potential, with a value greater than 0.1 indicating the potential need to perform an in vivo 
DDI study for an investigational drug. In the current study, 18β-glycyrrhetinic acid exhibited 
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strong inhibition of hOAT1 with an estimated IC50 of 2.7 ± 0.2 µM or Ki of 2.5 ± 0.2 µM 
(Figures 6.3). Human exposure studies reported Cmax values ranging from 0.11 to 2.9 µM (Table 
6.1), perhaps due to interindividual variability, different doses, and/or dosing regimen (single 
dose vs. repeated dose). As such, the maximum DDI for 18β-glycyrrhetinic acid is ~1.1; 
although this value does not account for plasma protein binding as this is unknown. However, if 
we assume it to be highly plasma protein bound, e.g., 90%, the DDI index would be 0.12, 
meeting the FDA guidance threshold of 0.1. Therefore, 18β-glycyrrhetinic acid may affect 
hOAT1-mediated renal elimination of coadministered therapeutics that are hOAT1 substrates. 
1,3-Dicaffeoylquinic acid is a major component found in artichoke and Echinacea purpurea 
(192, 193). Pharmacological studies demonstrated that it exhibits antimicrobial and antioxidant 
activity (192, 194). Moreover, it has garnered increased interest because of its anti-HIV and 
immunosuppressive properties. 1,3-Dicaffeoylquinic acid blocked HIV-1 integrase activity, 
leading to interference of insertion of viral DNA into the genome of the victim cell (181). 
Another study demonstrated that it inhibited the interaction between CD28 of T-cell receptor and 
CD80 of antigen presenting cells, blocking “signal 2” of T-cell activation (193). Due to its 
potential development as a therapeutic agent, systemic exposure in clinical applications may 
reach high levels. In the present study, 1,3-dicaffeoylquinic acid showed high affinity with 
hOAT1 (IC50 = 1.2 ± 0.4 µM; Ki = 1.1 ± 0.2 µM). Therefore, the dose-systemic exposure 
relationship and plasma protein binding should be elucidated as part of the future drug 
development process for this compound. 
It has been reported that flavonoids can interact with OATs (48). Therefore, catechin and 
epicatechin, two flavonoid components from green tea were investigated for potential interaction 
with hOAT1, hOAT3 and hOAT4. Both compounds exhibited significant inhibition of hOAT4 
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and hOAT3 when present at a 50 fold excess, however no inhibition was observed for hOAT1. 
Because of low reported clinical plasma concentrations (Table 6.1), these flavonoids were 
determined to be unlikely to cause DDIs after normal consumption of tea products. However, 
OATs might promote entry of these antioxidants into renal proximal tubules, providing a 
nephroprotective effect. 
In summary, we investigated the potential interaction of nine flavonoids, phenolic acids, 
chlorogenic acids, and other organic acids with hOAT1, hOAT3, and hOAT4. Among the 
examined compounds, 1,3-dicaffeoylquinic acid and 18β-glycyrrhetinic acid showed marked 
affinity with hOAT1. In humans, systemic exposure of 18β-glycyrrhetinic acid may induce 
significant hOAT1-associated DDIs. Future in vivo interaction studies between 18β-
glycyrrhetinic acid or 1,3-dicaffeoylquinic acid and clinical therapeutics known to be hOAT1 
substrates may be necessary to establish safety guidelines for use of pharmaceutical products 
containing these compounds to avoid potential DDIs.  
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CHAPTER 7 
 
SIMULTANEOUS DETERMINTION OF GALLIC ACID AND GENTISIC ACID IN 
ORGANIC ANION TRANSPORTER EXPRESSING CELLS BY LIQUID 
CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY 
 
 
 
Drawn from manuscript submitted in J Chromatogr B. 2013 
 
 
 
 
 
 
7.A INTRODUCTION 
Over the last two decades, impressive progress has been made to elucidate the impact of drug 
transporters in drug absorption, disposition, and elimination, therapeutic efficacy and adverse 
drug reactions (3, 177). In order to understand the role of drug transporters in pharmacokinetics 
and avoid potential drug-drug interactions (DDIs), the United States Food and Drug 
Administration (FDA) has recently issued guidance documents, requiring investigations on 
potential new drug entity-drug transporter interaction on seven identified transporters; organic 
anion transporter 1 (OAT1), OAT3, organic cation transporter 2, organic anion transporting 
polypeptide 1B1, organic anion transporting polypeptide 1B3, multidrug resistance transporter 1, 
and breast cancer resistance protein, prior to approval (52). 
Numerous studies demonstrated that OATs handle substances carrying negative charge(s) at 
physiological pH (3, 177). Phenolic acids (plant secondary metabolites that are widely 
distributed in fruits, vegetables, and beverages) might be OAT substrates, since the PKa values 
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for these compounds are much less than 7.4 (43). They are characterized by hydroxylated 
aromatic ring(s) bearing carboxyl substituents (140). In general, phenolic acids, including gallic 
acid and gentisic acid, possess anti-oxidant, anti-carcinogenic, and anti-inflammatory activities 
(162, 163). Gallic acid, in addition to fruits and vegetables, is a major component in herbal 
supplements, homeopathic remedies, and pharmaceutical products (139, 162, 163). Gentisic acid 
was identified as a major metabolite of salicylate (143). Pharmacokinetic studies have shown that 
these compounds undergo renal elimination as the unchanged parent form (144, 163). Our 
previous work demonstrated that gallic acid and gentisic acid have high affinity for human 
OAT1 and OAT3, with IC50 values in the low micromolar range (52). However, whether these 
compounds are actually OAT substrates, or only non-transported inhibitors, remains unclear. 
This information is key to determining whether OAT-mediated active secretion is involved in the 
renal elimination of these compounds. In addition, since such interaction would result in 
preferential tissue distribution, the findings would be helpful to show the target organ(s) in which 
these compounds exert beneficial therapeutic effects. 
To address this issue, a sensitive, robust, and precise bioanalytical method is required for 
quantification of gallic acid and gentisic acid in cell lysate. Compared with other routine 
analytical techniques, liquid chromatography (LC) interfaced to mass spectrometry (MS) or 
tandem mass spectrometry (MS/MS) has facilitated sensitive and selective quantification in 
pharmaceutical studies. For published assays describing LC-MS/MS based measurement of 
gallic acid and gentisic acid in a biological matrix, insufficient sensitivity (LLOQ of 0.5 and 9.4 
ng/mL, respectively) and limited linear dynamic range (0.5-500 and 9.4-191.5 ng/mL, 
respectively) make these methods less desirable for quantifying drug transporter mediated-
cellular uptake of gallic acid and gentisic acid (195, 196). In addition, the run-time of the 
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reported quantification method for gentisic acid is long (17 min) (196). Furthermore, 
electrospray ionization (ESI), which allows analysis of non-volatile, polar molecules compared 
with other ion source designs (e.g., atmospheric pressure chemical ionization (APCI)), is more 
susceptible to matrix effects, exhibiting as impaired assay accuracy and precision. Unfortunately, 
previously published assays did not evaluate matrix effect (195, 196), or only investigated 
plasma-derived matrix effect (195, 196). For the purpose of cell-based bioassay, the potential 
matrix effect caused by cell lysate matrix should be studied. To the best of our knowledge, 
however, no liquid chromatography-tandem mass spectrometry (LC/MS-MS) based assay has 
been established to directly measure the uptake of gallic acid or gentisic acid in cell lysate. 
In the present study, a rapid, sensitive, and reproducible LC/MS-MS method was developed 
and validated to simultaneously determine the concentrations of gallic acid and gentisic acid in 
cell lysate. The method requires 100 μL of cell lysate to obtain a lower limit of quantification of 
0.33 ng/mL and a chromatographic run time of 3 min for both analytes. Results from post-
column infusion and the post extraction addition method indicate that the quantification of both 
analytes was not affected by matrix effects. Compared with previously described methods, this 
new method exhibits higher analytical performance with respect to sensitivity, linear dynamic 
range, and speed. Following validation, the assay utility was demonstrated in a measurement of a 
cellular uptake study of gallic acid and gentisic acid in OAT-expressing cells. 
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7.B MATERIAL AND METHODS 
7.B.1 Chemicals and reagent 
Gallic acid, gentisic acid, probenecid, and sodium L-ascorbate (≥ 97% purity) were 
purchased from Sigma-Aldrich (St. Louis, MO). Danshensu (≥ 96% purity) was used as the 
internal standard (IS) and purchased from Tauto Biotech (Shanghai, China). The chemical 
structures of gallic acid, gentisic acid, and the IS are shown in Figure 7.1. HPLC-grade acetic 
acid (CH3COOH, 99.93%), acetonitrile (CH3CN 99.9%), ethyl acetate (EtOAc, 99.84%), and 
formic acid (HCOOH, 99.93%) were purchased from Merck (Darmstadt, Germany). Deionized 
water was generated from a Direct-Q1 3 UV water purifying system (Millipore, Bedford, MA). 
7.B.2 Instrumentation 
An API 4000Qtrap hybrid triple quadrupole/linear ion trap mass spectrometer (AB Sciex., 
Foster City, CA) was interfaced with an electrospray ionization source with liquid 
chromatography including a Waters Acquity UPLC® system (Waters Corporation, Milford, PA). 
Analyst 1.5 data acquisition software (Waters Corp., Milford, MA, USA) was used to control the 
LC-MS/MS system, as well as for data acquisition and processing. Nitrogen gas was generated 
from a Parker Hannifin (Haverhill, MA, USA) Tri-Gas Generator LC/MS 5000. 
7.B.3 LC-MS/MS condition 
The analytes and the IS were separated on a Gemini C18 column (100 mm × 2.0 mm I.D., 5 
μm) with a Security Guard column (Gemini C18, 4 mm × 2.0 mm, 5 μm) from Phenomenex 
(Torrance, CA, USA). Mobile phases consisted of 0.1% acetic acid in water (A) and 0.05% 
formic acid in acetonitrile (B). An isocratic elution (40% A) was conducted with a flow rate of 
0.35 mL/min. The total run time was 3 min. 
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Figure 7.1. Chemical structures of gallic acid, gentisic acid, and Danshensu (IS) were 
drawn using ChemDraw Ultra (PerkinElmer Inc., Waltham, MA) 
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The mass spectrometer was operated in the negative ESI mode with selected reaction 
monitoring (SRM). The optimized mass spectrometric parameters were as follows: ion source 
temperature (TEM = 325 °C), ion transfer voltage (ITV = ‒4500 V), collision gas (CAD = high), 
curtain gas (CUR = 14), ion source gas 1 (GS1 = 55) and ion source gas 2 (GS2 = 20). The units 
for gases are arbitrary. The dwell time was 200 ms for all test compounds. SRM transitions, 
collision energies (CE), declustering potential (DP), and Q3 fragment ion descriptions are shown 
in Table 7.1. 
7.B.4 Cell culture 
Derivation of stably transfected Chinese hamster ovary (CHO) cells expressing murine Oat1 
(CHO-mOat1) and murine Oat3 (CHO-mOat3), and corresponding empty vector transfected 
background control cell line (CHO-FRT), has been described previously (82). CHO cell lines 
were maintained at 37°C with 5% CO2 in DMEM F-12 media (Mediatech, Inc., Herndon, VA) 
containing 10% serum, 1% Pen/Strep and 125 µg/ml hygromycin B. 
7.B.5 Sample preparation 
Cell lysate samples (100 µL) were mixed with 10 µL of the 1000 ng/mL IS working solution 
and 10 µL of the 50 µM ascorbic acid working solution to prevent oxidation. Then the sample 
was acidified with 5 µL of 2N hydrochloric acid and extracted with 900 µL of EtOAc by vortex-
shaking for 10 min. After centrifugation at 13000 rpm for 5 min, the upper EtOAc phase (800 µL) 
was removed and reduced to dryness under a stream of nitrogen at 40°C at 15-20 PSI. The dry 
residue was reconstituted in 150 µL of reconstitution solvent (acetonitrile/H2O; 25:75 v/v) 
containing 0.1% acetic acid and 5 µM ascorbic acid, centrifuged at 13000 rpm for 5 min, and 20 
µL of the supernatant was introduced into the LC-MS/MS system. 
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7.B.6 Calibration and validation. 
Blank cell lysate samples (995 µL) were spiked with 5 µL of the gallic acid and gentisic acid 
working solution (1000 µg/mL) and then serially diluted with blank cell lysate to generate 
nominal concentrations of 2400, 1000, 500, 200, 80, 32, 12.8, 5.12, 2.05, 0.82 and 0.33 ng/mL 
for both analytes, respectively. These matrix-based calibration standards were extracted with 
EtOAc for analysis. Calibration curves were constructed using linear regression of the peak area 
ratio of the analytes to the IS (Y) against the corresponding nominal concentrations of the 
analytes in cell lysate (X, ng/mL) with a weighting factor of 1/x2. 
The extraction efficiency was assessed by comparing the peak areas of the analytes added to 
blank cell lysate at three levels (1, 50, and 2000 ng/mL) before sample clean-up with the same 
amount of the analytes added to post-extraction cell lysate blanks (n=6). The stability test 
included freeze/thaw stability in cell lysate during and after three -80°C↔25°C (room 
temperature) cycles at two levels (1 and 2000 ng/mL), short-term stability in cell lysate at 25°C 
for 6 h and long term stability in cell lysate at -80°C for 1 month at two levels (1 and 2000 
ng/mL), and post-preparation stability in reconstitution solution at 4°C for 24 h at three levels (1, 
50, and 2000 ng/mL). The long term stock solution stability (6 months) was also investigated. 
For each concentration level, quality control (QC) standards were prepared and extracted n=6. 
QC samples at 1, 50, and 2000 ng/mL (n=6) were determined on the same day or three 
different days to evaluate intra-day or inter-day precision and accuracy, respectively. Intra-
day/inter-day accuracy and precision were calculated as the percentage of mean measured 
concentration to the corresponding nominal concentration and coefficient of variation of the 
measured concentrations. The lower limit of quantification (LLOQ) was determined based on the 
criterion of being within ±20% of precision and accuracy. 
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7.B.7 Matrix effects evaluation 
Matrix effects were assessed by both post-column infusion and post extraction method. The 
procedure for post-column infusion was described previously (197). Briefly, the prepared blank 
cell lysate sample was injected while infusing the analytes and the IS (1000 ng/mL) in 
reconstitution solution at 15 µL/min into the ESI interface through a mixing tee. Compared to 
resulting profiles of mobile phase injection, response change observed from the blank cell lysate 
sample indicates ionization suppression or enhancement. Post extraction method was conducted 
by comparing the peak areas of the analytes (1, 50, and 2000 ng/mL) and the IS (100 ng/mL) 
dissolved in reconstitution solution versus post-spiked extracted cell lysate (n=6). The ratio of 
mean peak areas for the test compounds in pure reconstitution solution to those with sample 
matrix was used to quantify matrix effects.  
7.B.8 Application to cellular uptake study 
The protocol for the cellular accumulation studies was adapted from a previously published 
study with minor modifications (52). In brief, cells were seeded in 24-well tissue culture plates at 
a density of 2 × 105 cells/well and grown in the absence of antibiotics for 48 h. Then, the cells 
were equilibrated with 500 µL of transport buffer [Hanks’ balanced salt solution containing 10 
mM HEPES (Sigma-Aldrich, St. Louis, MO), pH 7.4] for 10 min. The equilibration buffer was 
then replaced with 500 µL of fresh transport buffer containing 10 µM gallic acid or gentisic acid. 
After incubation for 10 min, cells were immediately rinsed three times with ice-cold transport 
buffer, and lysed with 200 µL 1 N NaOH. Cell lysate was neutralized with 2 M HCl (100 µL). 
Aliquots (100 µL) were extracted as described in Section 2.4 for LC-MS/MS analysis and total 
protein determination using a Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA). 
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7.C RESULTS AND DISCUSSION 
7.C.1 LC-MS/MS 
The chemical structures of gallic acid and gentisic acid indicate that they are more likely to 
be deprotonated to produce [M–H]– in the ESI source, and this was confirmed by comparing the 
response of the analytes between positive and negative ESI mode. Parameters for mass 
spectrometry were optimized for quantification of gallic acid and gentistic acid in negative mode. 
Product ions for gallic acid and gentisic acid were chosen based upon intensity and 
reproducibility. A fast isocratic program was used to achieve optimal chromatographic behavior, 
with total run time of 3 min. Retention times were 0.98, 2.09, and 1.03 min for selected 
transitions of gallic acid (m/z 169.0→125.0), gentisic acid (m/z 153.1→108.0), and the IS (m/z 
196.8→135.2), respectively. The chosen mobile phase additive conditions (0.1% acetic acid in 
mobile phase A and 0.05% formic acid in mobile phase B) improved chromatographic peak 
shape and intensity of the analytes. However, other mobile phase additives (0.1% acetic acid in 
mobile phase A and B, 0.05% formic acid in mobile phase A and B, and 0.1% formic acid in 
mobile phase A and B) were not suitable for gallic acid, as they resulted in asymmetrical peak 
shape or poor retention. Gallic acid and gentisic acid fragmentation patterns were identical with 
those previously described (196). Representative chromatograms of blank cell lysate, blank cell 
lysate spiked with gallic acid (200 ng/mL), gentisic acid (200 ng/mL), and the IS (100 ng/mL) 
are shown in Figure 7.2. 
7.C.2 Validation of the analytical method 
7.C.2.1 Linearity and specificity 
The intensity, shown as peak area ratio of gallic acid or gentisic acid to the IS in cell lysate, 
was linear over the range 0.33-2400 ng/mL. The calibration curves for quantification of the 
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tested compounds in cell lysate showed a correlation coefficient (r2) greater than 0.995. A 
weighting factor of 1/x2 was used for both analytes. The magnitude of linear dynamic range was 
much wider than previously reported methods (195, 196). The percent relative standard deviation 
for the mean back-calculated values fell within 15%, showing good accuracy for calibration 
standards. As shown in Figure 7.2, no co-elution of matrix components from cell lysate was 
observed at retention times corresponding to the analytes, demonstrating that the method had 
good specificity. Moreover, no cross-interference among the analytes and the IS was found. No 
significant peaks were found at retention times corresponding to the analytes and the IS in blank 
sample immediately following the calibration standards at upper limit of quantification (2400 
ng/mL), suggesting insignificant carryover for this method. An extract peak with constant signal 
(1500-3000 cps) was observed in the gallic acid channel, which was not seen in the blank cell 
lysate. While the exact reason for this extra peak is unknown, the proposed isocratic elution was 
capable of separating this peak from the peak for gallic acid, with retention times of 1.30 min 
and 0.98 min, respectively. This extra peak did not affect the calculation of peak area for gallic 
acid.  
7.C.2.2 Accuracy and precision 
Intra-day and inter-day precision and accuracy for the analytes are shown in Table 7.2. The 
maximum deviation of accuracy and precision for intra-day and inter-day validation were well 
below 13.5%. The LLOQ was determined at 0.33 ng/mL for both analytes, with the precision 
and accuracy within +14.1%.  
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7.C.2.3 Extraction recovery 
The mean extraction efficiency for gallic acid in cell lysate determined by analyzing the cell 
lysate QC standards at 1, 50, and 2000 ng/mL were 77.3 ± 9.8%, 76.5 ± 4.8% and 88.2 ± 4.6% 
respectively. The results for gentisic acid show a mean extraction recovery of 77.6-86.9% with 
the RSD below 3.5% (86.0 ± 3.5%, 86.9 ± 2.2% and 77.6 ± 0.9% for 1, 50, and 2000 ng/mL, 
respectively). The extraction recovery of the IS was 51.7 ± 2.3% at 100 ng/mL. As gallic acid, 
gentisic acid and the IS each carry a carboxylic group, a low pH environment favors maintaining 
unionized compounds in the sample, facilitating extraction. In this study, the chosen condition (5 
µL 2N hydrochloric acid) markedly improved extraction efficiency compared with the untreated 
condition. 
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Table 7.1. Selected reaction monitoring transitions and the optimum LC-MS/MS 
conditions 
 
Compound Q1 (Da) Q3 (Da) DPa CEb 
Gallic acid 169.0 125.0 ‒26 ‒25 
Gentisic acid 153.1 108.0 ‒26 ‒39 
Danshensu (IS) 196.8 135.2 ‒27 ‒24 
 
a Declustering potential; b Collision energy. 
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Figure 7.2. Example chromatograms for the analytes and IS in a typical blank cell lysate (upper panels), analytes and the IS 
dissolved in pure reconstitution solution (middle panels), and extracted cell lysate sample spiked with the analytes at LLOQ 
and the IS at 100 ng/mL (lower panels)  
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Figure 7.3. Post-column infusion profiles of the analytes and the IS (1000 ng/mL) in the absence (left panels) or presence (right 
panels) of cell lysate-derived matrix. Dashed lines indicate the retention time of the test compound 
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Table 7.2. Intra- and inter-day precision and accuracy in determination of gallic acid and gentisic acid 
 
 
Nominal Conc. (ng/mL) 
Gallic acid  Gentisic acid 
1 50 2000  1 50 2000 
Intra-day         
Measured Conc. (ng/mL) 
mean ± SD, n =6  1.06±0.11 50.6±2.08 1745±68.8 
 1.09±0.08 55.5±1.94 1832±56.9 
Precision (RSD, %) 10.4 4.11 3.94  7.34 3.50 3.11 
Accuracy (% bias) 6 1 -12.7  9 11 -8.4 
Inter-day*        
Measured Conc. (ng/mL) 
mean ± SD, n =6  0.99±0.10 45.2±5.00 1845±143 
 1.00±0.10 49.1±6.59 1868±100 
Precision (RSD, %) 10.1 11.1 7.75  10.0 13.4 5.35 
Accuracy (% bias) -0.7 -9.5 -7.7  0 -1.8 -6.6 
 
*QCs analyzed n =3 in three separate days 
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7.C.2.4 Matrix effects 
Matrix effects were firstly evaluated by post-column infusion of test compounds dissolved in 
reconstitution solution at 1000 ng/mL. Post-column infusion profiles were obtained in the ESI 
negative mode (shown in Figure 7.3) exhibiting matrix effects of EtOAc-extracted cell lysate on 
the response of the tested compounds. When compared to post-column infusion profiles for 
mobile phase, no significant matrix effects (indicated by ionization suppression or enhancement) 
were observed throughout the entire sample-run window in the presence of matrix components in 
the ESI source. The post-extraction addition study revealed that co-eluting matrix failed to 
exhibit significant suppression or enhancement (<15%) on the ESI response of both gallic acid 
and gentisic acid, confirming that matrix effects did not impact the established assay method.  
7.2.C.5 Stability 
Stability assessment was conducted by determination of QC standards treated under different 
conditions representing post-preparation stability, short and long term storage stability, stock 
solution stability, and freeze-thaw stability. Since phenolic compounds can be easily oxidized, an 
anti-oxidant was necessary to keep the analytes and the IS stable in the sample during 
preparation. In the present study, ~5 µM of ascorbic acid was determined to be sufficient for 
preventing oxidation while 20 µM impaired the chromatographic peak shape of gallic acid (data 
not shown). The accuracy of treated QC standards was calculated by freshly prepared calibration 
standards. QC standards for post-preparation stability exhibited acceptable accuracy and 
precision (±7%) at 1, 50, and 2000 ng/mL. Short and long term storage stability results ranged 
from −4.2% to 12.5% biases for test levels (1 and 2000 ng/mL). Gallic acid and gentisic acid in 
stock solution stored at ‒80°C for 6 months was stable, with peak area response difference never 
exceeding 1.7%. Freeze-thaw stability was assessed for three cycles at two levels (1 and 2000 
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ng/mL), resulting in biases ranged from 3.6 to 8.2%. The IS, Danshensu, failed to show 
significant degradation in reconstitution solution at 4°C for 24h, with a peak area response 
difference of 10.9%. 
7.C.3 Determination of the intracellular concentration of gallic acid and gentisic acid in OAT-
expressing cells. 
The suitability of the LC-MS/MS method presented here to determine gallic acid and gentisic 
acid levels in cell lysates from a cellular uptake study using murine (m)Oat1- or mOat3-
expressing cells (CHO-mOat1 cells and CHO-mOat3 cells, respectively) was tested. Inhibitor 
(probenecid)-sensitive transport activity of these transfected cells was confirmed previously (49). 
When incubated with gallic acid (10 µM) for 10 min, the intracellular concentration of gallic 
acid in CHO-mOat1 cells was 1.12 ± 0.33 ng/mL, while the concentrations of gallic acid in 
CHO-mOat3 cells, CHO-FRT(control cells), or probenecid-treated cells were below the LLOQ 
(Figure 7.4). These data indicate markedly increased intracellular uptake in the CHO-mOat1 
cells, as compared with CHO-FRT and CHO-mOat3 cells. The absorptive uptake was completely 
inhibited by probenecid (known OAT inhibitor) at 1 mM. Normalized with the protein content in 
cell lysate, the cellular uptake rate of gallic acid in mOat1-expressing cells was 10.4 ± 3.7 
ng/mL/mg protein/10 min. The intracellular concentration of gentisic acid in CHO-mOat1, CHO-
mOat3 and CHO-FRT background control cells after incubation were below the LLOQ (Figure 
7.4). 
These results indicate that gallic acid is a substrate for mOat1 and suggest that human OAT1 
might be involved in the active renal secretion of gallic acid. This finding is consistent with a 
previous clinical pharmacokinetic study showing that the unbound renal clearance of gallic acid 
was 1.7 fold higher than the glomerular filtration rate (~120 mL/min) (163). Collectively, these 
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data show that the newly developed analytical method can be used to assess cellular uptake of 
gallic acid and gentisic acid. 
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Figure 7.4. Cellular uptake of gallic acid and gentisic acid in mOat1- and mOat3-
expressing cells, as well as empty vector transfected background control cell line (CHO-
FRT). The concentration of gallic acid, gentisic acid, and probenecid (known OAT 
inhibitor) for incubation were 10 µM, 10 µM, and 1000 µM. LLOQ, lower limit of 
quantification; BLQ, below LLOQ. 
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7.D CONCLUSIONS 
As the FDA has suggested that potential drug transporter-mediated DDI should be 
investigated to avoid unexpected adverse effects, validated bioanalytical methods to directly 
measure drug transporter-mediated cellular uptake are needed. In the present study, we reported 
a specific, sensitive, and reliable LC-MS/MS method for analysis of gallic acid and gentisic acid 
from complex cell lysate samples, with LLOQ of 0.33 ng/mL. Good linearity was obtained with 
concentrations ranging from 0.33 to 2400 ng/mL. Method validation results showed acceptable 
intra-/inter-day accuracy and precision as well as stability, and insignificant matrix effects. 
Compared with previous reported methods, this assay was highly sensitive and rapid, with wider 
linear dynamic range, which fits for the purpose of cell-based in vitro novel substrate 
identification and screening of potential DDI. Finally, the suitability of this method was 
demonstrated in a cellular uptake study in which the intracellular concentrations of gallic acid 
and gentisic acid in OAT-expressing cells was measured. The method described here can be 
applied to study potential interaction of gallic acid or gentisic acid with any transporter family, 
e.g., OATs (SLC22 transporter family), multidrug resistance-associated proteins (MRPs; ABCC 
transporter family), and organic anion transporting polypeptides (OATPs; SLCO family), as well 
as to investigate their absorption and metabolism profiles with in vitro models, e.g., Caco-2 cells 
and primary hepatocytes. 
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CHAPTER 8 
 
 
 
SYSTEMIC LEVEL EVALUATION OF ORGANIC ANION TRANSPORTER-
MEDIATED DRUG-DRUG INTERACTION POTENCY IN SALVIA MITIORRHIZA 
(DANSHEN) PREPARATIONS: FOCUSING ON CUMULATIVE EFFECTS FROM 
MULTIPLE COMPONENTS 
 
 
 
 
 
 
8.A INTRODUCTION 
Danshen, the dried root of Salvia miltiorrhiza, is used by patients as a part of traditional 
Chinese medicine in the treatment of cardiovascular disease (100, 101). The major 
pharmacological effects in cardiovascular therapy may include improvement of microcirculation, 
preventing platelet adhesion and aggregation, and inhibiting the formation of thromboxane (100, 
101). Presently, there are more than 900 commercial Danshen preparations manufactured in 
China, and injectables account for ~30% of total Danshen products 
(http://www.sda.gov.cn/WS01/CL0001/). Typical of herbal medicines, Danshen pharmaceutical 
products are actually a mixture of ingredients, including phenolic acids such as lithospermic acid 
(LSA), rosmarinic acid (RMA), salvianolic acid A (SAA), salvianolic acid B (SAB, also named 
lithospermic acid B), and tanshinol (TSL, also named danshensu), each of which has been 
identified as a major component in these preparations (103, 104, 116, 198). However, because of 
variations in cultivars, cultivation regions, manufacturing, and lack of standard quality control 
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criteria, the content of such components in Danshen preparations can exhibit wide variation 
among products from different sources. Such lack of standardization of the major Danshen 
components makes it difficult to predict systemic and peak exposure of these components 
between products, or to evaluate any exposure-related toxicity and drug-drug interaction (DDI) 
potential in clinical applications for products from various manufacturers (103, 199). 
The number of reports on drug transporter-mediated DDIs from numerous preclinical and 
clinical studies has increased (136). Among these transporter families, the organic anion 
transporter (OAT; SLC22) family mediates the renal transcellular solute flux of a multitude of 
endogenous substances and xenobiotics that carry negative charge(s) at physiological pH (3). 
Because of their broad substrate specificity, many clinically important therapeutics have been 
identified as OAT substrates and/or inhibitors, such as antibiotics, antiviral and anticancer agents, 
statins, and angiotensin-converting enzyme inhibitors (3). As a result, United States Food and 
Drug Administration (FDA) regulatory, industrial and scientific experts have developed 
recommendations under what circumstances DDIs with seven selected transporters, including 
OAT1 and OAT3, need to be investigated (118, 136).  
The DDI index is introduced as the unbound maximum plasma concentration (Cmax or Css) of 
a drug component of interest at the highest clinically relevant dose over the in vitro transporter 
inhibition potency of the compound (Ki or IC50) as an indicator of DDI potential. Conservatively, 
follow-up clinical DDI investigations are recommended when the DDI index ≥ 0.1 (136). For the 
majority of drug products, the DDI index is affected by only one or a few ingredients with 
constant content even between different manufacturers. However, for herbal medicines and 
natural products, the DDI index estimation becomes more complicated as they contain numerous 
components that can interfere with drug transporter activity, whether identified as an active 
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component or not. These components, in most cases, show marked similarity in chemical 
structure. This fact is quite important for assessment of DDI potential, since drug transporters, 
including OATs, interact with an array of compounds with marked diversity in their chemical 
structure (136). As a result, it is highly probable that more than one component in an herbal 
product could demonstrate a strong potential to interact with any specific transporter. Therefore, 
a new parameter to express this multifaceted inhibition potential on transporters, the cumulative 
DDI index, is proposed. This parameter, shown as the sum of each component’s DDI index, 
reflects the overall DDI potential for multiple-component herbal preparations at clinically 
relevant concentrations.  
Using Danshen as an example of herbal medicine, our previous work demonstrated that LSA, 
RMA, SAA, SAB and TSL each showed significant competitive inhibitory effects on human 
(h)OAT1- and hOAT3-mediated substrate uptake, and their corresponding Ki values on hOAT1 
and hOAT3 are shown in Table 8.1 (190). Since all of these Danshen components showed 
competitive inhibition on human OAT transport activity, it is likely that these compounds share 
the same binding site such that cumulative inhibitory effects would emerge after administration 
of Danshen products with varying composition of these ingredients. The first aim of the present 
study was to compare the inhibitory effects of individual Danshen components (LSA, RMA, and 
TSL) vs. a mixture of components on hOAT1 and hOAT3. Pharmacokinetic modeling was used 
to predict plasma concentrations for Danshen products after i.v. bolus and i.v. infusion 
administration of clinically relevant doses. Finally, the new index, the cumulative DDI index, 
was evaluated for Danshen injectables from different manufacturers and different lots/batches 
from the same manufacturer. Results from this study demonstrate that the cumulative DDI index, 
which shows the overall inhibition potential of Danshen preparations, was significantly higher 
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than the DDI index from any single component, indicating that the DDI index for any single 
component in a complex mixture is likely to underestimate the true DDI potential of that product. 
Additionally, the cumulative DDI indices are highly variable between Danshen injectables from 
different manufactures as well as between different lots/batches produced by the same 
manufacturer. Such information might be useful in guiding quality control in the manufacture 
and clinical application of such pharmaceutical products. 
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8.B MATERIALS AND METHODS 
8.B.1 Materials 
The Danshen components LSA, RMA, and TSL (≥ 96% purity) were obtained from Tauto 
Biotech (Shanghai, China). Tritiated PAH ([3H]PAH) and ES ([3H]ES) were purchased from 
PerkinElmer Life and Analytical Sciences (Waltham, MA) and unlabeled PAH, ES, and 
probenecid were purchased from Sigma-Aldrich (St. Louis, MO).   
8.B.2 Tissue culture 
Derivation of stably transfected Chinese hamster ovary (CHO) cells expressing hOAT1 and 
stably transfected human embryonic kidney 293 (HEK) cells expressing hOAT3, and their 
corresponding empty vector transfected control cell lines, has been described previously (52). 
CHO cell lines were cultured in phenol red-free RPMI 1640 medium (Gibco Invitrogen., Grand 
Island, NY) containing 1 mg/mL G418. HEK cell lines were cultured in DMEM High glucose 
medium (Mediatech, Inc., Herndon, VA) containing 125 µg/ml hygromycin B. All cultures 
contained 10% FBS and 1% Pen/Strep, and were maintained at 37°C with 5% CO2. 
8.B.3 Cell accumulation assays 
Cell transport assay procedures were adapted from those previously published (52). In brief, 
2 × 105 cells/well were seeded in 24-well tissue culture plates and grown in the absence of 
antibiotics for 48 hr. On the day of the experiment cells were equilibrated with transport buffer 
for 10 min [500 µL of Hanks’ balanced salt solution containing 10 mM HEPES, pH 7.4]. 
Equilibration buffer was replaced with 500 µL of fresh transport buffer containing 1 µM 
[3H]PAH (0.5 µCi/mL) or 1 µM [3H]ES (0.25 µCi/mL) with or without inhibitors. After 
incubation, cells were immediately rinsed three times with ice-cold transport buffer, lysed, and 
analyzed via liquid scintillation counting. Substrate accumulation was reported as picomoles of 
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substrate per milligram protein. The concentrations of LSA, RMA, and TSL were chosen to 
exhibit mild inhibition (≤ 61%). Results were confirmed by repeating all experiments at least 
three times with triplicate wells for each data point in every experiment. 
8.B.4 Derivation of cumulative DDI index 
Commonly, the influence of a single competitive inhibitor on transporter activity is described 
as follows; 
 
 
where V0, Vi, and I represent Vmax in the absence of inhibitor, Vmax in the presence of inhibitor 
and the relevant concentration of the inhibitor, respectively. According to the “Guidance for 
Industry: Drug Interaction Studies” issued by the FDA, I/Ki was proposed as an indicator for 
estimating the DDI potential (118). However, assuming independent competitive inhibition by 
all inhibitors in the presence of multiple (n) inhibitors, the influence on transport activity 
becomes;  
 
 
where In and Ki,n represent the relevant concentration and inhibition constant of the individual 
inhibitors (n), respectively. As illustrated, the sum of In/Ki,n for n inhibitors plays an equivalent 
role on transporter function as I/Ki for a single competitive inhibitor. As a result, for Danshen 
preparations, which include multiple components known to be competitive OAT inhibitors (190), 
the sum of In/Ki,n, designated as the cumulative DDI index, was used to describe the DDI 
potential of these complex mixtures. 
8.B.5 Pharmacokinetic modeling  
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In order to determine relevant plasma concentrations for various doses of the different 
Danshen components, pharmacokinetic models had to be developed. Pharmacokinetic modeling 
was performed with WinNonlin software (version 5.2.1, Pharsight, St. Louis, MO, USA) using 
plasma concentration data from a previously reported clinical pharmacokinetic study on human 
subjects after a single 60 min i.v. infusion of a Danshen injectable (104). The doses were 5 mg, 3 
mg, 160 mg, 65 mg, and 90 mg for caffeic acid (CA), LSA, RMA, SAB, and TSL, respectively 
(104). All observed plasma concentrations were above the assay LLOQ (8 ng/mL for all 
components), except for those of RMA at the last two time points (104).  As a result, these two 
points were excluded from pharmacokinetic calculations. Initially, several pharmacokinetic 
compartment models were investigated during the model selection process. An i.v. infusion two-
compartment model with first-order elimination was chosen as the final pharmacokinetic model 
based on the law of parsimony (simplest model) and goodness of fit including Akaike Criteria 
(AIC), Schwarz Bayesian Criterion (SBC), Weighted Sum of Square of Residuals (WSSR), 
visual inspection of weighted residuals versus observed concentrations, and fitted and observed 
plasma concentrations versus time. The schematic representation of this model is as follows 
 
 
 
 
 
where k10 is the elimination rate constant from compartment 1, k12 is the distribution rate constant 
from compartment 1 to compartment 2, k21 is the distribution rate constant from compartment 2 
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to compartment 1, and V1 represents volume of compartment 1. Compartments 1 and 2 represent 
central and peripheral compartments, respectively. 
8.B.6 Simulation of plasma concentrations and estimation of cumulativeDDI index 
The content of the Danshen components, LSA, RMA, SAB and TSL in Danshen injectables 
from different manufacturers, or from different lots/batches produced by a single manufacturer, 
were obtained from the literature (103, 104, 138, 198, 200). In order to estimate the DDI index, 
the plasma concentration-time profile of each Danshen component was simulated for patients 
administered these Danshen injectables under two clinically relevant scenarios: i.v. bolus 
administration and 60 min i.v. infusion administration. Simulated plasma concentration-time 
profiles were generated using a two compartment model with first-order elimination, assuming 
that all four Danshen components follow dose-proportional pharmacokinetics. The final 
pharmacokinetic model parameters were fixed. In addition, Yang et al. (2007) determined that, 
for RMA, SAB, and TSL, the fraction unbound in human plasma was 9.5%, 6.8%, and 100% 
(137). In the absence of LSA plasma binding data, it was assumed that LSA is highly protein 
bound (90%), leaving the fraction unbound in human plasma as 10%. Unbound plasma 
concentrations were estimated as the product of plasma concentration times, the fraction 
unbound in plasma. The DDI index was estimated as the predicted unbound Cmax or Css in 
plasma over Ki for each component. The cumulative DDI index for a specific Danshen 
preparation was calculated as the sum of individual DDI indices for each component. 
8.B.7 Statistics 
Data are reported as mean ± S.D. Statistical differences were assessed using one-way 
ANOVA followed by post-hoc analysis with Dunnett’s t-test (α = 0.05). 
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Figure 8.1. Cumulative inhibitory effects of LSA, RMA, and TSL on hOAT1 and hOAT3 
 
A: Inhibition of hOAT1-mediated uptake of [3H]PAH (1 µM) by LSA (10 µM), RMA (1 µM), 
and TSL (50 µM) individually or the mixture of these three components was measured in CHO-
hOAT1 cells (10 min). B: Inhibition of hOAT3-mediated uptake of [3H]ES (1 µM) by LSA (0.5 
µM), RMA (0.5 µM), and TSL (10 µM) individually or as mixture of these three components 
was measured in the HEK-hOAT3 cells (10 min). All data were corrected by background 
substrate accumulation measured in corresponding empty vector control cells. OAT-expressing 
cell showed signicantly reduced cellular uptake of substrate (p < 0.001) when treated with single 
Danshen component or the mixture. Values are mean ± S.D. of triplicate values. All treated 
groups showed significant inhibiton on hOAT1 and hOAT3 (p < 0.001). *** denotes p < 0.001 
and *denotes p < 0.05 as determined by one-way ANOVA followed by Dunnett’s t-test to 
compare invidual compounds group vs. mixed group. 
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Figure 8.2. Modeling of published experimental data for human plasma concentrations of Danshen components, LSA, RMA, 
SAB, and TSL after i.v. infusion using a two-compartment model.  
Original data (shown as open circle) were taken from reference (104). The doses were 3 mg, 160 mg, 65 mg, and 90 mg for LSA, 
RMA, SAB, and TSL, respectively. 
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Table 8.1. Estimated Ki values (µM) of Danshen components for hOAT1 and hOAT3 
 
Compound hOAT1 hOAT3 
LSA 20.8 ± 2.1 0.59 ± 0.26 
RMA 0.35 ± 0.06 0.55 ± 0.25 
SAA 5.6 ± 0.3 0.16 ± 0.03 
SAB 22.2 ± 1.9 19.8 ± 8.4 
TSL 40.4 ± 12.9 8.6 ± 3.3 
 
Values are reported as mean ± S.E.M. (n=3). These values were obtained from reference (190). 
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Table 8.2. Estimated parameters for two-compartment model with first-order elimination 
to describe pharmacokinetic properties of Danshen components after i.v. infusion 
 
Compound V1  (L) 
k10  
(1/hr) 
k12  
(1/hr) 
k21  
(1/hr) 
Vdss  
(L) 
CLtot 
(L/hr) 
t1/2elimination 
(hr) 
LSA 1.9±0.1 0.25±0.03 0.29±0.07 0.35±0.15 3.43±0.53 0.48±0.04 6.04±1.78 
RMA 18.9±3.3 3.30±0.34 0.28±0.07 0.44±0.09 23.4±4.0 61.6±2.8 0.81±0.23 
SAB 4.1±0.6 2.74±0.38 0.86±0.34 0.60±0.25 9.44±1.94 11.2±0.7 1.45±0.48 
TSL 10.4±1.3 1.58±0.19 0.32±0.21 0.55±0.35 16.4±3.4 16.4±1.1 1.62±0.87 
 
Values are reported as mean ± S.E.M. 
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Table 8.3. Reported content of Danshen components in injectables from different 
manufacturers 
 
Manufacturer 
Maximum Dose (mg)a 
Reference 
LSA RMA SAB TSL 
1 NRb 10.2 17.2 21.2 (103) 
2 NR 4.2 13.8 41.4 (103) 
3 NR 4.6 7.0 31.2 (103) 
4 NR 5.6 16.2 29.8 (103) 
5 NR 12 12.6 80.6 (103) 
6 3.88 10.3 39.5 37.8 (198) 
7 1.7 3.4 6.8 45.2 (198) 
8 NR 6.6 NDc 98.4 (200) 
9 NR 14.1 343 ND (200) 
10 NR 5.1 2.0 25.4 (200) 
11 NR 18.1 50.16 42.9 (200) 
12 NR 4.4 2.9 59.7 (200) 
13 NR 3.2 2.5 49.0 (200) 
14 NR 7.7 16.8 52.5 (200) 
15 NR 3.5 10.0 51.5 (200) 
16 3 160 63 90 (104) 
 
a Used for i.v. infusion administration, which is four-fold of the maximum dose for i.v. 
bolus administration; bNot reported; cNot detectable (value set to 0 for DDI index 
calculations in Tables 8.5 and 8.6) 
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Table 8.4. Reported content of Danshen components in injectables from a single 
manufacturer with different batches/lots. Data were reported from reference (138). 
 
Batches 
Maximum Dose (mg)a 
RMA SAB TSL 
1 1.9 1.3 24.7 
2 3.5 1.7 29.0 
3 2.5 1.5 25.9 
4 2.7 2.0 24.9 
5 2.4 1.6 23.1 
6 2.0 1.0 19.1 
7 3.3 1.4 27.1 
8 2.5 1.7 24.8 
9 2.2 1.1 21.3 
10 2.5 1.9 27.3 
11 1.2 0.3 9.0 
12 2.6 1.7 27.1 
13 2.7 1.6 28.5 
14 3.4 1.9 28.9 
 
a Used for i.v. infusion administration, which is four-fold of the maximum dose for i.v. 
bolus administration 
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Table 8.5. Estimation of individual and cumulative DDI indices for Danshen injectables from different manufacturers after i.v. 
bolus administration on hOAT1 and hOAT3 
 
Manufacturers Dose-related DDI index for hOAT1  Dose-related DDI index for hOAT3 LSA RMA SAB TSL Cumulative LSA RMA SAB TSL Cumulative 
1 —a 0.10 <0.005 0.06 0.16 — 0.06 0.01 0.30 0.37 
2 — 0.04 <0.005 0.12 0.16 — 0.03 <0.005 0.58 0.61 
3 — 0.05 <0.005 0.09 0.14 — 0.03 <0.005 0.44 0.47 
4 — 0.06 <0.005 0.09 0.15 — 0.04 <0.005 0.42 0.46 
5 — 0.12 <0.005 0.24 0.36 — 0.08 <0.005 1.14 1.22 
6 0 0.10 0.01 0.11 0.21 0.16 0.07 0.01 0.54 0.78 
7 0 0.03 <0.005 0.14 0.17 0.07 0.02 <0.005 0.64 0.73 
8 — 0.07 0 0.30 0.37 — 0.04 0 1.40 1.44 
9 — 0.14 0.09 0 0.23 — 0.09 0.10 0 0.19 
10 — 0.05 <0.005 0.08 0.13 — 0.03 0 0.36 0.39 
11 — 0.18 0.01 0.13 0.32 — 0.11 0.01 0.61 0.73 
12 — 0.04 <0.005 0.18 0.22 — 0.03 <0.005 0.85 0.88 
13 — 0.03 <0.005 0.15 0.18 — 0.02 <0.005 0.70 0.72 
14 — 0.08 <0.005 0.16 0.24 — 0.05 <0.005 0.74 0.79 
15 — 0.03 <0.005 0.15 0.18   0.02 <0.005 0.73 0.75 
16 <0.005 1.60 0.02 0.27 1.89  0.13 1.02 0.02 1.27 2.43 
 
a— DDI index could not be calculated as no value was reported (NR in Table 8.3). Values in italic indicate DDI index ≥ 0.1 threshold 
value. Values in bold italic indicate DDI index ≥ 1. 
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Table 8.6. Estimation of individual and cumulative DDI indices for Danshen injectables from different manufacturers after i.v. 
infusion administration on hOAT1 and hOAT3 
  
Manufacturers Dose-related DDI index for hOAT1  Dose-related DDI index for hOAT3 LSA RMA SAB TSL Cumulative LSA RMA SAB TSL Cumulative 
1 —a 0.11 0.01 0.12 0.24 — 0.07 0.01 0.55 0.63 
2 — 0.05 <0.005 0.23 0.28 — 0.03 <0.005 1.08 1.11 
3 — 0.05 <0.005 0.17 0.22 — 0.03 <0.005 0.81 0.84 
4 — 0.06 <0.005 0.16 0.22 — 0.04 0.01 0.77 0.82 
5 — 0.13 <0.005 0.45 0.58 — 0.08 <0.005 2.09 2.17 
6 0.01 0.11 0.01 0.21 0.33 0.51 0.07 0.01 0.98 1.57 
7 0.01 0.04 <0.005 0.25 0.29 0.22 0.02 <0.005 1.17 1.41 
8 — 0.07 0 0.54 0.61 — 0.05 0 2.56 2.61 
9 — 0.15 0.10 0 0.26 — 0.10 0.12 0 0.22 
10 — 0.06 <0.005 0.14 0.20 — 0.04 <0.005 0.66 0.70 
11 — 0.20 0.02 0.24 0.46 — 0.13 0.02 1.11 1.26 
12 — 0.05 <0.005 0.33 0.38 — 0.03 <0.005 1.55 1.58 
13 — 0.03 <0.005 0.27 0.30 — 0.02 <0.005 1.27 1.29 
14 — 0.08 0.01 0.29 0.38 — 0.05 0.01 1.36 1.42 
15 — 0.04 <0.005 0.28 0.32  — 0.02 <0.005 1.34 1.36 
16 0.01 1.76 0.02 0.50 2.28  0.39 1.12 0.02 2.34 3.87 
 
a— DDI index could not be calculated as no value was reported (NR in Table 8.3). Values in italic indicate DDI index ≥ 0.1 threshold 
value. Values in bold italic indicate DDI index ≥ 1. 
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Table 8.7. Estimation of DDI index for Danshen injectables from different batches in the same manufacturer after i.v. bolus 
administration on hOAT1 and hOAT3 
 
Batches Dose-related DDI index for hOAT1  Dose-related DDI index for hOAT3 RMA SAB TSL Cumulative RMA SAB TSL Cumulative 
1 0.02 <0.001 0.07 0.09 0.01 <0.001 0.35 0.36 
2 0.03 <0.001 0.09 0.12 0.02 <0.001 0.41 0.43 
3 0.02 <0.001 0.08 0.10 0.02 <0.001 0.37 0.39 
4 0.03 <0.001 0.07 0.10 0.02 <0.001 0.35 0.37 
5 0.02 <0.001 0.07 0.09 0.02 <0.001 0.33 0.35 
6 0.02 <0.001 0.06 0.08 0.01 <0.001 0.27 0.28 
7 0.03 <0.001 0.08 0.11 0.02 <0.001 0.38 0.40 
8 0.02 <0.001 0.07 0.09 0.02 <0.001 0.35 0.37 
9 0.02 <0.001 0.06 0.08 0.01 <0.001 0.30 0.31 
10 0.02 <0.001 0.08 0.10 0.02 <0.001 0.39 0.41 
11 0.01 <0.001 0.03 0.04 0.01 <0.001 0.13 0.14 
12 0.03 <0.001 0.08 0.11 0.02 <0.001 0.38 0.40 
13 0.03 <0.001 0.09 0.12 0.02 <0.001 0.40 0.42 
14 0.03 <0.001 0.09 0.12 0.02 <0.001 0.41 0.43 
 
Values in italic indicate DDI index ≥ 0.1 threshold value. 
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Table 8.8 Estimation of DDI index for Danshen injectables from different batches in the same manufacturer after 1 hr i.v. 
infusion administration on hOAT1 and hOAT3 
 
Batches Dose-related DDI index for hOAT1  Dose-related DDI index for hOAT3 RMA SAB TSL Cumulative RMA SAB TSL Cumulative 
1 0.02 <0.001 0.14 0.16 0.01 <0.001 0.64 0.65 
2 0.04 <0.001 0.16 0.20 0.02 <0.001 0.75 0.77 
3 0.03 <0.001 0.14 0.17 0.02 <0.001 0.67 0.69 
4 0.03 <0.001 0.14 0.17 0.02 <0.001 0.65 0.67 
5 0.03 <0.001 0.13 0.16 0.02 <0.001 0.60 0.62 
6 0.02 <0.001 0.11 0.13 0.01 <0.001 0.50 0.51 
7 0.04 <0.001 0.15 0.19 0.02 <0.001 0.70 0.72 
8 0.03 <0.001 0.14 0.17 0.02 <0.001 0.64 0.66 
9 0.02 <0.001 0.12 0.14 0.02 <0.001 0.55 0.57 
10 0.03 <0.001 0.15 0.18 0.02 <0.001 0.71 0.73 
11 0.01 <0.001 0.05 0.06 0.01 <0.001 0.23 0.24 
12 0.03 <0.001 0.15 0.18 0.02 <0.001 0.70 0.72 
13 0.03 <0.001 0.16 0.19 0.02 <0.001 0.74 0.76 
14 0.04 <0.001 0.16 0.20 0.02 <0.001 0.75 0.77 
 
Values in italic indicate DDI index ≥ 0.1 threshold value. 
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8.C RESULTS 
8.C.1 Cumulative inhibitory effects of LSA, RMA, and TSL on hOAT1 and hOAT3 
Accumulation of PAH in the CHO-hOAT1 cell line (4.6 ± 0.3 pmol/mg protein/10 min) was 
markedly greater than that in the empty vector background CHO-EV cells (0.9 ± 0.3 pmol/mg 
protein/10 min; Figure 8.1A). LSA (10 µM), RMA (1 µM) and TSL (50 µM) produced 61 ± 3%, 
60 ± 1%, and 52 ± 6% inhibition on hOAT1-mediated PAH uptake, respectively. Further, 
application of these three compounds together (at the specified concentrations) yielded a 
significantly increased inhibition (72 ± 7%) on hOAT1 transport activity, compared to the 
individual inhibitory effects of each compound (Figure 8.1A). Stably transfected hOAT3-
expressing (HEK-hOAT3) cells showed significantly enhanced accumulation of ES (~4 fold) 
relative to empty vector background HEK-EV cells (6.2 ± 0.5 vs. 1.5 ± 0.2 pmol/mg protein/10 
min, respectively; Figure 8.1B). Similarly, LSA (0.5 µM), RMA (0.5 µM) and TSL (10 µM) 
produced approximately 20 ± 2%, 53 ± 6%, and 45 ± 2% inhibition, respectively. When these 
compounds were included as a mixture in the incubation solution at the above concentrations, the 
observed inhibition significantly increased to 81 ± 10%. Therefore, LSA, RMA and TSL, known 
competitive inhibitors for hOAT1 and hOAT3, showed a cumulative inhibitory effect on 
hOAT1- and hOAT3-mediated uptake. 
8.C.2 Pharmacokinetic modeling of clinical data 
Performing an iterative model discrimination process revealed that an open two-
compartmental model with i.v. infusion and first-order elimination yielded the lowest values of 
AIC, SBC, and WSSR, and this model was used to fit the plasma concentration-time profile data 
for LSA, RMA, SAB and TSL (Figure 8.2). Moreover, weighted residuals were randomly 
distributed in the weighted residuals vs. observed concentrations plot (data not shown). The 
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observed and predicted concentration-time profiles for each Danshen component are shown in 
Figure 8.2. Final pharmacokinetic model parameter estimates for each Danshen component are 
summarized in Table 8.2. Data for CA, another component in Danshen preparations, failed to fit 
any of the tested models. Overall, the model produced excellent fits of the actual data. 
8.C.3 Estimation of cumulative DDI index and evaluation of OAT-mediated DDI potency for 
Danshen injectables 
In clinical practice, Danshen injectables are commonly administered by i.v. bolus injection or 
i.v. infusion. The model parameters for LSA, RMA, SAB and TSL were used to simulate plasma 
concentration using the two compartment model with i.v. bolus or i.v. infusion administration 
and first-order elimination for a given dose, assuming the examined Danshen components exhibit 
“dose-proportional pharmacokinetics” and that the pharmacokinetic behavior of each Danshen 
component is not affected by the presence of any of the other components. As the plasma 
concentration of LSA, RMA, SAB or TSL did not reach steady-state (Css) after 60 min i.v. 
infusion, Cmax values (plasma concentration at 1 h) were used for estimation of individual DDI 
index and cumulative DDI index.  
As shown in Table 8.3, the content of Danshen components in injectables from different 
manufacturers has been determined (103, 104, 198, 200). Marked variation was observed 
between Danshen products from different manufacturers, with the content of LSA, RMA, SAB 
and TSL, showing 2.3-, 73-, 175-, and 4.9-fold variation, respectively. In addition, for Danshen 
injectables produced by a single manufacturer, the content of RMA, SAB, and TSL showed 3-, 
6.7-, and 3.2-fold variation between different lots/batches (Table 8.4). As a consequence, the 
predicted Cmax values of of LSA, RMA, SAB and TSL in these injectables exhibited the same 
range of variation. With this information, the DDI index (for individual components) and the 
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cumulative DDI index (for mixtures) were calculated (Tables 8.5 and 8.6). Most of these 
investigated Danshen injectables showed hOAT1- and hOAT3-mediated DDI potential 
(cumulative DDI index > 0.1), and the majority of preparations exhibited stronger interaction 
potential with hOAT3 compared to hOAT1. Among Danshen components, TSL emerged as 
making the greatest contribution to DDI potential, while LSA and RMA also showed substantial 
individual contribution in some products. SAB failed to exhibit DDI potential in most injectables. 
The DDI indices for individual components and the cumulative DDI indices were also calculated 
for different batches/lots of a Danshen injectable produced by the same manufacturer (Tables 8.7 
and 8.8) (138). These Danshen products showed significant hOAT3-mediated DDI potential for 
both i.v. bolus injection and i.v. infusion use. In addition, the RMA and TSL content in some 
batches were high enough to cause hOAT1-mediated DDIs when delivered as i.v. bolus or i.v. 
infusion administration.  
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8.D DISCUSSION 
Botanical drug products are currently increasing in popularity because of renewed interest in 
complementary and alternative therapies. Herbal medicines, which are derived from plants, are 
always considered “natural” and, therefore, are often perceived as safe by patients and the 
general public. However, because of their wide use as complementary and alternative medicines, 
they are often used in combination therapy with other prescribed and OTC drugs. As a result, 
numerous clinical cases of phytomedicine-associated DDIs have been identified (201-203), 
making it necessary to explore the DDI potential between herbal medicines and co-administered 
drugs more systemically. Because herbal drugs contain mixtures of plant components or extracts, 
they are extraordinarily complex in their composition, particularly when compared with 
prescription medications, which commonly contain a few active ingredients. An important caveat 
to herbal medicines is that some of the major components may not have any therapeutic benefit, 
but still possess significant DDI potential due to high systemic/peak exposure in vivo. Further, 
these components often share structural and physicochemical properties and, as such, might exert 
cumulative DDI effects. Currently, most transporter-mediated DDI studies focus on the 
interaction of each single component with the drug in question and, therefore, may underestimate 
the overall DDI potential for complex botanical drug products (201-203).  
Presently, the individual DDI index, calculated as [unbound]Cmax/Ki (or IC50), is thought to 
reasonably predict in vivo DDI potential for a compound on a specific transporter. However, for 
herbal medicines, it is necessary to consider the overall inhibitory effects induced by all of the 
components in order for the DDI index to reflect the interaction potential for the product as a 
whole. In addition, the content of major components in herbal products is often influenced by 
factors such as extraction methods, cultivars, cultivation region, manufacturing processes, and 
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quality control criteria, which differ among manufacturers. Therefore, it might be more relevant 
to explore pharmaceutical product-specific DDI indices rather than compound-related indices. 
In this study, the cumulative inhibitory effect of major Danshen components on OAT-
mediated substrate uptake was assessed. Human OAT1 and hOAT3 transport activity was 
significantly lower when the components were applied as a mixture (LSA, RMA and TSL) as 
compared with being applied individually. These results suggested that in some situations the 
traditional DDI index might not reflect the true inhibition level of a multi-component system. 
Therefore, the cumulative DDI index, calculated as the sum of DDI indices for each individual 
component, was proposed in the present study to evaluate the DDI potential for such mixture. 
The individual DDI indices for the single compounds, LSA (10 µM), RMA (1 µM), and TSL (50 
µM), as well as the cumulative DDI index for a mixture at those concentrations, on hOAT1 were 
0.45, 2.9, 1.2, and 4.6, respectively. Such DDI indices predicted inhibition levels of 33%, 74%, 
55%, and 82% for LSA, RMA, TSL, and the mixture, respectively, which corresponded closely 
with the observed inhibition profiles, 61 ± 3%, 60 ± 1%, 52 ± 6%, and 72 ± 7% for RMA, TSL, 
and the mixture, respectively. Similarly, the individual DDI indices for LSA (0.5 µM), RMA 
(0.5 µM) and TSL (10 µM), as well as the cumulative DDI index for the mixture, were 0.9, 0.9, 
1.2, and 3.0, respectively, indicating that the predicted inhibition levels (46%, 48%, 54%, and 74% 
for LSA, RMA, TSL and the mixture, respectively) were comparable with the observed values, 
(61 ± 3%, 60 ± 1%, 52 ± 6%, and 81 ± 10% for LSA, RMA, TSL and the mixture, respectively). 
These data support use of the cumulative DDI index as a suitable indicator for evaluation of the 
DDI potential for complex mixtures. 
The same threshold value of DDI index ≥ 0.1  (transport activity decreased by 9%), as 
currently recommended for further individual component assessment, was maintained for the 
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cumulative DDI index. The estimated cumulative DDI indices for investigated Danshen 
injectables on hOAT1 and hOAT3 were greater than 0.1 in most cases. In addition, the 
cumulative DDI indices for hOAT3 were much greater than those for hOAT1 for most 
investigated Danshen injectables. As shown in Tables. 8.5 and 8.6, the cumulative DDI indices 
for hOAT3 exceeded 1 for a number of Danshen injectables, administered by i.v. bolus injection 
and 60 min i.v. infusion administration, indicating that more than 50% of hOAT3 transport 
function could be inhibited. Only one product induced a cumulative DDI index ˃ 1 on hOAT1 
due to a high RMA content. In general, the results demonstrate a strong potential that OAT 
function likely would be impaired in vivo after administration of these products, manifesting as 
reduced renal elimination of co-administered drugs that undergo OAT-mediated active secretion 
(Tables 8.5-8.8).  
Among these Danshen components, TSL can be identified as the main contributor to the 
cumulative DDI index because of its relatively high content in preparations and low degree of 
plasma protein binding. Collectively, TSL exhibited higher DDI indices for hOAT1 and hOAT3 
compared to the other components. Further, the data suggested that the contribution of SAB can 
be ignored. However, the impact of LSA and RMA on DDI potential cannot be ignored. In some 
Danshen injectables, RMA showed equal or greater contribution to the cumulative DDI index for 
hOAT1 (Tables 8.5 and 8.6). The content of LSA was available only for two investigated 
products. Nevertheless, LSA’s high affinity for hOAT3 yielded an individual DDI index for LSA 
that accounts for a significant portion of the cumulative DDI index (Tables 8.5 and 8.6). 
Similarly, as shown in Table 8.7, such effects can yield a cumulative DDI index above the 
threshold value (0.1), while neither of the single component (RMA and TSL) DDI indices were 
greater than 0.1. In other words, considering only single component DDI assessment would 
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suggest no concern for Danshen-mediated in vivo DDIs, whereas the cumulative DDI index 
would indicate such a concern. 
Like other herbal medicines, there is great variation in the content of major constituents of 
Danshen injectables. The content of LSA, RMA, SAB, and TSL, showed 2.3-, 73-, 175-, and 
4.9-fold variation between Danshen products from different manufacturers (Table 8.3). 
Additionally, RMA, SAB and TSL showed 3-, 6.7- and 3.2-fold variation in content between 
different lots/batches of a product produced by a single manufacturer (Table 8.4). As a result, 
such variation leads to marked differences in the cumulative DDI indices for these products. 
According to Tables 8.5 and 8.6, Danshen products from different manufacturers exhibited 2.3- 
and 3.1-fold difference in the hOAT1-associated cumulative DDI index for i.v bolus and i.v. 
infusion administration, respectively. Such discrepancy was even higher for the hOAT3-
associated cumulative DDI index, which exhibited 7.6- and 11.9-fold differences for i.v bolus 
and i.v. infusion administration, respectively. Variability in composition between batches/lots led 
to ~3-fold range in cumulative DDI indices (Tables 8.7 and 8.8). Clearly, estimating a general 
DDI potential for the range of Danshen injectables is difficult. In order to help address this 
problem, standardization of content and quality control measures should be established. 
Danshen also is used in clinical therapy as tablets and “dripping pills” (100). The phenolic 
acid components investigated in the present work are also major components in these oral dosage 
forms. Unlike injections, TSL was the only component detectable in plasma after oral 
administration of Danshen products (116, 204). Therefore, TSL might be the only component 
with the potential of causing OAT-mediated DDIs in vivo after oral administration of Danshen 
preparations. However, there is a marked discrepancy in plasma concentration of TSL in clinical 
pharmacokinetic studies. Pei et al. reported that Cmax of TSL was ~7.5 µg/mL (38 µM) after oral 
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administration of 250 mg Danshen pills (204), while another independent investigation revealed 
that the Cmax of TSL was much lower (~50 ng/mL or 0.25 µM) even with a higher dose (750 mg 
Danshen pills) (116). Knowing that Danshen pills used in these studies were produced by the 
same manufacturer, the large difference in TSL Cmax might be due to variation in the content of 
TSL between different batches. Unfortunately, the actual content of TSL was not reported (204). 
Without further studies to demonstrate the peak exposure of TSL, it is impractical to estimate 
DDI potential for Danshen oral dosages forms. However, a TSL Cmax = 7.5 µg/mL might be 
sufficient to cause significant DDI (DDI index = 0.9 and 6 for hOAT1 and hOAT3, respectively), 
while a Cmax of 50 ng/mL is not (DDI index < 0.1 for both hOAT1 and hOAT3). 
There are some limitations to the present study. Currently, there is a lack of clinical 
pharmacokinetic data for the Danshen components CA and SAA, which are also potent OAT 
inhibitors (51, 190). Potential phase 2 metabolites of Danshen components may also impact OAT 
function. As a result, the contribution of these compounds to OAT-mediated DDIs cannot be 
estimated, potentially indicating that even the cumulative DDI potentials reported herein may 
actually underestimate the true DDI potential of Danshen injectables. Additionally, DDIs 
between each compound likely may occur, especially for TSL, which could undergo OAT-
mediated renal elimination in vivo. The presence of CA, LSA, SAA and SAB in Danshen 
preparations might affect this renal elimination of TSL, and plasma concentration of TSL may be 
elevated depending on the achieved systemic exposures of CA, LSA, SAA and SAB, which in 
turn, influences TSL-associated DDIs. Finally, such DDI potential estimation was based on the 
peak exposure level. As shown in Table 8.2, considering the relative t1/2elimination of these Danshen 
components, especially for TSL (t1/2elimination = 1.6 hr), the main determinant for DDI potential of 
Danshen injectables, the DDI duration window might be short (< 2 hr). 
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In conclusion, the major Danshen components, LSA, RMA, and TSL, were demonstrated to 
elicit cumulative inhibitory effects on hOAT1- and hOAT3-mediated substrate uptake. The 
cumulative DDI index was introduced as a more comprehensive index to evaluate DDI potential 
for multiple-component Danshen injectables. Even though TSL appears to exert a dominant 
contribution to the cumulative DDI index, the potential impact of LSA and RMA cannot be 
ignored. The large cumulative DDI indices (particularly those ˃ 1)  suggested that Danshen 
injectables have a strong potential to cause OAT-mediated DDIs in vivo and underscore the need 
for improved manufacturing standards to eliminate such wanton product variability and protect 
the public. 
 
 
 
 
 
 
 
 
 
 
 
 162 
 
 
 
 
 
 
CHAPTER 9 
 
 
 
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
 
 
 
Natural products have been used as first-line therapeutics, complementary/alternative 
medicines, and dietary supplements for thousands of years (205). Currently, herbal therapy is 
receiving renewed interest throughout the world as products produced from plants are considered 
“natural” and therefore often perceived as having no potential for toxic effects by patients. 
However, information about the safety and efficacy profiles for these compounds is still limited 
compared to western drugs. Indeed, many side effects associated with natural products have been 
reported over the last two decades (131, 132). A number of studies have demonstrated that 
transporter proteins, including OATs, can be sites of DDIs, and that transporter-mediated DDIs 
contributed to reported side effects (39, 77, 129). While some natural compounds are known 
substrates (e.g., aristolochic acid, caffeic acid, dihydrocaffeic acid, dihydroferulic acid, and 
ferulic acid ) or inhibitors (ellagic acid, stevioside, and caffeic acid) of OATs, the interaction of 
most natural products with OATs are virtually unknown (48, 50, 51). As a result, it is necessary 
to explore OAT-mediated natural product-drug interactions to improve herbal product safety and 
efficacy. This dissertation thus characterized the potential interaction of 22 selected natural 
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compounds as major organic acid components of herbal medicines/food and exhibiting 
significant systemic exposure. 
Danshen (Salvia miltiorrhiza) is a commonly used Chinese herbal medicine for the treatment 
of cardiovascular diseases (100-102). In Chapters 3 and 4, the inhibitory effects of hydrophilic 
Danshen components on the function of mOat1 and mOat3 were assessed. At 1 mM, all of tested 
compounds, including LSA, RMA, SAA, SAB, and TSL, showed significant inhibition on 
mOat1 and mOat3. Kinetic analysis demonstrated a competitive mechanism of inhibition for 
LSA, RMA, SAA. Ki values were estimated as 14.9 ± 4.9 µM for LSA, 5.5 ± 2.2 µM for RMA, 
4.9 ± 2.2 µM for SAA, 236 ± 90 µM for SAB, and 136 ± 17 µM for TSL on mOat1-mediated 
transport and as 31.1 ± 7.0 µM for LSA, 4.3 ± 0.2 µM for RMA, 21.3 ± 7.7 µM for SAA, 845 ± 
287 µM for SAB, and 1940 ± 486 µM for TSL on mOat3-mediated transport. Further work was 
conducted to study the influence of five Danshen components (LSA, RMA, SAA, SAB, and TSL) 
on human OATs, including hOAT1, hOAT3, and hOAT4 (shown in Chapter 4). Similarly, these 
compounds exhibited competitive inhibition of hOAT1 and hOAT3. At clinical plasma 
concentrations, the calculated DDI indices were much greater than 0.1, indicating a strong 
interaction potential for LSA, RMA and TSL on both hOAT1 and hOAT3 and for LSA on 
hOAT3. In addition, notable species differences appeared to exist in terms of inhibitory potency 
among mouse and human. Generally, Danshen components showed preferential affinity (by 1-2 
orders of magnitude) for human OATs compared with their murine orthologs.  
Numerous studies have demonstrated that phenolic acids exert beneficial health effects such 
as anti-oxidant, anti-carcinogenic, and anti-inflammatory activities (140). In addition, people are 
exposed to these compounds from dietary sources, including common fruits, vegetables, and 
beverages (43). Some phenolic acids have been identified as the substrates or inhibitors of OATs 
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(50, 51). In Chapter 5, the potential interaction of nine dietary phenolic acids, including p-
coumaric acid, ferulic acid, gallic acid, gentisic acid, 4-hydroxybenzoic acid, protocatechuic acid, 
sinapinic acid, syringic acid, and vanillic acid with hOAT1, hOAT3, and hOAT4 was investigated. 
At 100 µM, all compounds significantly inhibited hOAT3 transport, while ferulic, gallic, 
protocatechuic, sinapinic, and vanillic acid significantly blocked hOAT1 activity. Sinapinic acid 
was the only test compound exhibiting significant inhibition on hOAT4 (~35%). Estimated IC50 
values ranged from 1.24 to 18.1 µM for hOAT1 and from 7.35 to 87.4 µM for hOAT3 for 
selected compounds exhibiting potent inhibition from the preliminary screening. Given the 
expected clinical unbound plasma concentrations, maximum DDI indices for gallic and gentisic 
acid are much greater than 0.1, indicating a very strong potential for DDIs on hOAT1 and/or 
hOAT3. Therefore, gallic acid from foods or herbal supplements, or gentisic acid from 
salicylate-based drug metabolism, may significantly alter the pharmacokinetics of concomitant 
drugs that are hOAT1 and/or hOAT3 substrates. 
As shown in Chapter 6, the potential interaction of some natural dietary/herbal anionic 
compounds, including flavonoids (catechin and epicatechin), chlorogenic acids (1,3- and 1,5-
dicaffeoylquinic acid), phenolic acids (ginkgolic acids (13:0), (15:1), and (17:1)), and other 
anionic compounds (ursolic acid and 18β-glycyrrhetinic acid), with hOAT1, hOAT3, and 
hOAT4 were also investigated. The most important finding of this part was that 1,3-
dicaffeoylquinic acid and 18β-glycyrrhetinic acid exhibited high affinity with hOAT1, with IC50 
values estimated as 1.2 ± 0.4 μM and 2.7 ± 0.2 µM, respectively. These data indicate that 1,3-
dicaffeoylquinic acid and 18β-glycyrrhetinic acid have the potential to cause significant hOAT1-
mediated DDIs in vivo, which should be considered during clinical use and in future drug 
development. 
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Among test phenolic acids, gallic acid and gentisic acid undergo renal elimination as their 
unchanged form (144, 163). As mentioned in Chapter 5, gallic acid and gentisic acid showed 
strong affinity with hOAT1 and hOAT3. Therefore, OATs might be involved in urinary 
excretion of these compounds. In Chapter 7, a new, rapid, and sensitive LC-MS/MS method was 
developed and validated for the simultaneous determination of gallic acid and gentisic acid in 
cell lysate, using Danshensu as the IS. Compared to previously reported LC-MS/MS-based 
methods, the established method increased speed, sensitivity and linear dynamic range. The total 
run time was 3 min and calibration curves were linear over the concentrations of 0.33–2400 
ng/mL for both compounds (r2>0.995). In addition, adverse matrix effects were investigated in 
samples with cell lysate-derived biological matrix. This assay was successfully applied in a 
cellular uptake study to determine the intracellular concentrations of gallic acid and gentisic acid 
in mOat1- and mOat3-expressing cells. Gallic acid was identified as a novel substrate of mOat1 
using the method. 
Most herbal medicines contain multiple components. Because of the marked similarity in 
their chemical structures, some, if not all, of these components may be involved in drug 
transporter-mediated DDI. As a result, investigations on a single component may underestimate 
the combined DDI potency for botanic products. In Chapter 4, five Danshen components (LSA, 
RMA, SAA, SAB, and TSL) showed significant inhibition on hOAT1 and hOAT3. In Chapter 8, 
the cumulative DDI index, defined as the sum of DDI indices for individual components, was 
calculated for Danshen injectables. Clearly, the cumulative DDI index was significantly higher 
as compared to individual component-related DDI indices for most Danshen pharmaceutical 
products. These results indicate that it is necessary to identify major components of herbal 
therapeutics, whether considered as active ingredients or not, and to investigate their DDI 
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potential. In addition, due to the variation in cultivation regions, extraction strategy, and 
manufacturing processes, quality control for herbal medicines is always difficult. In the present 
study, the cumulative DDI indices were highly variable among different manufacturers or 
batches. As a result, DDI potency could be different if patients take the same nominal dose of 
Danshen product, but from different sources. For herbal therapeutics like Danshen, standardized 
quality control criteria should be established.  
These in vitro studies have essentially explored the potential inhibitory effects of natural 
anionic compounds on human and murine OATs. However, to the best of my knowledge, there 
have been no studies to demonstrate OAT-mediated natural product-drug interaction in vivo. 
Indeed, the findings in this work suggest further in vivo studies to confirm DDIs. To achieve this 
goal, species differences in transporter affinity need to be considered when choosing an 
appropriate animal model to demonstrate DDI. In Chapter 4, human OATs showed markedly 
higher affinity with Danshen components compared to murine orthologs. As a result, a clinically 
relevant concentration in mice would underestimate the clinical DDI magnitude. To solve this 
problem, a suitable animal model with minimal species differernce should be chosen. Otherwise, 
the dosing regimen for animal studies would need to be adjusted in order to balance the 
discrepancy between species. Additionally, DDI evaluations should be conducted with 
combination of multiple ingredients in addition to single components. With this information and 
in vitro results, the effects of the complete preparation or particular components can be specified 
from pharmacokinetic studies. 
Previous studies demonstrated that typical substrates of OATs are small or medium 
molecules with negative charge(s) at physiological pH (3). However, it is not well defined what 
the influences of physicochemical properties are for interaction. In 2013, VanWert et al. 
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investigated the in-depth structure-activity relationship (SAR) of β-lactam antibiotics with 
respect to their inhibitory activity on mOat3 and hOAT3 (206). They found that a prohibitive 
hydrogen bond donor group in noninhibitors adjacent to a hydrophobic moiety was important for 
binding to Oat3 (206). In our study, SAR for phenolic acids with OATs was also performed 
through collaboration with scientists in the Medicinal Chemistry Department of our University. 
Unfortunately, there were no conclusive results, possibly due to an insufficient number of test 
compounds. In the future, as information on the interaction of natural anionic compounds and 
OATs becomes available, additionally SAR studies should be conducted to provide better 
understanding on OAT-substrate interaction and potentially indentify new strategy for target-
delivered drug synthesis.  
In Chapter 7, a sensitive, specific, and robust LC-MS/MS method was developed to 
determine the concentration of gallic acid and gentisic acid in cell lysate, and gallic acid was 
identified as a substrate of mOat1. However, the intracellular concentration of gallic acid in both 
mOat3-expressing and empty vector control cells were below the LLOQ, leaving open the 
possibility of gallic acid may be a substrate of mOat3. Similarly, whether gentisic acid is a 
substrate of mOat1 or mOat3 is still unclear. Future research requires modifications (e.g., 
increased assay sensitivity, number of cells, incubation time, and subsrate concentrations) to 
accurately measure the cellular uptake of gallic acid and gentisic acid in these cell lines. In 
addition, it is necessary to determine cellular uptake of gallic acid and gentisic acid in hOAT1- 
and hOAT3-expressing cells. Unbound renal clearance of gallic acid is higher compared to GFR, 
indicating that gallic acid undergoes net renal tubular secretion (163). If marked cellular 
accumulation of gallic acid is observed in hOAT1- and hOAT3-expressing cells, these 
transporters might be involved in the active secretion of gallic acid. For gentisic acid, although a 
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significant portion is eliminated in the urine as the unchanged form, it is still necessary to 
determine unbound renal clearance in clinical studies in order to clarify the potential contrition of 
hOATs. Even if hOAT1 and hOAT3 transport gentisic acid, their actual contribution for renal 
elimination might be negligible if unbound renal clearance is not higher than GFR. 
Overall, the results indicated a strong DDI potential on OATs for natural anionic components. 
Future studies need to elucidate such interactions in different populations. As indicated in 
Chapter 1, OAT-associated SNPs have been found in the human population. These OAT SNPs 
may lead to ultra, normal, reduced, or null transport activity. In addition, pathological conditions 
(e.g., acute and chronic renal failure) influence OAT expression in the kidney. Other factors, 
including gender and age, also are known to have an impact on OAT expression and function. As 
a result, OAT-mediated DDI potential may be highly variable among these groups. Information 
on OAT expression and activity regulation would be helpful to predict OAT-mediated DDIs in 
patients with specific biological or pathological characters, moving towards personalized 
medicine. Another aspect for future study is to demonstrate potential interaction of other OATs 
(e.g., OAT2, OAT7, and OAT10) with these test compounds. As OATs have a broad 
substrate/inhibitor specificity, it is highly possible that test compounds may interact with these 
transporters and affect organic anion solute flux in other organs such as liver. Furthermore, 
pharmaceutical industries which are developing herbal products need to refine standardization 
criteria for the manufacturing process. Finally, generation of humanized transgenic mice 
becomes increasingly important in an attempt to develop a model system that minimizes inter-
species variation of drug transporter affinities. The combination of humanized transgenic mice 
with knockout mice might serve as suitable complementary preclinical animal models to 
demonstrate clinically relevant DDIs. 
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 APPENDIX I 
 
ORGANIC ANION TRANSPORTER SUBSTRATES AND INHIBITORS (REPORTED FROM 2010 TO 2012) 
 
Compound Transportera Interactionb Systemc 
Kinetics (µM) 
Reference Km Ki IC50d 
1-butanesulfonic acid 
hOAT1 
mOat1 
rbOat1 
I CHO   
514±72.1 (0.25 PAH) 
313±26.9 (0.25 PAH) 
421±89.4 (0.25 PAH) 
(207) 
1-propanesulfonic acid 
hOAT1 
mOat1 
rbOat1 
I CHO   
2036±28.3 (0.25 PAH) 
4156±1079 (0.25 PAH) 
 
(207) 
2,3-dimercapto-1-propanesulfonic acid 
hOAT1 
I 
CHO   83±3 (0.25 PAH) (207) 
HEK293   104.6±13.1 (5 CF) 85.1±8.8 (5 CF) (208)
e 
mOat1 CHO   55±4.9 (0.25 PAH) (207) 
rbOat1 
CHO   72±9.9 (0.25 PAH) (207) 
HEK293   237.4±23 (5 CF) 123±14 (5 CF) (208)
e 
3-mercapto-1-propanesulfonic acid 
hOAT1 
mOat1 
rbOat1 
I CHO   
204±54.2 (0.25 PAH) 
151±19.8 (0.25 PAH) 
204±34.9 (0.25 PAH) 
(207) 
3-monoglucuronyl-glycyrrhetinic acid hOAT1 S HEK293 49.0±18.3   (209) 
Aminopterin hOAT1 I X.laevis   160±58 (0.221 PAH) (210) 
Amitriptyline hOAT1 I S2  573.9 354 (5 PAH) (211) 
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Compound Transportera Interactionb Systemc Kinetics (µM) Reference Km Ki IC50d 
Arginine mOat1 I CHO   1600±300 (5 CF) (212) 
Aristolochic acid I 
hOAT1 I HEK293  0.5  (39) 
hOAT1 I S2  0.80±0.15 0.44±0.08 (5 PAH) (40) 
hOAT1 S HEK293    (41) 
mOat1 S CHO 0.79±0.01   (36) 
rOat1 S HEK293    (213) 
Aristolochic acid II hOAT1 I S2   1.06±0.09 (5 PAH) (40) mOat1 S CHO 1.50±0.37   (36) 
Bestatin hOAT1 S HEK293 679±7   (214) 
Caffeic acid hOAT1 S/I HEK293 28.6±3.7  5.22 (25 PAH) (50) hOAT1 I X.laevis   16.6±3.7 (0.221 PAH) (51) 
Caffeic acid-3-O-glucuronide hOAT1 S/I HEK293    (50) 
Caffeic acid-4-O-glucuronide hOAT1 S HEK293    (50) 
Caffeic acid-3-O-sulfate hOAT1 S HEK293 38.9±3.3   (50) 
Caffeic acid-4-O-sulfate hOAT1 S HEK293    (50) 
Cephalexin hOAT1 S HEK293    (215) 
Chlorpyrifosmethyl hOAT1 I S2  324.6 191.5 (5 PAH) (211) 
Cyclo-trans-4-L-hydroxyprolyl-L-
serine hOAT1 S HEK293    (215) 
Daidzein-7-O-glucuronide hOAT1 I HEK293    (119) 
Daidzein-7,4’-O-disulfate hOAT1 I HEK293    (119) 
Diazepam hOAT1 I S2  83.5 133.3 (5 PAH) (211) 
Dihydrocaffeic acid hOAT1 S/I HEK293 21.4±4.2   (50) 
Dihydroferulic acid hOAT1 S/I HEK293    (50) 
Dihydrocaffeic acid-3-O-glucuronide hOAT1 S HEK293    (50) 
Dihydrocaffeic acid-4-O-glucuronide hOAT1 S HEK293    (50) 
Dihydrocaffeic acid-3-O-sulfate hOAT1 S/I HEK293 76.7±16.3   (50) 
Dihydrocaffeic acid-4-O-sulfate hOAT1 S/I HEK293 115±31   (50) 
Dihydroferulic acid-4-O-sulfate hOAT1 S/I HEK293    (50) 
Ferulic acid-4-O-sulfate hOAT1 S HEK293 54.2±3.6   (50) 
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Compound Transportera Interactionb Systemc Kinetics (µM) Reference Km Ki IC50d 
Fenitrothion hOAT1 I S2  51.2 26.6 (5 PAH) (211) 
Ferulic acid hOAT1 S/I HEK293   9.01 (25 PAH) (50) I CHO    (52) 
Gaboxadol rOat1 S X. laevis 151±58   (216) 
Gallic acid hOAT1 I CHO   1.24±0.36 (1 PAH) (52) 
Genistein-4’-O-sulfate hOAT1 S/I HEK293 5.07±1.81   (119) 
Genistein-7-O-glucuronide hOAT1 I HEK293    (119) 
Glycitein-7-O-glucuronide hOAT1 I HEK293    (119) 
Indoxyl sulfate mOat1 I X. laevis   18 (30 CF) (217) 
Isoferulic acid hOAT1 I HEK293    (50) 
Isoferulic acid-3-O-glucuronide hOAT1 S HEK293    (50) 
Isoferulic acid-3-O-sulfate hOAT1 S/I HEK293 32.7±5.3   (50) 
Lithospermic acid mOat1 I CHO  14.9±4.9  (49) 
Lumiracoxib hOAT1 I X. laevis   3.3±1.1 (0.221 PAH) (218) 
Ketoconazole hOAT1 I X. laevis   319 (1 PAH) (219) 
α-Ketoglutarate mOat1 I X. laevis   40±3 (30 CF) (212) 
Malathion  hOAT1 I S2  134.0 114.2 (5 PAH) (211) 
Mianserin  hOAT1 I S2  99.0 312.6 (5 PAH) (211) 
Probenecid hOAT1 I X. laevis   17 (3 PAH); 14 (10 MTX) (220) 
Protocatechuic acid hOAT1 I CHO   18.08±2.59 (1 PAH) (52) mOat1 I    (49) 
Pyruvate mOat1 I CHO   4300±600 (5 CF) (212) 
Quercetin-3-O-glucuronide hOAT1 S/I HEK293    (119) 
Quercetin-3’-O-glucuronide hOAT1 I HEK293    (119) 
Quercetin-3’-O-sulfate hOAT1 S/I HEK293 1.73±0.38  1.22 (25 PAH) (119) 
Quercetin-7-O-glucuronide hOAT1 S/I HEK293    (119) 
Rifampin hOAT1 I X. laevis  62.2 79.1 (1 PAH) (219) 
Rosmarinic acid mOat1 I CHO  5.5±2.2  (49) 
Salvianolic acid A mOat1 I CHO  4.9±2.2  (49) 
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Compound Transportera Interactionb Systemc Kinetics (µM) Reference Km Ki IC50d 
Salvianolic acid B mOat1 I CHO    (49) 
Sinapinic acid hOAT1 I CHO   11.02±1.55 (1 PAH) (52) 
Spermidine mOat1 I X. laevis   2000±700 (30 CF) (212) 
Spermine mOat1 I X. laevis   1600±600 (30 CF) (212) 
Sulfasalazine hOAT1 I X. laevis   4.6 (10 MTX) (220) 
Tanshinol mOat1 I CHO    (49) 
Triazolam hOAT1 I S2  86.0 185.2 (5 PAH) (211) 
Vanillic acid hOAT1 I CHO   7.65±2.92 (1 PAH) (52) 
Aristolochic acid I mOat2 S CHO 0.36±0.05   (36) 
Aristolochic acid II mOat2 S CHO 0.67±0.19   (36) 
Orotic acid hOAT2 rOAT2 S HEK293    (221) 
Uric acid hOAT2 S HEK293 1168±335   (222) 
N-({(5S)-3-[4-(1,1-
dioxidothiomorpholin-4-yl)-3,5-
difluorophenyl]- 
2-oxo-1,3-oxazolidin-5-
yl}methyl)acetamide 
hOAT3 S HEK293 44±5   (223) 
1-butanesulfonic acid 
hOAT3 
mOat3 
rbOat3 
I CHO   
5098±184.3 (0.015 ES) 
10975±2647 (0.015 ES) 
5640±715.9 (0.015 ES) 
(207) 
1-propanesulfonic acid rbOat3 I CHO    (207) 
2,3-dimercapto-1-propanesulfonic acid 
hOAT3 
I 
CHO   40±7.4 (0.015 ES) (207) 
HEK293   31.6±6.6 (5 CF) 172±36 (5 CF) (208)
e 
mOat3 CHO   85±16.9 (0.015 ES) (207) 
rbOat3 
CHO   18±2.5 (0.015 ES) (207) 
HEK293   52.4±7.6 (5 CF) 172±22 (5 CF) (208)
e 
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Compound Transportera Interactionb Systemc Kinetics (µM) Reference Km Ki IC50d 
2,4-dichlorophenoxyacetate mOat3 I CHO  2.0±0.4  (109) 
2,4-dihydroxyphenylacetic acid mOat3 I CHO  347±98  (109) 
3-mercapto-1-propanesulfonic acid 
hOAT3 
mOat3 
rbOat3 
I CHO   
2139±289 (0.015 ES) 
2325±268 (0.015 ES) 
2320 ±785 (0.015 ES) 
(207) 
3-monoglucuronyl-glycyrrhetinic acid hOAT3 S HEK293 30.1±2.9   (209) 
4-hydroxybenzoic acid hOAT3 I HEK293    (52) 
5-hydroxyindoleacetic acid mOat3 I CHO  67.8±7.2  (109) 
Aminopterin hOAT3 I X. laevis   59.2±14.9 (0.0184 ES) (210) 
Aristolochic acid I 
hOAT3 I HEK293  0.4  (39) 
hOAT3 I S2  0.84±0.10 0.65±0.08 (0.05 ES) (40) 
hOAT3 S HEK293    (41) 
mOat3 S CHO 0.51±0.06   (36) 
Aristolochic acid II hOAT3 I S2   1.28 ± 0.18 (0.05 ES) (40) mOat3 S CHO 1.05±0.36   (36) 
Bestatin hOAT3 S HEK293 632±14   (214) 
Bumetanide hOAT3 I X. laevis   7.8 (2 ES); 5.4 (10 MTX) (220) 
Caffeic acid hOAT3 S/I HEK293   30.8 (100 CF) (50) hOAT3 I X.laevis   5.4±1.3 (0.0175 ES) (51) 
Caffeic acid-3-O-glucuronide hOAT3 S HEK293    (50) 
Caffeic acid-4-O-glucuronide hOAT3 S HEK293    (50) 
Caffeic acid-3-O-sulfate hOAT3 S HEK293    (50) 
Caffeic acid-4-O-sulfate hOAT3 S HEK293    (50) 
Celecoxib hOAT3 I S2  35.3  (224) 
Cephalexin hOAT3 S HEK293    (215) 
p-Coumaric acid hOAT3 I HEK293    (52) 
Cyclo-trans-4-L-hydroxyprolyl-L-
serine hOAT3 S HEK293    (215) 
Daidzein-7-O-glucuronide hOAT3 S/I HEK293 19.1±1.9   (119) 
Daidzein-7,4’-O-disulfate hOAT3 S/I HEK293    (119) 
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Compound Transportera Interactionb Systemc Kinetics (µM) Reference Km Ki IC50d 
Dehydroepiandrosterone sulfate mOat3 I S 
CHO 
X. laevis  
3.8±1.1 
  
(109) 
(109, 225) 
Dihydrocaffeic acid hOAT3 S/I HEK293 21.4±4.2  14.2 (100 CF) (50) 
Dihydrocaffeic acid-3-O-glucuronide hOAT3 S HEK293    (50) 
Dihydrocaffeic acid-4-O-glucuronide hOAT3 S HEK293    (50) 
Dihydrocaffeic acid-3-O-sulfate hOAT3 S HEK293    (50) 
Dihydrocaffeic acid-4-O-sulfate hOAT3 S HEK293    (50) 
Dihydroferulic acid-4-O-glucuronide hOAT3 S HEK293    (50) 
Dihydroferulic acid-4-O-sulfate hOAT3 S HEK293    (50) 
Ferulic acid hOAT3 I HEK293   7.35±3.73 (1 ES) (52) 
Ferulic acid-4-O-glucuronide hOAT3 S HEK293    (50) 
Ferulic acid-4-O-sulfate hOAT3 S HEK293    (50) 
Gallic acid hOAT3 I HEK293   9.02±3.24 (1 ES) (52) 
Genistein-4’-O-glucuronide hOAT3 S/I HEK293    (119) 
Genistein-7-O-glucuronide hOAT3 S/I HEK293 7.94±1.42   (119) 
Gentisic acid hOAT3 I HEK293   86.81±21.78 (1 ES) (52) 
Glycitein-7-O-glucuronide hOAT3 S/I HEK293 17.6±3.9   (119) 
Hippuric acid mOat3 I CHO  79.3±4.0  (109) 
Homovanillic acid mOat3 I CHO  135±27  (109) 
Isoferulic acid-3-O-glucuronide hOAT3 S HEK293    (50) 
Isoferulic acid-3-O-sulfate hOAT3 S HEK293    (50) 
Lithospermic acid mOat3 I CHO  31.1±7.0  (49) 
Lumiracoxib hOAT3 I X. laevis   1.9±0.4 (0.0184 ES) (218) 
Penicillin G mOat3 I CHO  60.7±5.9  (109) 
Probenecid mOat3 I CHO  0.8±0.2  (109) 
Protocatechuic acid hOAT3 I CHO   87.36±28.57 (1 ES) (52) mOat3 I CHO    (49) 
Quercetin-3-O-glucuronide hOAT3 S/I HEK293   0.43 (100 CF) (119) 
Quercetin-3’-O-glucuronide hOAT3 S/I HEK293 5.25±0.86  1.31 (100 CF) (119) 
Quercetin-3’-O-sulfate hOAT3 S/I HEK293   0.75 (100 CF) (119) 
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Compound Transportera Interactionb Systemc Kinetics (µM) Reference Km Ki IC50d 
Quercetin-7-O-glucuronide hOAT3 S/I HEK293    (119) 
Rosmarinic acid mOat3 I CHO  4.3±0.2  (49) 
Salicylate mOat3 I CHO  343±93  (109) 
Salvianolic acid A mOat3 I CHO  21.3±7.7  (49) 
Salvianolic acid B mOat3 I CHO    (49) 
Sinapinic acid hOAT3 I HEK293   25.74±1.56 (1 ES) (52) 
Sulfasalazine hOAT3 I X. laevis   3.0 (10 MTX) (220) 
Syringic acid hOAT3 I HEK293    (52) 
Tanshinol mOat3 I CHO    (49) 
Vanillic acid hOAT3 I HEK293    (52) 
Aristolochic acid I hOAT4 I HEK293  22.4  (39) hOAT4 I S2   61.3±8.35 (0.05 ES) (40) 
Aristolochic acid II hOAT4 I S2   72.0±9.32 (0.05 ES) (40) 
Caffeic acid-3-O-sulfate hOAT4 S HEK293    (50) 
Caffeic acid-4-O-sulfate hOAT4 S HEK293    (50) 
Ferulic acid-4-O-sulfate hOAT4 S HEK293    (50) 
Isoferulic acid-3-O-sulfate hOAT3 S HEK293    (50) 
Perfluorooctanoate hOAT4 S CHO 
172±46 
(pH6); 
310± 30 
(pH7.4) 
  (226) 
Sinapinic acid hOAT4 I CHO    (52) 
6-Hydroxybenzbromarone hURAT1 I MDCK   0.23±0.05 (100 U) (227) 
Benzarone hURAT1 I MDCK   0.12±0.03 (100 U) (227) 
Benzbromarone hURAT1 I MDCK   0.05±0.02 (100 U) (227) 
Captopril hURAT1 I MDCK   >5000 (100 U) (227) 
Enalapril hURAT1 I MDCK   648±77 (100 U) (227) 
Fenofibric acid hURAT1 I HEK293   35.7±3.9 (20 U) (228) 
Fenofibric acid (reduced) hURAT1 I HEK293   570±25 (20 U) (228) 
Indomethacin hURAT1 I MDCK   40.7±2.20 (100 U) (227) 
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Compound Transportera Interactionb Systemc Kinetics (µM) Reference Km Ki IC50d 
Irbesartan hURAT1 I X. laevis   121.7 (20 U) (229) 
Losartan hURAT1 I HEK293X. laevis   
571±28 (20 U) 
 
(228) 
(229) 
Orotate hURAT1 S HEK293 5.2±0.4   (230) 
Perfluorooctanoate hURAT1 S HEK293 64.1±30.5   (226) 
Phenylbutazone hURAT1 I MDCK   197±48.5 (100 U) (227) 
Probenecid hURAT1 I MDCK   86.39±0.07 (10 U) 41.7±3.70 (100 U) 
(231) 
(227) 
Sulfinpyrazone hURAT1 I MDCK   716±34.3 (100 U) (227) 
Telmisartan hURAT1 I X. laevis    (229) 
Valsartan hURAT1 I X. laevis    (229) 
2,4-dichlorophenoxyacetate mOat6 I CHO  15.7±2.0  (109) 
2,4-dihydroxyphenylacetic acid mOat6 I CHO  61.4±7.1  (109) 
5-hydroxyindoleacetic acid mOat6 I CHO  48.9±10.3  (109) 
Dehydroepiandrosterone sulfate mOat6 I CHO  38.8±3.1  (109) 
Hippuric acid mOat6 I CHO  59.9±4.9  (109) 
Homovanillic acid mOat6 I CHO  3.0±0.5  (109) 
Penicillin G mOat6 I CHO  1450±480  (109) 
Probenecid mOat6 I CHO  8.3±2.5  (109) 
Salicylate mOat6 I CHO  49.0±4.4  (109) 
 
aTransporter species: h, human; m, mouse; r, rat; rb, rabbit; bInteraction: I, inhibitor; S, substrate; cExpression system: CHO, Chinese 
hamster ovary cells; HEK293, human embryonic kidney cell line; MDCK, Madin Darby canine kidney cell line; S2, cell line derived 
from second segment of proximal tubule; X. laevis, Xenopus laevis oocytes; dIC50: concentration of inhibited substrate is shown in 
parentheses (in µM), substrate abbreviations: CF, carboxyfluorescein; ES, estrone sulfate; MTX, methotrexate; PAH, para-
aminohippurate; U, Urate; eThis reference reported values for both the oxidized and reduced forms of this substrate, respectively. 
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